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IV 
Summary	
The	transcription	factor	GATA6	was	recently	recognised	as	a	master	regulator	of	the	phenotype	and	function	of	peritoneal	resident	macrophages	(pResMf),	whose	deficiency	results	 in	 dysregulated	 proliferative	 renewal	 during	 homeostasis	 and	 altered	inflammatory	responses,	associated	with	delays	in	resolution.	Herein,	 I	 show	 using	microarray	 analysis	 that	mice	with	 a	myeloid	 deficiency	 of	
Gata6	 (Gata6-KOmye	 mice)	 have	 significant	 changes	 in	 genes	 associated	 with	 lipid	metabolism,	in	particular	sphingolipids	(SL).	Three	of	the	most	notable	alterations	were	the	 downregulation	 of	 genes	 responsible	 for	 the	 degradation	 of	 glucosylceramides	(GlcCer)	and	sphingomyelins	(SM)	(Gba2	and	Smpd1),	as	well	as	a	gene	involved	in	the	regulation	of	lysosomal	pH,	and	consequently,	lysosomal	function.	To	characterise	the	metabolic	defect,	I	compared	the	lipidome	of	Gata6-KOmye	and	wild-type	(WT)	pResMf	using	 a	 high-resolution	 LC-MS	 based	 global	 lipidomics	 approach	 and	 replicated	 my	findings	using	targeted	LC-MS/MS.	SL	showed	a	high	percentage	of	changes	(25%	of	all	lipids	levels	were	altered	significantly)	with	a	marked	increase	in	Gata6-KOmye	pResMf.	SL	are	 important	constituents	of	 the	plasma	membrane	 in	eukaryotes	and,	as	second	messengers,	 modulate	 apoptosis,	 cell	 proliferation	 and	 differentiation.	 Targeted	lipidomics	by	LC-MS/MS	showed	that	the	most	significantly-increased	molecular	species	were	 long	 chain	 GlcCer	 and	 SM.	 This	 linked	 with	 downregulation	 of	 Gba2,	 Ctse	 and	
Smpd1,	observed	during	the	microarray	analysis,	and	was	confirmed	by	supressing	these	pathways,	in	RAW	264.7	cells,	using	knockdown	(shRNA)	approaches.	Accumulation	of	SL	metabolites	in	tissues	is	implicated	in	a	plethora	of	patho-physiological	complications	such	as	development	of	neurological	dysfunctions,	atherosclerosis,	diabetes,	and	heart	failure,	whilst	in	cells	it	correlates	with	defects	in	cell	migration,	cholesterol	traffic	and	efflux,	lipid	transport,	cell	activation,	proliferation	and	apoptosis.	Overall,	 I	 concluded	 that	GATA6	regulates	 lipid	metabolism	 in	pResMf,	on	both	a	transcriptional	 and	metabolic	 level,	 with	 particular	 focus	 on	 SL	 levels.	 Furthermore,	there	 is	 indication	 that	 this	 regulation	 may	 at	 least	 in	 part	 control	 phenotype	 and	function	in	pResMf	through	altering	SL	signalling.	Thus,	my	studies	propose	GATA6	as	a	new	lipid-regulating	transcription	factor	and	highlight	the	importance	of	lipid	regulation	in	pResMf	biology.		 	
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Chapter	1 General	Introduction	
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1.1 Macrophages	
The	 theory	 and	 proof	 of	 natural,	 innate	 immune	 host	 defence,	 by	 cellular	mechanisms	such	as	phagocytosis	and	recruitment	of	phagocytes	during	acute	and	 chronic	 inflammation,	 was	 first	 described	 by	 Ilya	 Mechnikov,	 a	 Russian	comparative	zoologist	known	as	the	father	of	innate	immunity	and	discoverer	of	the	 significance	of	phagocytosis	 in	development,	 homeostasis	 and	disease1.	 In	1883,	 he	 observed	 specialized	 phagocytic	 cells,	 microphages	 and	 larger	macrophages	(Mf),	consuming	pathogens	during	inflammation,	which	led	him	to	develop	the	theory	of	immunity	by	phagocytosis1,2.	Since	then,	the	interest	in	Mf	biology	has	steadily	increased,	and	it	has	become	evident	that	the	multiplicity	of	Mf	functions	play	a	vital	role	in	tissue	development,	homeostasis	and	defence3,4.			
Phagocytic	 cells,	 can	 be	 divided	 into	 two	 groups:	 the	 polymorphonuclear	phagocytes	 (granulocytes)	 and	 the	 mononuclear	 phagocytes.	 Mononuclear	phagocytes	 comprise	 tissue	 circulating	 monocytes,	 resident	 Mf	 (ResMf),	promonocytes,	and	their	precursor	cells	in	the	bone	marrow5.	More	recently,	the	concept	 that	 has	 emerged	 that	 Mf	 represent	 an	 evolutionarily	 ancient,	disseminated,	 homeostatic	 system,	 on	 a	 par	 with	 the	 nervous	 and	 endocrine	systems6.	 They	 are	 present	 in	 all	 vertebrate	 tissues,	 from	 mid-gestation	throughout	 life,	 representing	 a	 tissue-distributed	 mononuclear	 phagocyte	system	 (MPS)5,7.	 They	 maintain	 homeostasis	 by	 responding	 to	 physiological	changes	 and	 external	 insults,	 which	 results	 in	 a	 wide	 range	 of	 reactions,	 as	phagocytes	in	defence	against	microbes	and	in	clearance	of	dead	and	senescent	cells,	 in	 addition	 to	 providing	 regulatory	 and	 repair	 functions8.	 During	organogenesis,	Mf	orchestrate	tissue	remodelling	and	relay	long-range	signals	between	 non-immune	 cells9,10.	 They	 do	 this	 by	 regulating	 pigmentation	 in	zebrafish	skin11,	and	fostering	spermatogonial	differentiation	in	the	murine	testis	before	 birth12.	 During	 puberty13,	 they	 achieve	 it	 by	 promoting	 branching	morphogenesis	in	the	developing	kidney14,	carving	the	developing	cornea15	and	wiring	neurons	in	the	developing	brain16,	among	others.	Mf	also	have	a	crucial	role	 during	 erythropoiesis	 in	 the	 foetal	 liver	 by	 enucleating	 primitive	erythrocytes17.	Murine	 heart	Mf	 are	 responsible	 for	 tissue	 regeneration	 after	
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birth18.	Last,	 they	also	control	 the	 inflammatory	responses	 required	 for	 tissue	repair	and	wounding	during	adulthood19.		The	past	few	years	have	witnessed	an	immense	advance	in	our	understanding	of	the	origins	and	distinct	functions	of	monocyte/Mf	subsets	(Figure	1.1)	as	well	as	 their	 differential	 roles	 in	 health	 and	disease8,20,21.	 In	 the	 classical	 view,	Mf	develop	from	self-renewing	hematopoietic	stem	cells	(HSC)	in	the	bone	marrow	via	blood	monocyte	intermediates22.	In	the	1960s,	Von	Furth	and	Cohn	proposed	that	all	Mf,	not	only	those	in	inflammatory	foci	but	also	those	in	tissues	in	the	steady	state,	are	derived	from	monocytes,	which	differentiate	via	promonocytes	from	monoblasts	originating	in	bone	marrow5.	Hence,	Mf	and	Mo	were	classified	as	 part	 of	 the	 MPS,	 and	 ResMf	 were	 instead	 considered	 to	 be	 short-lived,	terminally	differentiated	cells23,24.	This	model	was	broadly	accepted	until	recent	fate-mapping	studies	demonstrated	that	some	adult	ResMf	populations,	such	as	Kupffer	 cells,	 Langerhans	 and	microglia,	 develop	 from	embryonic	 progenitors	independent	 of	 HSCs	 and	 can	 self-renew25.	 Local	 proliferation	 of	 ResMf	 can	assure	 homeostatic	maintenance	 and	 dramatically	 increase	 cell	 number	 upon	challenge25,26.	ResMf	are	of	embryonic	origin	and	are	maintained	throughout	life	autonomously	 from	 conventional	 haematopoiesis	 by	 self-renewal	 and/or	longevity	 (Figure	 1.1)27–29.	 In	 contrast,	 Mf	 infiltrating	 the	 tissues	 during	 an	inflammatory	response	are	derived	from	blood	monocytes30,31.		 	
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Figure	1.1	Mf	origin	and	self-renewal.		The	figure	illustrates	the	precursor	cells	of	different	ResMf.	Microglia	derive	from	immature,	erythromyeloid	 progenitors	 (EMPs):	 that	 is,	 stem	 cells	 that	 are	 formed	 during	 primitive	haematopoiesis	 in	 the	 yolk	 sac	 in	 mice.	 By	 contrast,	 other	 ResMf	 arise	 from	 definitive	haematopoiesis,	 first	 in	 the	 aorta–gonad–mesonephros	 region	 or	 later,	 in	 the	 foetal	 liver.	Postnatally,	 monocytes	 are	 formed	 in	 the	 bone	 marrow.	 Haematopoietic	 stem	 cells	 (HSCs)	generate	monocytes	from	myeloid	precursors	(MPs)	and	Mf	and/or	dendritic	cell	progenitors	(MDPs).
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1.1.1 Tissue-resident	Mf	
Mf	activities	such	as	mediating	host	protection	versus	tissue	injury,	are	kept	in	a	fine	balance.	Mf	phagocytosis,	clearance	and	secretion	contribute	to	innate	and	 adaptive	 defences	 against	 infection	 and	 support	 inflammation,	whilst	 the	same	processes	with	different	signals	restore	tissue	homeostasis	and	promote	repair32,33.	 They	 are	 a	 versatile,	 heterogeneous	 group	 of	 cells	 with	 similar	functions	 and	phenotypes,	 crucial	 for	 tissue	defence	 and	homeostasis.	Mf	 are	adaptable	and	have	 the	ability	 to	perform	trophic	and	defence	 functions,	both	locally	 and	 systemically34.	 Lymphocytes	 and	 Mf	 interact	 on	 different	 levels,	initiating	cellular	and	antibody	immune	responses,	while	executing	effector	roles	which,	if	excessive	or	perpetuated,	lead	to	tissue	destruction35.		
Although	 ResMf	 are	 anatomically	 distinct	 from	 one	 another,	 and	 have	different	transcriptional	profiles	and	functional	capabilities,	they	are	all	essential	for	the	maintenance	of	 tissue	homeostasis36.	For	example,	 in	the	 lungs,	ResMf	prompt	 tissue-specific	 responses	 such	 as	 immune	 surveillance	 of	 inhaled	pathogens37.	 Nevertheless,	 chronic	 insults	 subvert	 their	 reparative	 and	homeostatic	functions,	leading	to	a	causal	association	between	Mf	with	disease	states,	such	as	fibrosis,	obesity	and	cancer36.	During	malignancy,	ResMf	play	an	important	role	in	promoting	the	survival,	growth	and	spread	of	tumour	cells35,38,	whereas	 in	 the	 CNS	 ResMf	 (microglia)	 have	 been	 shown	 to	 induce	 astrocyte	activation39.		In	the	past	few	years,	research	has	highlighted	that	the	tissue	environment	itself	 controls	 the	ResMf	 phenotype,	 by	 influencing	 the	 expression	 of	 specific	genes40.	 Thus,	 ResMf	 have	 specialized	 functions	 dictated	 by	 their	 physical	locations	 and	 distinct	 gene	 expression	 profiles.	 This	 suggests	 that	 ResMf	will	have	 different	 responses	 to	 inflammation,	 depending	 on	 their	 location41.	However,	 there	 is	still	a	 lot	 that	 is	not	yet	 fully	understood	concerning	ResMf	tissue	diversity/plasticity,	categorization	of	specific	tissue	environments,	and	the	role	of	different	stimuli	in	ResMf	metabolism,	in	particular	lipids.	New	insights	
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on	how	Mf	subsets	can	be	manipulated	to	control	the	inflammatory	environment	in	a	tissue-specific	manner	for	therapeutic	purposes	are	now	required2.			
Despite	the	fact	that	we	currently	know	of	a	variety	of	ResMf	and	they	have	been	 the	 focus	 of	 numerous	 studies,	 it	 is	 still	 unclear	whether	 all	 ResMf	 are	equally	 capable	 of	 self-renewal	 or	 if	 ‘progenitor	 cells’	 exist	 within	 the	population42.	 In	the	 lungs,	 it	has	 long	been	thought	that	 following	depletion	of	alveolar	 Mf,	 the	 majority	 of	 repopulation	 occurs	 by	 stochastic	 cellular	proliferation43.	More	recently,	studies	in	the	dermis44,	gut45,	and	heart46,47	have	led	 to	 a	 change	 of	 thinking.	 Clonal	 self-renewal	 among	 Langerhans	 cells	 (LC)	suggest	the	existence	of	a	multitude	of	LC	progenitors	or	mechanisms	that	enable	subsets	 of	 LCs	 to	 acquire	 potentially	 transient	 and	 limited	 progenitor-like	properties48.	 Embryonic	 precursor	 cells	 were	 shown	 to	 seed	 the	 intestinal	mucosa	 and	 demonstrated	 extensive	 in	 situ	 proliferation	 during	 the	 neonatal	period.	 However,	 at	 the	 time	 of	 weaning,	 these	 cells	 become	 replaced	 by	monocytes	that	later	differentiate	into	mature,	inflammatory	Mf45.	Furthermore,	in	the	heart,	embryo-derived	Mf	show	declining	self-renewal	with	age	and	are	progressively	 substituted	 with	 monocyte-derived	 Mf,	 even	 in	 the	 absence	 of	inflammation46,47.	Interestingly,	in	these	tissues,	the	decline	of	self-renewal	and	subsequent	 substitution	 by	 monocyte-derived	 Mf	 increases	 with	 age	 and	accompanies	the	loss	of	proliferation	within	the	embryonic	population.		
ResMf	 are	 thought	 to	 be	 long-lived	 cells	 that	 arise	 from	 a	 transient	hematopoietic	wave	of	erythro-myeloid	progenitors	(EMPs)	emerging	in	the	yolk	sac.	There	are	currently	three	possible	origins	for	ResMf:		
(i) EMPs	emerging	from	the	yolk	sac,	which	are	c-Myb-	independent,	and	lead	to	the	formation	of	yolk	sac	Mf49.		(ii) c-Myb-dependent,	arise	when	EMPs	seed	the	foetal	liver	where	they	generate	 foetal	monocytes	 that	 differentiate	 into	 primitive	Mf,	 and	seed	tissues,	giving	rise	to	microglia	in	the	brain49,50.		
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(iii) HSC-derived	monocytes,	emerging	from	the	foetal	liver,	contribute	to	the	long-lived	ResMf	pool	established	at	birth3.		
Nevertheless,	 it	 is	 still	 unclear,	 to	 which	 extent	 a	 self-renewing	 resident	population	of	Mf	is	maintained	through	life27.	
a) ResMf	Heterogeneity		
Mf	express	a	plethora	of	sensing	molecules,	as	well	as	scavenger,	hormone,	cytokine	 and	pattern	 recognition	 receptors,	 that	 allow	 them	 to	oversee	 tissue	microenvironments	and	act	as	sentries	 for	 infection	and	tissue	damage51.	This	sensing	capacity,	renders	them	plastic	and	remarkably	adapted	to	their	specific	local	 environments52,53.	 Moreover,	 ResMf	 can	 perform	 tissue	 specialised	functions	that	reflect	their	phenotypic	diversity,	further	suggesting	that	tissue-derived	signals	may	control	the	development	of	tissue-specific	phenotypes54,55.	These	 signals	 are	 largely	 unknown,	 with	 few	 exceptions,	 such	 as,	 the	 RANK	signalling	pathway	in	osteoclasts	(which	share	a	lineage	with	Mf)51,56.		
In	order	 to	 fully	 comprehend	ResMf	 heterogeneity	 it	 is	 imperative	 to	 first	understand	 their	 detailed	 transcriptional	 regulation36.	 It	 is	 increasingly	appreciated	that,	the	development	of	ResMf	phenotypes	is	controlled	by	distinct	transcriptional	 master	 regulators	 (Figure	 1.2)57.	 In	 several	 cases	 (described	below),	 the	 deletion	 of	 transcription	 factors	 that	 regulate	 tissue-specific	transcription	 programs,	 results	 in	 ablation	 of	 Mf	 subsets.	 For	 example,	 Spi-C	deficient	mice	exhibit	 a	defect	 in	 the	development	of	 red	pulp	Mf,	 that	 fail	 to	phagocytose	red	blood	cells	efficiently,	and	develop	an	 iron	overload	 localized	selectively,	that	drives	inflammation58.	Liver	X	receptor	(LXR)	deficient	mice	are	defective	 in	 the	 generation	 of	 marginal	 zone	 and	 metallophilic	 Mf,	 causing	abnormal	responses	to	blood-borne	antigens59.	Nuclear	factor	of	activated	T-cells	(NFATC1)	 deficient	 embryonic	 stem	 cells	 fail	 to	 differentiate	 into	osteoclasts60,whilst	 loss	of	Spi-1	proto-oncogene	(SFPI1)	(also	known	as	PU.1)	results	in	complete	depletion	of	CD11b+F4/80+	Mf,	including	those	derived	from	the	 yolk	 sac61.	 The	 loss	 of	 these	 cell	 populations,	 when	 specific	 transcription	
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factors	are	knocked-down,	makes	it	extremely	difficult	to	study	the	mechanisms	by	which	they	are	regulated.	 It	does	however	 indicate	that	these	transcription	factors	are	essential	for	ResMf	survival/development2.		
In	2012,	the	Immunological	Genome	Project	(ImmGen)	assessed	ResMf	gene	expression	in	several	mouse	organs	(lung,	liver,	peritoneum,	spleen	and	brain).	This	showed	a	significant	diversity	in	the	transcriptional	profiles	based	on	tissue	of	 origin,	 including	 transcripts	 that	 were	 universally	 associated	 with	 mature	ResMf.	In	particular,	TCEF3,	C/EBPα,	BACH1,	and	CREG-1	were	among	the	top	transcriptional	regulators	predicted	to	regulate	core	ResMf-associated	genes57.	The	 ImmGen	algorithms	predicted	additional	 transcription	 factor	mRNAs	 that	were	strongly	associated	with	single	Mf	populations,	such	as,	Spi-C	for	red	pulp	Mf,	confirming	a	regulation	that	was	already	known58,	and	GATA6	as	a	regulator	of	pResMf62.	They	also	found	that	pResMf	specific	genes	could	either	be	GATA6-dependent	or	-independent.	Accordingly,	tissue-specific	Mf	phenotypes	can	be	described	by	an	arrangement	of	 several	 transcription	 factors,	where	each	one	controls	distinct	transcription	functional	programs51.	This	work	underscored	the	shared	and	distinctive	characteristics	of	different	ResMf	and	provided	significant	evidence	to	distinguish	these	cells	from	dendritic	cells.			 	
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Figure	1.2	Regulation	of	Mf	development	and	function	in	peripheral	tissues.		The	 figure	 depicts	 how	 the	 expression	 of	 different	 transcription	 factors	 and	 the	 local	enviromnment	mould	 the	phenotype	 and	 function	of	ResMf.	 In	 the	brain,	 incoming	yolk	 sac-derived	cells	are	exposed	to	locally	expressed	transforming	growth	factor-β	(TGFβ),	which	drives	SMAD	phosphorylation	and	the	expression	of	genes	that	are	unique	to	microglia.	 In	the	 lungs,	proliferator-activated	receptor-γ	(PPARγ),	drives	differentiation	into	alveolar	Mf.	In	the	spleen,	SPIC	expression	controls	differentiation	and	maintenance	of	red	pulp	Mf.	In	the	marginal	zone	of	the	 spleen,	 liver	 X	 receptor-α	 (LXRα)	 is	 responsible	 for	Mf	maintenance.	 In	 the	 peritoneum,	GATA-binding	protein	6	(GATA6),	promotes	the	differentiation	of	resident	Mf.	In	the	epidermis	ID2	and	RUNX3	are	responsible	for	Langerhans	maintenance.	
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b) The	 peritoneal	 cavity:	 a	 model	 for	 tissue-specific	 transcriptional	
control		The	peritoneal	cavity	has	long	been	known	to	be	home	to	a	mix	of	immune	cells	 with	 important	 functions	 in	 monitoring	 visceral	 organs	 and	 related	mesothelium.	pResMf	are	characterised	by	a	high	expression	of	F4/80	and	share	a	 transcriptional	 similarities	 with	 other	 ResMf57.	 However,	 there	 is	 a	 less	abundant	 and	phenotypically	distinct	 group	of	 phagocytes	 also	present	 in	 the	peritoneum,	 characterized	 by	 lower	 F4/80	 and	 higher	MHCII	 expression63.	 In	2010,	 the	 murine	 7/4	 antigen	 was	 used	 to	 distinguish	 between	monocytes/monocyte-derived	cells	recently	recruited	to	a	site	and	the	resident	cells	 already	 present.	 Thus,	 the	 F4/80loMHCIIhi	 cells	 were	 characterised	 as	potential	Mo	derived	with	an	immature	phenotype64.		Recently,	Bain	et	al.	showed	that	the	peritoneal	cavity	is	initially	seeded	by	embryo-derived	Mf.	 After	 birth,	 these	 are	displaced	by	bone-marrow	derived	monocytes	 which	 widely	 phenocopy	 the	 embryo	 derived	 cells,	 displaying	extensive	proliferative	capacity42.	This	disproved	the	previous	view	that	in	situ	self-renewal	is	synonymous	with	embryonic	origin.	Moreover,	it	was	established	that	 F4/80loMHCIIhi	 peritoneal	Mf	 are	 intermediaries	 between	 newly	 arrived	monocytes	 and	 mature	 F4/80hi	 pResMf.	 This	 indicates	 that	 homoeostasis	 of	pResMf	occurs	as	a	combination	of	 self-maintenance	and	renewal	 from	bone-marrow-derived	monocytes	(BMDM)42.	
pResMf	 are	 among	 the	 best-studied	 ResMf	 in	 terms	 of	 cell	 biology,	development,	and	inflammatory	responses51,65,66.	They	play	essential	roles	in	the	control	 of	 infections	 and	 inflammatory	 pathologies	 when	 studied	 in	 model	systems67,68.	 Nonetheless,	 the	 tissue-specific	 function	 of	 pResMf	 as	 a	 cell	population	remains	unclear51.	
Since	 the	 ImmGen	 study	 was	 published,	 pResMf	 have	 been	 used	 as	 an	experimental	 model	 to	 investigate	 tissue-specific	 functions	 and	 external	 cues	that	control	their	specific	transcriptional	program.	Okabe	et	al.	performed	a	gene	expression	 analysis	 where	 the	 transcription	 factor	 GATA6	 was	 once	 more	
  
11 
identified	 as	 a	 regulator	 of	 a	 tissue-specific	 gene	 expression	 program	 in	pResMf51.	 	 Separately,	 a	microarray	 analysis	 performed	by	Prof.	 Phil	 Taylor’s	group	 (Cardiff	 University),	 on	 monocyte	 and	 Mf	 populations,	 with	 distinct	lineage	 origins63,	 including	 several	 isolated	 during	 peritoneal	 inflammation,	enabled	 the	 characterisation	 and	 comparison	 of	 transcriptional	 profiles	 of	pResMf	 and	 inflammatory	 Mf	 (InfMf)69	 (see	 Table	 1.1	 for	 full	 list	 of	 cells	analysed).	This	analysis	defined	the	ResMf-restricted	transcriptional	profile	and	pResMf-specific	probes	(cluster	15).	Among	these	probe	sets	was	the	zinc	finger	transcription	 factor	 GATA6,	 which	 was	 selectively	 expressed	 in	 pResMf,	CD11bhiF4/80hiMHCIIlo	 cells	 (Figure	 1.3).	Gata6	 was	 one	 of	 the	many	 targets	linked	 to	 proliferation	 and	 enriched	 in	 pResMf,	 and	 its	 deficiency	 led	 to	dysregulated	 proliferative	 renewal	 during	 homeostasis	 and	 in	 response	 to	inflammation69.		
Of	relevance,	Gata6	is	selectively	expressed	in	pResMf	and	alveolar	Mf57,	and	its	 expression	 is	 induced	 by	 tissue-derived	 retinoic	 acid	 (RA)51(Figure	 1.4A).	Additionally,	Okabe	et	al	 found	 that	when	 the	precursor	 for	RA	(vitamin	A)	 is	depleted	from	the	diet,	mice	present	a	decrease	in	Gata6	expression	and	pResMf	levels51	 (Figure	 1.4B).	 However,	 when	 stimulated	 with	 retinoic	 acid,	 pResMf	from	 vitamin	 A	 depleted	 mice	 exhibit	 an	 increased	 expression	 of	 Gata6	 and	pResMf-specific	genes70(Figure	1.4C).	Thus	showing	that	Gata6	expression	can	be	induced	by	vitamin	A	signalling	in	foetal	liver	derived	Mf51.	However,	this	has	not	yet	been	demonstrated	in	monocytes	or	other	Mfs	from	adult	mice,	including	Mo-derived	 Mf	 recruited	 to	 the	 peritoneum	 during	 thioglycollate-elicited	inflammation20.	This	indicates	that	the	heterogeneity	of	ResMf	might	be	due	to	a	transcriptional	 program	 triggered	 by	 tissue-derived	 signals.	 Moreover,	 in	 the	absence	of	GATA6,	the	CD11bhiF4/80hiMHCIIlo	Mf	population	in	the	peritoneum	is	 greatly	 contracted,	 but	 the	 CD11bloF4/80loMHCIIhi	 population	 that	 typically	lacks	Gata6	expression	remains	at	normal	 frequency,	 indicating	that	GATA6	 is	not	essential	for	pResMf	development	but	is	required	for	their	maintenance	in	the	peritoneum51,69,71.		
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In	the	next	section	I	will	introduce	the	GATA6	transcription	factor	in	greater	detail,	with	particular	focus	on	the	aims	of	this	thesis.		 	
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Table	 1.1	 Purification	 criteria	 for	 monocyte	 and	 Mf	 populations	 (Rosas,	 M.	 et	 al.	
Science	344,	645–648	(2014)).	
	
	
Figure	1.3	Selective	expression	of	Gata6	in	pResMfs.		Relative	expression	of	Gata6	in	monocyte	and	Mf	subsets	during	an	inflammatory	challenge	with	zymosan,	at	different	time	points.	Data	published	in	“Rosas,	M.	et	al.	The	transcription	factor	GATA6	links	tissue	Mf	phenotype	and	proliferative	renewal.	Science	344,	645–648	(2014)”.		 	
Cell type Zymosan Purification Criteria Description 
Bone marrow 
monocytes 0 hours Ly-6B
hi, Ly-6G- Naïve bone marrow monocytes 
Inflammatory 
macrophages 4 hours Ly-6B
hi, Ly-6G- Early recruited monocytes 
Inflammatory 
monocytes/ Mf 18 hours Ly-6B
+, Ly-6G- Late recruited monocytes/InfMf 
Mf 3 days F4/80+/hi, CD11b+/hi Mixed ResMf/InfMf 
Ly-6B+Mf 7 days F4/80hi, Ly-6B+ Ly-6B+ InfMf 
Ly-6B+Mf 7 days F4/80hi, Ly-6B- Predominantly ResMf 
ResMf 0 hours F4/80hi, CD11bhi Naïve ResMf 
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Figure	 1.4	 Tissue-specific	 signals	 control	 reversible	 program	 of	 localization	 and	
functional	polarisation	of	Mf.	A	–	under	normal	conditions,	Vitamin	A	acts	as	a	precursor	for	retinoic	acid.	Which	in	turn,	induces	Gata6	expression	in	pResMf;	B	–	Vitamin	A	depleted	mice	have	a	reduced	expression	of	
Gata6	and	number	of	pResMf	 to	when	compared	to	control	diet	 fed	mice;	C	-	Treatment	with	retinoic	acid	recovers	Gata6	expression.			 	
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1.1.2 GATA6	transcription	factor	The	GATA	family	is	a	group	of	evolutionarily	conserved	class	IV	zinc	finger	transcription	factors,	in	vertebrates,	that	comprises	six	members,	named	GATA1	to	-6,	characterised	by	their	ability	to	bind	the	DNA	motif	(G/A)GATA(A/T)72.	All	are	related	by	a	high	degree	of	amino	acid	sequence	homology	within	their	zinc	finger	 DNA-binding	 domains	 and	 protein-protein	 interaction	 with	 other	transcriptional	 partners	 and/or	 cofactors73.	 The	GATA	 family	 plays	 important	roles	in	lineage	specification	and	transdifferentiation,	and	was	the	first	family	of	transcription	 factors	 shown	 to	 be	 able	 to	 substitute	 for	 octamer-binding	transcription	 factor	 4	 (Oct4),	 a	 highly	 important	 pluripotency	 factor74,75,	 and	function	as	inducers	of	the	reprograming	process76.	GATA	proteins	are	classified	into	two	subgroups:	(i)	GATA1/2/3	are	expressed	in	hematopoietic	cell	lineages	and	 are	 crucial	 for	 the	 proliferation	 of	 hematopoietic	 stem	 cells	 and	differentiation	of	megakaryocytes	and	erythrocytes72,	(ii)	GATA4/5/6	are	largely	found	in	tissues	of	mesodermal	and	endodermal	origin,	such	as,	heart,	gut,	and	gonads	where	they	play	vital	roles	in	controlling	tissue-specific	gene	expression	76,77.	GATA6	is	particularly	associated	with	embryonic	mesoderm/	endoderm78,	as	well	as	mesoderm/	endoderm-derived	organs,	such	as	heart	and	gastrointestinal	tract79.	 The	Gata6	mRNA	encodes	 a	 single	 transcript	 containing	 two	potential	translational	initiation	sites.	Translation	at	the	first	site	encodes	a	long	GATA6	isoform	(L-type)	that	has	a	146	amino	acid	residue	extension	in	frame,	while	the	second	gives	 rise	 to	a	 shorter	 isoform	(S-type),	with	78	amino	acids80	 (Figure	1.5).	 GATA6	 binds	 to	 the	 consensus	 sequence	 (A/T/C)GAT(A/T)(A)	 in	 the	regulatory	 elements	 of	 target	 genes,	which	 is	 very	 similar	 to	 the	 GATA	motif	(A/T)GATA(A/G).	Additionally,	 GATA6	binds	 to	 a	 similar	 sequence	 containing	the	GATC	but	not	GATG,	indicating	that	it	displays	a	broader	sequence	specificity	for	DNA	binding	than	other	members	of	the	GATA	family81.	Even,	though	the	in	
vivo	roles	of	S-	and	L-type	GATA6	have	not	yet	been	determined,	in	vitro	reporter	gene	 assays	 have	 demonstrated	 that	 the	 molecular	 activity	 of	 S-type	 GATA6	should	 be	 lower	 than	 that	 of	 L-type	 GATA681,82.	 This	 difference	 has	 been	attributed	to	the	PEST	sequence,	found	in	L-type	GATA6	which	is	usually	linked	
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to	protein	degradation83.	However,	studies	show	that	the	PEST	sequence	in	Gata6	does	 not	 participate	 in	 protein	 degradation,	 but	 instead	 suggest	 a	 novel	mechanism	by	which	the	PEST	sequence	contributes	to	additional	DNA	binding	activity	and	the	stable	expression	of	L-type	GATA681.		The	Gata6	gene	is	positioned	upstream	of	other	transcription	factors,	and	its	disruption	 in	 mice	 causes	 embryonic	 lethality	 between	 E6.5	 and	 E7.582.	Moreover,	GATA6	is	suggested	be	a	vital	regulator	of	cell	cycle	progression84.	This	indicates	that	the	expression	level	and	modulation	of	GATA6	would	be	important	for	 the	 phenotype	 of	 cells.	 Confirmed	 by	 evidence	 that	 GATA6	 selectively	regulates	 pResMf	 transcripts	 (described	 in	 section	 1.1.1b)51,57,71.	 The	 cells	display	 a	 failure	 to	 proliferate	 in	 states	 of	 inflammation69	 and	 enhanced	apoptosis	in	the	resting	state71,	which	in	turn	results	in	phenotypical	changes	of	the	pResMf	population.	This	is	supported	by	the	reduction	of	pResMf	in	Gata6	deficient	mice85,	mentioned	in	section	1.1.1	b).		Importantly,	 the	microarray	 analysis	 performed	 in	2014	by	Rosas	et	 al.	 in	GATA6-deficient	pResMf	 identified	 significant	 changes	 in	73	 lipid	metabolism	related	 genes69.	 Among	 the	 first	 genes	 identified	 are	 Abca1	 (ATP-binding	cassette,	 sub-family	 A	 (ABC1),	 member	 1),	 Alox15	 (arachidonate	 15-lipoxygenase),	 Fabp4	 (fatty	 acid	 binding	 protein	 4)	 and	 Ldlr	 (Low	 Density	Lipoprotein	Receptor).				 	
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Figure	1.5	Schematic	representation	of	GATA-6.	L-type	GATA-6	has	an	extension	of	146	
amino	acid	residues	in	front	of	S-type	GATA-6.		Numericals	 indicate	 the	 amino	acid	 residue	numbers	 from	 the	 amino	 terminus	of	 L-type	GATA-6.	PEST	sequence	(Glu31–Cys46).		 	
1 31 46 147
L-type S-type
--R SR--EPSTPPSPISSSSSSC
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• ABCA1	 -	mediates	 cholesterol	 and	 phospholipids	 efflux	 to	 lipid-poor	apolipoproteins	(apo-A1	and	apoE),	and	mediates	the	transport	of	lipids	between	Golgi	and	cell	membrane86,87.	
• ALOX15	 -	 oxidises	 polyunsaturated	 fatty	 acids	 to	 their	 corresponding	hydroperoxy	derivatives,	lipoxygenases	are	key	players	in	regulation	of	the	cellular	redox	homeostasis,	which	is	an	important	element	in	gene	expression	regulation88.		
• FABP4	-	fatty	acid	uptake,	transport,	and	metabolism88.	
• LDLR	-	is	involved	in	receptor-mediated	endocytosis	of	specific	ligands,	apolipoproteins	E	and	B-10088.		
The	proteins	encoded	by	these	genes	participate	in	different	aspects	of	lipid	metabolism,	suggesting	that	alterations	in	their	levels	could	potentially	lead	to	a	significant	disruption	of	lipid	levels.	
Additionally,	when	 looking	 into	 pResMf-specific	 genes,	 from	 two	different	sources	(Gautier	et	al.	2012	and	Rosas	et	al.	2014),	 it	was	verified	that	GATA6	regulates	 the	 expression	 of	 lipid	 metabolism	 related	 genes	 that	 are	 also	responsible	for	pResMf	phenotype	(Figure	1.6).	This	indicated	that	Gata6	might	play	an	important	part	in	the	regulation	of	lipid	metabolism	in	pResMf69.	Thus,	it	is	important	to	determine	whether	its	deficiency	in	pResMf	has	a	significant	impact	in	lipid	levels.		 		 	
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Figure	1.6	Alterations	 in	peritoneal	 resident	selective	 transcripts	caused	by	GATA6	
deficiency.	Examination	of	 the	 genes	 identified	by	Gautier	et	 al.	 and	Rosas	et	 al.	 as	 pResMf-specific.	‘Volcano	 plot’	 of	 statistical	 significance	 against	 fold-change	 between	 Gata6-WT	 and	 -KOmye	pResMf,	 demonstrating	 the	 most	 significantly	 differentially	 expressed	 genes.	 Notably	 2-fold	down-regulated	 and	up-	 regulated	 genes	with	p-value<0.05	 are	 indicated;	 black-	 significantly	regulated	genes	identified	by	Gautier	et	al.	as	pResMf-specific;	blue-	significantly	regulated	genes	identified	by	Gautier	et	al.	and	confirmed	by	Rosas	et	al.	as	pResMf-specific	(cluster	15);	green-	significantly	regulated	genes	with	functions	related	to	lipid	metabolism.	A	total	of	67	genes	with	significantly	altered	expression	levels	were	found	(at	least	2-fold	altered	and	with	p-value	<	0.05),	with	8	genes	recognised	as	lipid	metabolism-related	genes.	Statistical	significance	was	assessed	using	 the	 empirical	 Baysian	 Benjamini-Hochberg	 corrected	 p-value	 corresponding	 with	 that	probeset.	Data	in	this	figure	was	obtained	from	Rosas	et	al.	2014.		 	
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1.2 Lipids	and	Mf	phenotype	
Lipids	are	important	players	in	the	regulation	of	cell	phenotype	and	innate	immune	responses.			Herein,	 my	 goal	 is	 to	 establish	 a	 comprehensive	 picture	 of	 how	 GATA6	regulates	lipid	metabolism	in	murine	peritoneal	Mf.	 I	will	use	novel	top-down	lipidomics	techniques,	for	detection	and	analysis.	I	will	first	characterise	the	lipid	pattern	of	Gata6-KOmye	versus	WT	pResMf	using	untargeted	mass	spectrometry	(described	 in	 detail	 in	 the	 next	 section).	 I	 will	 then	 validate	 any	 changes	 of	interest	 using	 targeted	 MS/MS.	 This	 data	 will	 then	 be	 combined	 with	transcriptomics	and	functional	data	to	create	a	picture	of	how	lipid	regulation	contributes	to	the	GATA6-dependent	pResMf	phenotype.	
Ultimately,	creating	predictive	models	by	developing/using	comprehensive	novel	lipidomics	methodologies	requires	a	degree	of	mechanistic	understanding	of	 lipid	 metabolism.	 Nevertheless,	 it	 is	 a	 major	 goal	 from	 a	 systems	 biology	standpoint	because	it	will	aid	in	the	understanding	of	Mf	biology	that,	in	turn,	may	result	in	therapeutic	outcomes.	 	
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1.2.1 Lipidomics	The	“omics”	revolution	has	afforded	an	 invaluable	understanding	of	genes,	mRNAs,	metabolites	 and	 proteins	 of	mammalian	 cells,	 biological	 systems	 and	disease89–91.	 Within	 this,	 lipidomics	 describes	 the	 analysis	 of	 the	 lipidome,	providing	 comprehensive	 description	 of	 all	 lipids	 in	 a	 sample.	 Lipidomics	involves	 systems-level	 identification	 and	 quantitation/comparison	 of	 lipid	molecular	species	92–96.	Several	technologies	have	been	used	to	identify,	quantify	and	understand	 the	molecular	structure	of	 lipids.	However,	 it	 is	 clear	 that	 the	advent	 of	 modern	 mass	 spectrometry	 (e.g.,	 electrospray	 ionization	 (ESI)	 and	matrix-assisted	 laser	 desorption/ionization)	 helped	 drive	 the	 progress	 of	lipidomics97.	This	made	possible	the	systematic	analysis	of	global	 lipidomes	of	mammalian	cells	and	tissues,	as	well	as	the	changes	in	the	lipids	associated	with	cellular	function	and	disease93,95,96,98.	The	 International	 Lipid	 Classification	 and	 the	 Nomenclature	 Committee,	together	 with	 the	 Lipid	 Metabolites	 and	 Pathways	 Strategy	 (LIPID	 MAPS)	Consortium,	described	eight	lipid	categories,	divided	into	classes	and	subclasses,	based	on	 their	 functional	 backbones	 and	biochemical	 principles99	 (Table	1.2).	Nevertheless,	a	comprehensive	database	of	lipid	structures	is	not	enough	to	fully	understand	their	multiple	biological	roles	in	cell	biology	and	pathology.	In	order	to	 clarify	 lipid	 functions	 and	 the	 enzymes	 related	 to	 their	 metabolism,	 it	 is	essential	to	organize	them	in	the	context	of	biological	pathways	and	derive	their	associations	 and	 interactions	 with	 enzymes	 and	 other	 molecules100.	 Lipid	metabolism	related	pathways	control	the	production	and	degradation	of	major	lipid	categories.	Even	though	some	of	these	pathways	have	been	studied	in	detail,	it	 is	 still	 unclear	 how	 they	 interact	 in	 homeostatic	 conditions101.	Nonetheless,	advances	 in	 mass	 spectrometry	 have	 made	 it	 possible	 to	 qualitatively	 and	quantitatively	 analyse	 lipids102–105.	 Currently,	 Liquid	 chromatography/mass	spectrometry	(LC-MS)	is	the	best	analytical	technique	to	separate,	identify,	and	quantitate	 lipids92,	 and	 together	 with	 transcriptional	 approaches,	 is	 helping	bridge	the	gap	in	our	knowledge	of	how	different	lipid	pathways	are	integrated.					
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Over	the	past	two	decades,	the	LIPID	MAPS	consortium	took	on	the	challenge	of	establishing	core	facilities	for	each	of	the	key	functional	classes	of	lipids,	in	an	effort	 to	 identify	 and	 quantify	 changes	 in	 metabolites	 by	 developing	 new	techniques	 for	 lipid	detection	and	analysis,	as	well	as	systematically	analysing	the	vast	amount	of	data	generated92.	The	consortium	initially	 focussed	on	Mf-like	cells,	due	to	the	fact	that	these	were	already	widely	studied	in	connection	to	lipid	metabolism.	However,	 their	analytical	strategy	comprised	the	use	of	gold	standard	 quantitative	 MRM	 methods,	 that	 measure	 only	 known	 lipids	 and	therefore	 do	 not	 provide	 information	 regarding	 lipids	 that	 have	 not	 been	previously	identified.		
The	study	of	the	lipidomic	response	of	the	murine	Mf	RAW	cell	line	to	Kdo2-lipid	 A	 was	 the	 first	 comprehensive	 systems-level	 quantitative	 analysis	 of	 a	mammalian	cell	 lipidome95.	This	 is	of	particular	relevance	because	 it	provides	information	on	the	lipid	species	I	can	expect	to	find	in	Mf-like	cells.	Additionally,	I	will	perform	a	lipidomic	comparison	between	RAW	and	pResMf	cells	which	will	help	establish	the	similarities/differences	among	the	two	lipidomes	under	basal	conditions.			 	
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Table	1.2	Lipid	Categories	and	classes106.	Lipid	Category	 Lipid	Class	Fatty	Acyls	[FA]	 Fatty	Acids	and	Conjugates	[FA01]	Octadecanoids	[FA02]	Eicosanoids	[FA03]	Docosanoids	[FA04]	Fatty	alcohols	[FA05]	Fatty	aldehydes	[FA06]	Fatty	esters	[FA07]	Fatty	amides	[FA08]	Fatty	nitriles	[FA09]	Fatty	ethers	[FA10]	Hydrocarbons	[FA11]	Oxygenated	hydrocarbons	[FA12]	Fatty	acyl	glycosides	[FA13]	Other	Fatty	Acyls	[FA00]	Glycerolipids	[GL]	 Monoradylglycerols	[GL01]	Diradylglycerols	[GL02]	Triradylglycerols	[GL03]	Glycosylmonoradylglycerols	[GL04]	Glycosyldiradylglycerols	[GL05]	Other	Glycerolipids	[GL00]	Glycerophospholipids	[GPL]	 Glycerophosphocholines	[GP01]	Glycerophosphoethanolamines	[GP02]	Glycerophosphoserines	[GP03]	Glycerophosphoglycerols	[GP04]	Glycerophosphoglycerophosphates	[GP05]	Glycerophosphoinositols	[GP06]	Glycerophosphoinositol	monophosphates	[GP07]	Glycerophosphoinositol	bisphosphates	[GP08]	Glycerophosphoinositol	trisphosphates	[GP09]	Glycerophosphates	[GP10]	Glyceropyrophosphates	[GP11]	Glycerophosphoglycerophosphoglycerols	[GP12]	CDP-Glycerols	[GP13]	Glycosylglycerophospholipids	[GP14]	Glycerophosphoinositolglycans	[GP15]	Glycerophosphonocholines	[GP16]	Glycerophosphonoethanolamines	[GP17]	Di-glycerol	tetraether	phospholipids	(caldarchaeols)	[GP18]	Glycerol-nonitol	tetraether	phospholipids	[GP19]	Oxidized	glycerophospholipids	[GP20]	Other	Glycerophospholipids	[GP00]	Sphingolipids	[SL]	 Sphingoid	bases	[SP01]	Ceramides	[SP02]	Phosphosphingolipids	[SP03]	Phosphonosphingolipids	[SP04]	Neutral	glycosphingolipids	[SP05]	Acidic	glycosphingolipids	[SP06]	Basic	glycosphingolipids	[SP07]	Amphoteric	glycosphingolipids	[SP08]	Arsenosphingolipids	[SP09]	Other	Sphingolipids	[SP00]	Sterol	Lipids	[ST]	 Sterols	[ST01]	Steroids	[ST02]	Secosteroids	[ST03]	
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Bile	acids	and	derivatives	[ST04]	Steroid	conjugates	[ST05]	Other	Sterol	lipids	[ST00]	Prenol	Lipids	[PR]	 Isoprenoids	[PR01]	Quinones	and	hydroquinones	[PR02]	Polyprenols	[PR03]	Hopanoids	[PR04]	Other	Prenol	lipids	[PR00]	Saccharolipids	[SL]	 Acylaminosugars	[SL01]	Acylaminosugar	glycans	[SL02]	Acyltrehaloses	[SL03]	Acyltrehalose	glycans	[SL04]	Other	acyl	sugars	[SL05]	Other	Saccharolipids	[SL00]	Polyketides	[PK]	 Linear	polyketides	[PK01]	Halogenated	acetogenins	[PK02]	Annonaceae	acetogenins	[PK03]	Macrolides	and	lactone	polyketides	[PK04]	Ansamycins	and	related	polyketides	[PK05]	Polyenes	[PK06]	Linear	tetracyclines	[PK07]	Angucyclines	[PK08]	Polyether	antibiotics	[PK09]	Aflatoxins	and	related	substances	[PK10]	Cytochalasins	[PK11]	Flavonoids	[PK12]	Aromatic	polyketides	[PK13]	Non-ribosomal	peptide/polyketide	hybrids	[PK14]	Phenolic	lipids	[PK15]	Other	Polyketides	[PK00]			
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1.2.2 Bioactive	lipids	The	concept	of	bioactive	lipids	originated	from	the	recognition	that	lipids	are	not	 only	 involved	 in	 cell	 membrane	 structure	 and	 energy	 storage107.	 Indeed,	some	lipids	have	a	plethora	of	roles,	such	as,	immune	regulation,	inflammation	and	maintenance	of	homeostasis108.	Accordingly,	variations	in	the	levels	of	such	lipids	 leads	 to	 pathophysiological	 consequences107.	 Studies	 over	 the	 past	 four	decades	have	defined	several	 lipid	families	as	key	inter-	and	intracellular	lipid	signalling	molecules109–112.		Bioactive	 lipids,	 can	 be	 divided	 into	 four	main	 families	 according	 to	 their	biochemical	 functions	 (Figure	 1.7),	 i.e.,	 classical	 eicosanoids,	 are	 primarily	involved	 in	 mediating	 or	 resolving	 inflammatory	 responses113,	 lyso-glycerophospholipids/SL	and	endocannabinoids	(eCBs),	are	generated	from	ω-6	or	ω-3	essential	polyunsaturated	fatty	acids	(PUFA)	precursors,	that	are	esterifed	into	membrane	 lipids	 and	 act	 by	binding	 to	 and	 activating	 specific	G	protein-coupled	receptors	(GPRs),	while	phospholipids	are	involved	in	metabolism	and	cell	 signalling108.	 Sphingolipids	 (SL),	 on	 the	 other	 hand,	 have	 key	 roles	 in	 cell	migration,	proliferation,	differentiation,	enhancing/dampening	immune	function	and	apoptosis114.		The	 first	 bioactive	 SL	 identified	 was	 sphingosine	 (So),	 which	 exerts	pleiotropic	effects	on	protein	kinases.	So	and	its	related	sphingoid	bases	regulate	endocytosis,	the	actin	cytoskeleton,	cell	cycle	and	apoptosis	(Figure	1.8)115.	Since	its	discovery,	even	more	emphasis	has	been	placed	on	other	bioactive	SL	such	as	ceramide	 (Cer)	 and	 sphingosine-1-phosphate	 (S1P).	 Cer	 mediates	 cell-stress	responses,	such	as	cell	senescence116	and	apoptosis117,	whilst	S1P	is	crucial	for	cell	survival,	cell	migration	and	inflammation118.	Other	additions	to	the	bioactive	SL	 family	 include	 ceramide-1-phosphate	 (C1P,	 has	 roles	 in	 inflammation	 and	vesicular	 trafficking119,120),	 and	 glucosylceramide	 (GlcCer)	 (involved	 in	 post-Golgi	trafficking	and	in	drug	resistance120).		Recently,	 SL	have	 emerged	as	 signalling	molecules	 that	 regulate	many	 cell	functions,	 including	 in	 the	 regulation	 of	 inflammatory	 responses114.	 In	 the	following	 Chapters	 I	 will	 perform	 a	 comprehensive	 analysis	 of	 the	 pResMf	
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lipidome,	 where	 I	 demonstrate	 that	 SL	 are	 significantly	 altered	 in	 GATA6	deficient	cells.	Thus,	due	to	their	relevance	in	Mf	metabolism,	and	to	this	project,	the	SL	category	will	be	further	introduced	in	the	next	section.		 	
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Figure	1.7	Metabolic	pathways	of	key	families	of	bioactive	lipids.		2-AG,	 2	 arachidonoylglycerol;	 AA,	 arachidonic	 acid;	AEA,	 arachidonoylethanolamide;	 C1P,	ceramide-1-phosphate;	CK,	ceramide	kinase;	COX,	cyclooxygenase;	DAGL,	diacylglycerol	lipase;	DHA,	docosahexaenoic	acid;	DPA,	docosapentaenoic	acid;	EPA,	eicosapentaenoic	acid;	FAAH,	fatty	acid	 amide	 hydrolase;	 HETEs,	 hydroxyeicosatetraenoic	 acids;	 LOX,	 lipoxygenase;	 LPA,	lysophosphatidic	 acid;	 LPC,	 lysophosphatidilcholine;	 LPI,	 lysophosphatidylinositol;	 LPSer,	lysophosphatidylserine;	LTs,	 leukotrienes;	LX,	 lipoxin;	Lyso-PLD,	lyso-phospholipase	D;	MAGL,	monoacylglycerol	 lipase;	MaR,	maresin;	NAPE-PLD,	N-arachidonoylphosphatidylethanolamide-specific	phospholipase	D;	Pal-CoASH,	palmitoyl	coenzyme	A;	PD,	protectin;	PDX,	protectin	DX;	PGs,	prostaglandins;	PLA2,	phospholipase	A2	;	Rv,	resolvin;	S1P,	sphingosine-1-phosphate;	SK,	sphingosine	kinase;	TXs,	thromboxanes.	(adapted	from	Chiurchiù,	V.,	Leuti,	A.	&	Maccarrone,	M.	Bioactive	lipids	and	chronic	inflammation:	Managing	the	fire	within.	Front.	Immunol.	9,	(2018)).		 	
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Figure	1.8	Roles	of	SL	in	biology.	The	figure	depicts	the	potential	participation	of	the	
bioactive	SL,	Cer,	So	and	sphingosine-1phosphate	(S1P)	in	cell	biological	responses.		Ceramide	 is	 at	 the	 centre	 of	 SL	 biology,	 it	 can	 be	 produced	 by	 the	 breakdown	 of	sphingomyelin	 by	 sphingomyelinases	 (SMases)	 or	 synthesized	 de	 novo	 by	 serine	 palmitoyl	transferase	 (SPT)	 and	Cer	 synthase.	 These	 reactions	 can	 be	 induced	 by	 diverse	 stimuli	 (grey	boxes).	So	and	S1P	can	be	generated	by	ceramidases	(CDases)	and	So	kinases	(SKs).	Which	in	turn	interact	 with	 specific	 protein	 targets	 such	 as	 phosphatases,	 kinases	 and	 G	 protein	 coupled	receptors	(S1P	receptors).	The	numbers	in	brackets	indicate	the	comparative	levels	of	these	SL.	CAPP,	 Cer	 activated	 Ser–Thr	 phosphatase;	 IGF,	 insulin-like	 growth	 factor;	 IL-1,	 interleukin-1;	oxLDL,	 oxidized	 low-density	 lipoprotein;	 PDGF;	 platelet-derived	 growth	 factor;	 PKC,	 protein	kinase	 C;	 PKH,	 PKB	 homologue;	 TNFa,	 tumour	 necrosis	 factor-a;	 VEGF,	 vascular	 endothelial	growth	factor;	YPK,	yeast	protein	kinase.	Adapted	from	Hannun,	Y.	A.	&	Obeid,	L.	M.	Principles	of	bioactive	lipid	signalling:	lessons	from	SL.	Nat.	Rev.	Mol.	Cell	Biol.	9,	139–150	(2008).		 	
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1.2.3 Sphingolipids	(SL)	SL	are	a	category	of	bioactive	lipids	where	the	defining	component	is	a	long-chain	or	sphingoid	base.	This	long	chain,	usually	a	So,	is	the	basic	element	and	the	simplest	 possible	 functional	 SL	 (Figure	 1.9).	 The	 first	 SL	 was	 described	 by	German	biochemist	J.	L.	W.	Thudichum	in	1884.	He	named	it	sphingomyelin	(SM)	after	 the	 sphinx	 in	 Greek	mythology	 (for	 the	many	 enigmas	 presented	 by	 its	chemical	structure),	isolated	from	myelin121.	However,	SM	is	not	restricted	to	the	brain,	it	is	one	of	the	most	abundant	SL122,	it	forms	a	concentration	gradient	along	the	secretory	pathway	with	the	highest	concentration	in	the	plasma	membrane	(where	it	accumulates	in	the	exoplasmic	leaflet)123.		Ceramides,	 which	 contain	 a	 fatty	 acid	 linked	 by	 an	 amide	 bond	 to	 the	sphingoid	 base,	 function	 both	 as	 a	 key	 players	 in	 cell	 signalling	 and	 as	 the	precursors	of	more	complex	SL	with	an	immense	range	of	functions	in	tissues124.	Complex	SL	may	be	formed	by	addition	of	head	groups	to	Cer	(Figure	1.9):	
• Sphingomyelins	 can	 have	 either	 a	 phosphocholine	 or	phosphoethanolamine	group	attached	with	an	ester	linkage	to	the	1-hydroxy	group	of	a	Cer.	
• Glycosphingolipids	(GSL)	are	Cer	molecules	with	one	or	more	sugar	residues	joined	with	a	glycosidic	linkage	at	the	1-hydroxyl	position.	
o Cerebrosides	 are	 Cer	 molecules	 with	 a	 single	 glucose	 or	galactose	at	the	1-hydroxy	position.	
§ Sulfatides	 are	 cerebrosides	 with	 a	 sulfate	 group	attached.	
o Gangliosides	have	at	least	three	sugars,	one	of	which	must	be	sialic	acid.	
Within	membranes,	SL	are	associated	with	cholesterol,	and	together	they	help	form	lipid	domains	such	as	caveolae	and	rafts125.	Their	metabolism	is	controlled	
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at	 multiple	 levels,	 through	 the	 regulation	 of	 enzyme	 expression,	 post-translational	alterations	and	allosteric	mechanisms126.	Some	of	these	are	specific	to	certain	cell	types,	either	regulating	which	SL	are	synthesized	during	different	stages	of	cell	development,	or	in	response	to	specific	signals.		At	least	five	different	long-chain	bases	are	known	in	mammalian	cells.	Over	20	species	of	 fatty	acid	(with	varying	chain	 lengths,	degrees	of	saturation	and	hydroxylation)	can	be	attached	to	the	sphingoid	base,	and	around	500	different	carbohydrate	structures	have	been	described	in	GSL.	Due	to	the	combinatorial	nature	of	SL	biosynthesis,	these	backbone,	headgroup,	and	acyl	chain	variations	give	 rise	 to	 tens	 of	 thousands	 of	 mammalian	 SL	 species	 and	 this	 complexity	demands	 highly	 organized	 and	 intricate	 mechanisms	 of	 regulation	 both	 at	cellular	 and	 biochemical	 levels,	 which	 still	 have	 not	 been	 fully	characterised124,127.		
1.2.4 The	interconnectivity	of	SL	metabolism	As	mentioned	 in	 the	 previous	 section,	 SL	metabolism	 can	 be	 regulated	 at	numerous	 stages,	 from	 control	 of	 enzyme	 expression,	 to	 post-translational	modifications	 and	 allosteric	 mechanisms124.	 Therefore,	 the	 coordinate	production	 and	 removal	 of	 SL	 species	 requires	 a	 delicate	 balance	between	de	
novo	biosynthesis,	turnover,	and	recycling128(Figure	1.10).				 	
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Figure	1.9	SL	classes.		SL	are	a	lipid	category,	where	the	lipid	backbone	is	a	sphingoid	base	(sphingosine	(So)	or	sphinganine	(Sa)).	Modifications	of	this	basic	structure	consist	in	the	addition	of	an	amide-linked	fatty	 acid	or	 sugar	 residues	 that	 lead	 to	 the	 formation	of	more	 complex	 lipid	 species	 such	as	ceramide	(Cer),	sphingomyelin	(SM),	cerebroside	or	ganglioside.	
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Figure	1.10	SL	metabolism	and	basic	structural	units	of	SL	biosynthesis.	Ceramide	 can	 be	 synthesized	 de	 novo	 from	 l-serine	 and	 palmitoyl-CoA	 (Endoplasmic	reticulum),	 through	 hydrolysis	 of	 sphingomyelin	 (plasma	 membrane	 and	Endosomes/lysosomes)	or	through	hydrolysis	of	GSL	and	sulfatides	(Golgi).	ASA:	Arylsulfatase	A;	 ASAH1:	 Acid	 ceramidase;	 SMPD1:	 Acid	 sphingomyelinase;	 Cer1P:	 Ceramide	 1-phosphate;	CERK:	 Ceramide	 kinase;	 CERS:	 Ceramide	 synthase;	 CERT:	 Ceramide	 transfer	 protein;	 CGT:	Ceramide	galactosyltransferase;	CST:	Cerebroside	sulfotransferase;	DEGS1/2:	Dihydroceramide	desaturase	1	or	2;	GCS:	Glucosylceramide	synthase;	KDS:	3-ketosphinganine	reductase;	LacCer	synthase:	 Lactosylceramide	 synthase;	 NSM:	 Neutral	 sphingomyelinase;	 S1P:	 Sphingosine	 1-phosphate;	 SGPL:	 S1P	 lyase;	 SGPP1/2:	 Sphingosine	 1-phosphate	 phosphatase	 1	 or	 2;	 SM:	Sphingomyelin;	SPHK1/2	:	Sphingosine	kinases	1	or	2;	SPT:	Serine	palmitoyltransferase.		 	
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a) De	novo	SL	biosynthesis		In	mammalian	cells,	the	SL	metabolic	pathway	(Figure	1.10)	begins	with	the	
de	 novo	 pathway,	 in	 the	 endoplasmic	 reticulum	 (ER)129,	 where	 four	 enzyme	groups	 cooperate	 to	 form	 Cer	 of	 different	 acyl	 chain	 lengths	 from	 non-SL	precursors130.	The	enzyme	complex	serine	palmitoyltransferase	(SPT)	catalyses	the	first	step	of	SL	biosynthesis,	the	condensation	of	L-serine	and	palmitoyl-CoA	to	 form	3-ketosphinganine	 (3KSa)128,131,132,	 followed	by	 the	 rapid	 reduction	of	3KSa	to	form	the	sphingoid	base	dihydrosphingosine	(a.k.a.	sphinganine)	(Sa)	a	by	3-ketosphinganine	reductase	(3KSR)129,133,134.	Then,	Sa	is	phosphorylated	by	So	kinase	 (SphK)	 to	 form	sphinganine	1-	phosphate	 (Sa1P)	or	 variable	 length	fatty	acid	chain	 is	 transferred	 to	 the	 free	amine	group	of	Sa	by	a	 family	of	 six	(dihydro)Cer	 synthases	 (CerS)135	 to	 form	 dihydroceramide	 (DH-Cer),	 each	 of	these	 enzymes	 utilizes	 fatty	 acyl-CoA	 substrates	 of	 relatively	 distinct	 chain	lengths	resulting	in	the	formation	of	distinct	DH-Cer	subspecies128,130.	After	 its	generation,	dihydroceramide	is	metabolised	by	a	desaturase	(DES1	and	2)	which	introduces	a	double	bond,	 thus	converting	DH-Cer	 into	Cer	with	various	chain	lengths.	These	Cers	will	then	act	as	precursors	to	complex	SL128,129,134,136,137.	This	 initial	 phase	 of	 SL	 synthesis	 is	 where	 complex	 SL	 emerge,	 through	differential	addition	of	acyl	chains	to	the	Sa/So	backbone	by	action	of	CerS124.	Cer	is	a	membrane	bound	molecule,	with	very	low	solubility	in	aqueous	environment,	its	hydrophobic	nature	prevents	spontaneous	relocation	through	the	cytosol138,	therefore	 it	 must	 travel	 from	 one	 membrane	 to	 another	 by	 facilitated	mechanisms118.	 The	 cell	 possesses	 two	 main	 mechanisms	 for	 Cer	 transport,	vesicular	transport	or	through	the	Cer	transfer	protein	(CERT)138.	Additionally,	Cer	 transported	 to	 the	 Golgi	 by	 CERT	 is	 preferentially	 incorporated	 into	 SM,	whilst	 vesicular	 transport	 is	 thought	 to	be	 the	major	pathway	 responsible	 for	conveying	Cer	to	the	cis-Golgi	for	GSL	synthesis123.	
b) Turnover	pathway	(DH)Cer	can	also	be	produced	by	the	breakdown	or	turnover	of	complex	SL	through	the	action	of	specific	hydrolases,	i.e.	sphingomyelinases,	glycohydrolases	and	 lipid	 phosphatases	 (Figure	 1.10)134.	 Furthermore,	 (DH)Cer	 can	 also	 be	
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metabolized	by	ceramidases	that	catalyse	the	hydrolysis	of	(DH)Cer	into	a	free	fatty	acid	and	a	sphingoid	base,	Sa	or	So134,139,140.	These	sphingoid	backbones,	can	then	be	recycled	via	reacylation	for	entry	back	into	the	SL	pathway134,139	or	it	can	be	 phosphorylated	 by	 SphK,	 producing	 Sa1P	 or	 So1P134,141.	 Conversely,	Sa1P/So1P	 can	 be	 de-phosphorilated	 through	 the	 action	 of	 phosphatases	 or	degraded	 by	 sphingosine	 1-phosphate	 lyase	 (lyase)	 to	 form	 ethanolamine	phosphate	and	hexadec(an/en)al134,142,	which	can	then	be	reduced	to	palmitate	and	re-incorporated	into	SL	biosynthesis134.	SL	biochemical	interconnections	allow	cells	to	organise	cellular	responses	by	regulating	 SL	 interconversions.	 For	 instance,	 activation	 of	 SMase	 leads	 to	 the	conversion	of	SM	into	Cer.	Conversely,	the	subsequent	action	of	ceramidase,	Cer	kinase,	 SM	 synthase	 or	GlcCer	 synthase	 converts	 the	Cer	 signal	 to	 one	 that	 is	mediated	by	either	So,	Cer1P,	DAG	or	GlcCer	(Figure	1.11)118.	In	the	majority	of	cell	types,	the	concentration	of	SM	is	one	order	of	magnitude	higher	than	that	of	Cer,	hence,	even	the	smallest	changes	in	SM	may	result	in	significant	changes	in	Cer	 amounts.	 Additionally,	 more	 than	 50	 distinct	 molecular	 species	 can	 be	classified	 as	 Cer,	 and	 they	may	 have	 their	 own	 separate	metabolic	 networks,	resulting	in	an	extremely	high	level	of	complexity	in	SL	signalling130.			 	
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Figure	1.11	SL	metabolic	pathway.		Ceramide	is	at	the	core	of	SL	metabolism,	it	can	be	synthesised	by	the	action	of	desaturases,	and	then	converted	into	other	bioactive	lipid	species.	Herein,	only	a	pathway	for	a	generic	Cer	is	depicted.	CDase,	 ceramidase;	CK,	Cer	kinase;	DAG,	diacylglycerol;	GCase,	 glucosyl	 ceramidase;	GCS,	 glucosylceramide	 synthase;	 PC,	 phosphatidylcholine;	 SK,	 sphingosine	 kinase;	 SMase,	sphingomyelinase;	SMS,	sphingomyelin	synthase;	SPPase,	sphingosine	phosphate	phosphatase;	SPT,	serine	palmitoyl	transferase.			
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1.2.6 Liquid	Chromatography–Mass	Spectrometry	The	 analysis	 of	 lipids	 advanced	 greatly,	when	 liquid	 chromatography	 (LC)	was	 combined	with	mass	 spectrometry	 (MS)143.	MS	 is	 an	 important	analytical	technique	that	measures	the	mass-to-charge	ratio	(m/z)	of	ions	to	identify	and	quantify	molecules	in	samples	with	various	degrees	of	complexity.	However,	it	was	 the	 advances	 in	MS,	 observed	 in	 the	past	 few	decades	 that	propelled	 the	progress	 in	 the	 field	of	 lipid	 research,	 in	particular,	 soft	 ionization	 techniques	such	as	ESI	and	MALDI.	A	mass	 spectrometer	 usually	 consists	 of	 an	 ion	 source,	 a	mass	 analyser,	 a	detector	 and	 a	 data	 processing	 system	 (Figure	 1.12).	 The	 current	 variety	 of	combinations	of	ionisation,	mass	analysing,	and	detection	methods,	make	MS	the	technique	 of	 choice	 for	 lipid	 analysis144.	 The	 ability	 to	 ionise	 non-volatile	molecules	and	allow	their	entry	into	analysers	has	revolutionised	lipid	research,	through	enabling	the	determination	of	molecular	weight,	elemental	composition,	abundance,	and	structure	97.	Though	 there	 are	 several	 instrument	 configurations	 available,	 MS	 system	operation	can	be	organized	into	three	main	divisions	(Figure	1.12):		(1)	generation	of	ions;		(2)	separation	of	ions	based	on	mass	and	charge	in	a	mass	analyser;		(3)	detection	of	ions	and	instrument	output.		Depending	 upon	 the	 type	 of	 ionization	 used,	 these	 steps	 fully	 or	 partially	occur	 under	 vacuum	 pressure	 to	 drive	 ion	 movement	 forward	 through	 the	instrument145.	The	 ionisation	 method	 determines	 the	 classes	 of	 substances	 that	 can	 be	analysed144.	For	an	MS-based	analysis,	molecules	must	be	ionized,	or	electrically	charged,	 to	 produce	 individual	 ions.	 MS	 instruments	 analyse	 molecules	 by	relating	the	mass	of	each	molecule	to	its	charge.	This	identifying	characteristic	is	specific	to	each	molecule	and	is	referred	to	as	m/z.	Thus,	if	the	molecule	has	a	
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single	charge	(z	=	1),	 the	m/z	 ratio	will	be	equal	 to	 the	molecular	mass	of	 the	ionized	species146.		 	
  
38 
				
	
Figure	1.12	Basic	components	of	a	triple	quadrupole	Mass	Spectrometer.		Sample	 inlet	 –	 introduction	of	 samples	 in	 the	 ion	 source,	while	maintaining	high	vacuum	requirements;	Ion	source	–	production	of	gaseous	ions	from	the	substance	being	studied;	Mass	analyser	–	for	resolving	the	ions	into	their	characteristics	mass	components	according	to	their	
m/z.;	Detector	–	detection	of	ions	and	recording	the	relative	abundance	of	each	of	the	resolved	species.;	Data	system	–	data	analysis	and	interpretation.		 	
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The	combination	of	mass	analyser	and	detector	determines	the	quality	and	reliability	of	analysis144.	Mass	analysers	can	be	divided	into	several	generic	types,	quadrupole,	magnetic	sector,	ion	trap,	time-of-flight	(TOF),	or	Fourier	transform	(FT).	 Depending	 on	 the	 combination,	 they	 can	 be	 used	 for	 analysis	 of	 both	analytes	 and	 their	 fragments147;	 e.g.	 triple	 quadrupole	 and	 quadrupole/TOF	hybrids.	Furthermore,	the	same	analyser	can	perform	both	MS	and	MSn(multi-stage	mass	spectrometry)	144.		The	analytical	power	of	a	mass	spectrometer	lies	in	its	resolution,	its	ability	to	 discern	 one	 molecular	 mass	 from	 another148.	 High-resolution	 instruments	possess	 increased	mass	 accuracy.	 Defined	 as	 the	mass	 difference	 that	 can	 be	detected	 by	 the	 analyser	 divided	 by	 the	 observed,	 or	 true	mass,	 in	 parts	 per	million149.		
Equation	1.1	!"##	"%%&'"%(	(∆++,) = /'&0	,"## − 23#0'405	,"##23#0'405	,"## × 109		Due	 to	 the	 great	 structural	 diversity	 in	 lipids,	 there	 is	 no	 single	methodological	 platform	 currently	 available	 that	 can	 perform	 the	 full	characterisation	of	the	lipidome.	Instead,	there	are	several	strategies,	tailored	to	different	 lipid	 categories/classes.	 Thus,	 it	 is	 necessary	 to	 combine	complementary	approaches	 in	order	 to	achieve	high	quality	datasets.	The	two	approaches	used	 in	 the	 course	 of	 this	 project	will	 be	 further	discussed	 in	 the	following	sections.		
a) Untargeted	LC-MS	-	Orbitrap	Elite	An	untargeted	MS	 approach	 uses	 ‘global	 profiling’	methods	 to	 detect	 lipid	species,	 i.e.,	 MS	 scans	 are	 performed	 over	 a	 wide	 m/z	 value,	 allowing	 the	detection	of	lipids	purely	based	on	their	m/z.	Herein,	I	opted	for	an	untargeted	LC-MS	approach	using	a	high-resolution	(up	to	240	000	at	m/z	400	for	a	768	ms	transient144)	mass	spectrometer,	belonging	to	the	FT	family,	the	Orbitrap	Elite.	This	instrument	measures	a	frequency	that	is	then	converted	to	m/z	via	a	Fourier	
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transform150.	The	Orbitrap	Elite	has	the	ability	to	differentiate	ions	with	closely	located	 m/z151.	 However,	 despite	 this	 high	 accuracy,	 with	 this	 untargeted	approach	I	can	only	provide	putative	annotations	for	the	ions.	No	distinction	can	be	made	between	structurally	different	lipids	of	the	same	mass	(isobars),	unless	LC-MS	is	used,	supplying	retention	time	information.	In	my	experiments,	I	will	use	LC-MS	on	an	Orbitrap	platform	and	then	analyse	my	data	using	multivariate	data	 analysis,	 in	 order	 to	 determine	which	 lipid	 categories	 should	 be	 further	studied	using	targeted	approaches.		
b) Targeted	lipidomics	–	Tandem	MS	In	order	to	perform	a	targeted	lipidomic	analysis	it	is	necessary	to	use	a	mass	spectrometer	possessing	multiple	mass	analysers152.	Herein	I	will	 focus	on	the	instrument	 selected	 for	 this	 project,	 a	 triple	 quadrupole	 mass	 spectrometer	(QTrap	6500).	 This	 instrument	 can	 be	 used	 in	 single	 scan	 MS	 to	 provide	information	about	precursor	masses	(similar	to	untargeted	analysis),	however	it	is	more	 commonly	 used	 in	 tandem	 scan	mode	 (MS/MS),	 providing	 additional	information	regarding	specific	lipid	species153.	This	mode	is	more	selective	and	sensitive	 because	 it	 uses	 specific	 parent-to-daughter	 transitions.	 Additionally,	when	 coupled	 with	 LC	 it	 also	 supplies	 retention	 time	 information,	 that	 can	further	be	used	to	complement	the	lipid	identification.	The	main	MS/MS	modes	are	 described	 in	 Figure	 1.13,	 product-ion	 analysis,	 neutral-loss	 scan	 (NLS),	precursor-ion	 scan	 (PIS),	 and	 selected	 reaction	 monitoring	 (SRM)154.	 SRM	 is	monitoring	 only	 a	 single	 fixed	 mass	 window.	 When	 multiple	 transitions	 are	monitored	during	a	chromatographic	run,	the	data	acquisition	method	is	called	multiple-reaction	monitoring	 (MRM).	 Thus,	MRM	 is	 the	 application	 of	 SRM	 to	multiple	 product	 ions	 from	one	 or	more	precursor	 ions,	which	 allows	 for	 the	quantitation	of	multiple	peaks	from	a	single	chromatographic	run	allowing	for	simultaneous	 detection	 and	 quantitation	 of	 many	 analytes	 (multiplexing)146.	When	a	precursor	ion	enters	the	MS,	it	is	selected	in	Q1	by	its	m/z	ratio	and	it	is	transferred	 to	 the	 collision	 cell	 (Q2)	 where	 it	 is	 fragmented.	 The	 fragments	obtained	 are	monitored	 in	Q3	 and	 the	 spectrum	 corresponding	 to	 the	m/z	 of	interest	is	recorded153.	Ions	with	different	m/z	ratios	will	be	filtered	out	and	will	not	reach	the	detector.	
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This	 type	of	 scan	 is	often	used	 for	 identification	and	quantitation	of	 lipids,	thus	providing	complementary	information,	to	that	obtained	using	an	untargeted	approach.	 Thus,	 the	 combination	 of	 the	 two	methodologies	 facilitates	 a	more	powerful	lipidomic	analysis.			 	
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Figure	 1.13	 Tandem	 mass	 spectrometry	 main	 scan	 modes	 of	 analysis	 in	 a	 triple	
quadrupole	mass	spectrometer.		CID	 stands	 for	 Collision	 induced	 dissociation,	 and	 symbolism	 for	 representation	 of	 the	various	scan	modes.	(A)	Product	ion	scan:	select	Q1	precursor	ion	and	scan	Q3	product	ion.	(B)	Neutral	loss	scan:	scan	all	ions	in	Q1	and	select	ions	with	neutral	loss	in	Q3.	(C)	Precursor	ion	scan:	 scan	 precursor	 ion	 in	 Q1	 and	 select	 certain	 fragment	 ion	 in	 Q3,	 all	 collision	 induced	dissociation	carried	out	in	Q2.	(D)	Selected	reaction	monitoring:	select	precursor	ion	in	Q1	and	monitor	one	or	more	fragment	ions	in	Q3.			 	
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1.3 General	Hypothesis	
As	described	earlier,	prior	to	this	study,	GATA6	was	recognised	as	a	master	regulator	of	pResMf	phenotype	and	the	expression	of	lipid	metabolism-related	genes	was	found	to	be	significantly	altered	in	murine	GATA6	deficient	pResMf.		
Herein	I	proposed	that,	myeloid	deficiency	of	GATA6	(Gata6-KOmye	mice)	is	associated	with	significant	changes	in	lipid	metabolism,	at	a	transcriptional	and	molecular	level.		In	order	to	prove	my	hypothesis,	it	is	crucial	to	undertake	a	detailed	analysis	of	lipid	metabolism	in	GATA6	deficient	pResMf.	This	will	include	studies	on	the	following:	
• Generation	 of	 appropriate	 targeted/untargeted	 mass	 spectrometry	workflows	
• Canonical	pathways	
• Gene	networks	
• Global	lipid	levels	
• Significantly	altered	lipid	categories	
• Integration	of	transcriptional	and	lipidomics	data	
• Quantitation	of	significantly	altered	lipids	
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Chapter	2 Materials	and	Methods	
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2.1 Buffers,	solutions	and	Media	
Unless	 otherwise	 stated,	 chemicals	 were	 from	 Merck	 chemicals	 Ltd	(Southampton,	UK)	or	Thermo	Fisher	Scientific	Ltd	 (Newport,	UK),	 and	 tissue	culture	 reagents	 were	 purchased	 from	 the	 Gibco	 Life	 Technologies	 (Dublin,	Ireland).	D10	DMEM	containing	4.5	g/L	L-glucose,	10	%	(v/v)	heat	 inactivated	 foetal	calf	serum	 (FCS;	 Invitrogen),	 250	units	 penicillin/streptomycin,	 0.26	mg/mL	 L-Glutamine,	and	97	mg/mL	sodium	pyruvate.	R10	RPMI	 containing	 4.5	g/L	 L-glucose,	 10	%	 (v/v)	 FCS,	 250	units	penicillin/streptomycin,	 0.26	mg/mL	 L-Glutamine,	 and	 97	mg/mL	 sodium	pyruvate.	LB	broth	20	g/L	of	LB	low	salt	broth	(Melford)	in	ddH2O.	LB	Agar	LB	broth,	15	%	(w/v)	agar	(Oxoid).	Ampicillin	solution	100	mg/mL	 ampicillin	 sodium	 salt	 (Melford)	 in	 ddH2O,	 sterilised	 through	0.22	µm	filter.	FACS	block	0.5	%	BSA	(w/v),	5	mM	EDTA,	5	%	rabbit	serum	(Merk),	4	ug/	mL	2.4G2	(BD	Pharmingen,	Catalog	No.	553142)	in	PBS.	FACS	buffer	2	%	(v/v)	FCS,	0.0	5%	(w/v)	sodium	azide	in	PBS.	Saponin	buffer	2	%	 (v/v)	 FCS,	 0.05	%	 (w/v)	 sodium	 azide,	 0.5	%	 (w/v)	 saponin	 (Acros	Organics)	in	PBS.	Mammalian	lysis	buffer	100	mM	TRIS	pH	8.5,	200	mM	NaCl,	5	mM	EDTA,	0.2	%	SDS.	
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2.2 Animal	studies	
2.2.1 Animals	All	 animal	 experiments	 were	 performed	 in	 accordance	 with	 the	 United	Kingdom	Home	Office	Animal	(Scientific	procedures)	act	of	1986.	C57BL/6J	male	mice	from	Charles	River	(UK),	were	given	free	access	to	water	and	standard	chow	and	 housed	 in	 conventional	 cages	 (12	h	 light/dark	 cycle)	 in	 accordance	 with	institutional	guidelines	at	Cardiff	University	and	10-12-week-old	C57BL/6	mice	were	sacrificed	using	a	schedule	one	method	(slow	rising	concentration	of	CO2,	and	death	was	confirmed	by	cervical	dislocation).	Mice	with	a	myeloid	deficiency	of	GATA6	(Gata6-KOmye	mice)	and	WT	mice	with	the	same	genetic	background	were	generated	in	Prof.	Phil	Taylor’s	lab,	as	previously	described69.	Briefly,		conditional	KO	Gata6tm2.1Sad/J	mice	were	crossed	with	LysozymeM	(Lyz2)	Cre-recombinase	knockin	mice	to	generate	mice	with	a	myeloid	deficiency	of	GATA669.		
2.2.2 Genotyping	A	mouse	 ear	 biopsy	 was	 placed	 into	 a	 1.5	mL	 Eppendorf	 tube	 containing	50	µL	lysis	buffer	(100	mM	Tris	(pH	8.5),	5	mM	ethylenediaminetetraacetic	acid	(EDTA),	0.2	%	sodium	dodecylsulphate	(SDS)	(w/v),	200	mM	NaCl,	100	μg/	mL	proteinase	K	–	all	from	Sigma).	The	tube	was	then	incubated	overnight	at	52	°C.	The	reaction	was	terminated	by	incubating	the	samples	at	72	°C	for	15	min.	After	cooling	down,	400	µL	of	nuclease-free	water	was	added	to	each	tube	to	reduce	the	concentration	of	SDS,	vortexed	for	5	sec	and	left	to	settle.	These	samples	then	underwent	polymerase	chain	reaction	(PCR)	at	1	µL	DNA	per	20	µL	reaction.	The	primers	used	are	listed	below.	Forward:	CAGGCATGCTTTCTCTAGTCAG	Reverse:	TGATCCTGGCAATTTCGGCT	GoTaq	 green	 polymerase	 (Promega,	 Southampton,	 UK)	 was	 used	 for	conventional	PCR	reaction	mixes,	and	the	reaction	mix	was	as	follows:	1×	Buffer	
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(MgCl2	final	made	up	to	2.5	mM),	250	–	500	nM	primers,	200	nM	of	each	dNTP,	0.05	Units/μl	GoTaq	DNA	polymerase.	The	final	volume	was	20	μl	per	reaction.	The	samples	were	inserted	in	a	Mastercycler®	nexus	(Eppendorf	Ltd,	Stevenage,	UK)	and	run	according	to	the	following	program:	94°C		-	3min		94°C		-	20	sec		64°C			-	30	sec	*	Reduce	by	-0.5°C	every	cycle		72°C			-	35	sec		Repeat	2-	4	for	12	cycles		94°C			-	20	sec		58°C	–	30	sec		72°C	–	35	sec		Repeat	6	–	8	for	25	cycles		72°C	–	2	min		4°C	¥		 	
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2.2.3 Peritoneal	lavage	Mice	 were	 killed	 by	 asphyxiation	 using	 CO2,	 and	 death	 confirmed	 using	cervical	 dislocation.	 Cadavers	 were	 placed	 on	 their	 back	 and	 sprayed	 with	ethanol.	The	outer	skin	of	the	peritoneum	was	cut	using	scissors	and	forceps	and	gently	 pulled	 back	 to	 expose	 the	 inner	 skin	 lining	 the	 peritoneal	 cavity.	 5	mL	lavage	solution	(PBS	+	5mM	EDTA)	was	injected	into	the	peritoneal	cavity	using	a	 21	G	 needle,	 being	 careful	 not	 to	 puncture	 any	 organs.	 After	 injection,	 the	peritoneal	 cavity	 was	 massaged	 to	 dislodge	 any	 attached	 cells	 into	 the	 PBS	solution,	the	lavage	solution	was	slowly	drawn	back	up	into	the	syringe,	avoiding	the	intestines	and	fat.	The	needle	was	then	removed,	lavage	fluid	was	transferred	to	a	15	mL	falcon	tube	and	place	on	ice	until	further	processing.	
2.3 Isolation	of	pResMf	
2.3.1 Gata6-WT	and	-KOmye	pResMf	phenotyping	and	isolation		
Peritoneal	 cells	 were	 recovered	 by	 lavage.	 Individual	 lavages	 were	phenotyped	using	F4/80-APC	(Bio-Rad,	Kidlington,	UK;	MCA497APC)	and	CD73-ef450	(eBioscience,	UK;	48-0731-80)	and	analysed	by	 flow	cytometry.	For	cell	purifications,	 lavages	 from	 phenotyped	 mice	 were	 pooled	 and	 stained	 with	F4/80-APC,	 CD73-ef450	 (eBioscience,	 UK)	 and	 MHCII-	 PercpCy5.5	 (BD	biosciences,	M5/114.15.2).	Cells	were	sorted	on	a	FACSAria	III	(BD	biosciences,	Berkshire,	 UK)	 for	 single	 events	 (via	 pulse	 width	 or	 FSCheight	 vs	 FSCarea
	
respectively)	with	the	defined	flow-cytometric	phenotype	(Figure	2.1,	Table	2.3).	Cell	purities	were	verified	by	flow	cytometry.		
a) Surface	staining	for	phenotyping	Lavages	 (50	 µL)	 were	 plated	 out	 onto	 a	 V-bottom	 96	 well	 plate	 (Fisher	Scientific,	Loughborough,	UK).	Cells	were	incubated	at	room	temperature	for	10	min	with	50	µL	anti-CD16/32	(BD	biosciences,	Berkshire,	UK)	diluted	1:500	in	FACS	block	to	block	Fc	receptors.	This	was	followed	by	cell	surface	staining	with	100	µL	ABmix1	diluted	in	MACS	buffer	and	incubated	at	4	°C	for	10	min.	ABmix1	is	described	in	Table	2.1.		
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b) Surface	 staining	 for	 isolation	 of	 Gata6-WT	 and	 -KOmye	 pResMf	 by	
FACS	Pooled	 samples	 were	 transferred	 to	 a	 15	mL	 falcon	 tube.	 Cells	 were	 then	washed	with	FACS	buffer	and	 incubated	at	4	°C	 for	40	min	with	anti-CD16/32	(BD	 biosciences,	 Berkshire,	 UK)	 diluted	 1:500	 in	 FACS	 block	 to	 block	 Fc	receptors.	 This	 was	 followed	 by	 cell	 surface	 staining	 with	 ABmix2	 diluted	 in	MACS	buffer	and	incubating	at	4	°C	for	40	minutes.	ABmix2	antibodies	are	listed	in	Table	2.2.			 	
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Table	2.1	Antibodies	used	in	flow	cytometry	for	phenotyping	of	Gata6-WT	and	-KOmye	
pResMf	(ABmix1).	
		
Table	 2.2	 Antibodies	 used	 in	 flow	 cytometry	 for	 isolation	 of	Gata6-WT	 and	 -KOmye	
pResMf	(ABmix2).	
			 	
Antibody Conjugate Clone Company Dilution Cat. number
F4/80 APC Cl:A3-1 Serotec 1:10 MCA497APC
CD73 ef450 eBioTY/11.8 eBioscience 1:15 M5/114.15.2
Antibody Conjugate Clone Company Dilution Cat.	numberF4/80 APC Cl:A3-1 Serotec 1:200 MCA497APCCD73 ef450 eBioTY/11.8 eBioscience 1:300 48-0731-80MHCII PercpCy5.5 M5/114 BD	biosciences 1:400 M5/114.15.2
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c) Phenotyping	and	purification	of	Gata6-WT	and	-KOmye	pResMf	
				
			
	
	
	
	
Table	2.3	Summary	of	Gata6-WT	and	-KOmye	pResMf	used	for	LC-MS.	
		
	 	
Cell	Type Abrev. Purification	criteria
F4/80highMHCIIlowCD73highF4/80highMHCIIlowCD73low
Peritoneal	tissue-resident	macrophage	wild	type pResMf-WT
Peritoneal	tissue-resident	macrophage	Gata6-KOmye pResMf-Gata6-KOmye
41.7% 
21.8% 
1.8% 
CD73	
WT	 KO	
Figure	2.1	Flow-cytometric	analysis	of	the	pResf-Gata6-WT/KOmye	phenotyping.		Data	are	representative	of	one	of	two	similar	experiments	with	1	female	11	week-old,	C57BL/6	mice.		
	
F4/80	
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2.4 Cell	culture	
2.4.1 Culture	of	adherent	cells	RAW	264.7	 cells	 and	 human	 embryonic	 kidney	 (HEK293T)	 cells	 were	cultured	in	D10	containing	1	%	Penicillin-Streptomycin	(GE	Healthcare,	Cardiff,	UK))	 at	 37	°C	 and	 5	%	 CO2.	 Cells	 were	 thawed,	 added	 to	 9	mL	 of	 D10	 and	centrifuged	at	400	g	for	5	min	at	4	°C.	The	supernatant	was	discarded,	and	the	cells	resuspended	in	1	mL	of	D10.	The	cells	were	added	with	50	mL	of	D10	into	a	T175	cell	culture	flask.	Once	a	confluency	was	of	80	-	90	%	was	reached,	the	D10	was	removed	and	the	 cells	 washed	 twice	 using	 PBS;	 10	mL	 trypsin	 was	 added,	 and	 the	 cells	incubated	at	37	°C	for	3	-	5	min.	In	order	to	stop	the	reaction,	D10	was	added	and	the	cell	suspension	transferred	into	a	50	mL	falcon	tube	and	centrifuged	at	400	g	for	5	min	at	4	°C.	The	supernatant	was	discarded,	and	the	cells	resuspended	in	10	mL	of	D10.	Cells	were	diluted	into	a	new	flask	at	required	ratios	and	incubated	at	37	°C	and	5	%	CO2.	
2.4.2 Culture	of	non-adherent	cells	Jurkat	cells	were	cultured	in	R10	containing	1	%	Penicillin-Streptomycin	(GE	Healthcare,	Cardiff,	UK)	at	37	°C	and	5	%	CO2.	Cells	were	thawed,	added	to	9	mL	of	R10	and	centrifuged	at	400	g	for	5	min	at	4	°C.	The	supernatant	was	discarded,	and	the	cells	resuspended	in	1	mL	of	R10.	The	cells	were	added	to	50	mL	of	R10	into	a	T175	cell	culture	flask.	Once	 a	 confluency	 of	 80	-	90	 %	 was	 reached,	 the	 cell	 suspension	 was	transferred	into	a	50	mL	falcon	tube	and	centrifuged	at	400	g	for	5	min	at	4	°C.	The	supernatant	was	discarded,	and	the	cells	resuspended	in	10	mL	of	R10.	Cells	were	diluted	into	a	new	flask	at	required	ratios	and	incubated	at	37	°C	and	5	%	CO2.	
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2.5 Molecular	biology		
2.5.1 Agarose	gel	electrophoresis	(AGE)	Agarose	 was	 dissolved	 in	 0.5	x	Tris-EDTA	 (TBE)	 solution	 (1	–	2	%	 (w/v)	agarose)	by	heating	the	solution	in	a	microwave	until	boiling.	Once	the	gel	had	cooled	sufficiently,	ethidium	bromide	(100	ng/mL)	was	mixed	into	the	solution,	which	was	poured	into	a	gel	caster	with	well	moulds.	Once	the	gel	was	set,	it	was	placed	in	a	gel	tank	filled	with	0.5	x	TBE,	and	the	samples	(with	DNA	loading	dye	(Promega))	and	DNA	ladders	(100	bp	(base	pair)	(Promega))	were	loaded	into	the	wells.	The	gel	was	run	at	100	volts	for	30	minutes	and	viewed	under	UV	light	source.	
2.5.2 In-fusion	cloning	
a) Primer	design	Primers	 used	 for	 in-fusion	 cloning	 were	 designed,	 using	 Primer-BLAST	(https://www.ncbi.nlm.nih.gov/tools/primer-blast/),	 to	 include	a	15	base	pair	(bp)	 region	 which	 overlapped	 with	 the	 regions	 flanking	 the	 restriction	endonuclease	 digestion	 site	 in	 the	 vector	 sequence,	 and	 to	 have	 a	 melting	temperature	 55	–	65	°C.	 All	 primers	 and	 oligonucleotides	were	 obtained	 from	Sigma	as	salt	free	purified	lyophilised	DNA	and	stored	at	-20	°C	(Table	2.4).		
b) Vector	linearization		SU6EW	vector	(3	µg)	was	mixed	with	the	restriction	enzyme	PmeI	(5	µL)	and	10	x	CutSmart	NEB	buffer	(5	µL),	and	the	total	volume	was	made	up	to	50	μl	with	RNAse-free	 water.	 The	 tubes	 were	 placed	 in	 a	 PTC-200	 thermal	 cycler	 and	incubated	at	37	°C	for	1	hour	followed	by	a	20	min	step	at	65	°C.	PCR	products	were	then	run	on	a	1	%	Agarose	gel	with	a	1	kb	ladder	(Promega).	DNA	from	the	tubes	with	linearized	vector	was	then	purified	using	a	Macherey-Nagel	kit	and	quantified	 using	 a	 Nanodrop	 spectofotometer	 (Thermo	 Scientific).	 Purified	linearized	vector	was	stored	at	-20	°C.		
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Table	2.4	In-fusion	cloning	primers.		Table	showing	in-fusion	cloning	primers	and	the	vectors/	restriction	endonucleases	used	to	produce	new	vectors.		
			 	
Starting	plasmid Restriction New	Plasmid Primer	PairsForward:AgaaaagccttgtttGCGAGTCCTGTAATGTGTATTCTCGAGAATACACATTACAGGACTCGCTTTTTGTTTaaacGAATTCctgcaReverse:TGCAGGAATTCGTTTAAACAAAAAGCGAGTCCTGTAATGTGTATTCTCGAGAATACACATTACAGGACTCGCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGCAGAACTTCACTGTCATCTTCTCGAGAAGATGACAGTGAAGTTCTGCTTTTTGTTTaaacGAATTCctgcaReverse:	TGCAGGAATTCGTTTAAACAAAAAGCAGAACTTCACTGTCATCTTCTCGAGAAGATGACAGTGAAGTTCTGCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGCCCGACAAGATCAAACATCTTCTCGAGAAGATGTTTGATCTTGTCGGGcTTTTTGTTTaaacGAATTCctgcaReverse:	TGCAGGAATTCGTTTAAACAAAAAGCCCGACAAGATCAAACATCTTCTCGAGAAGATGTTTGATCTTGTCGGGCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGTACAAATCTGCACTGTTCAACTCGAGTTGAACAGTGCAGATTTGTACTTTTTGTTTaaacGAATTCctgcaReverse:TGCAGGAATTCGTTTAAACAAAAAGTACAAATCTGCACTGTTCAACTCGAGTTGAACAGTGCAGATTTGTACAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGAAGTATTTCCTACCCTGCATCTCGAGATGCAGGGTAGGAAATACTTCTTTTTGTTTaaacGAATTCctgcaReverse:TGCAGGAATTCGTTTAAACAAAAAGAAGTATTTCCTACCCTGCATCTCGAGATGCAGGGTAGGAAATACTTCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGCCGAAAGAGATTCCCAAGTTCTCGAGAACTTGGGAATCTCTTTCGGCTTTTTGTTTaaacGAATTCctgcaReverse:	TGCAGGAATTCGTTTAAACAAAAAGCCGAAAGAGATTCCCAAGTTCTCGAGAACTTGGGAATCTCTTTCGGCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGGTGTACTGGACGGGAGATATCTCGAGATATCTCCCGTCCAGTACACCTTTTTGTTTaaacGAATTCctgcaReverse:	TGCAGGAATTCGTTTAAACAAAAAGGTGTACTGGACGGGAGATATCTCGAGATATCTCCCGTCCAGTACACCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGGAGCCTCCCAGATGCTAATACTCGAGTATTAGCATCTGGGAGGCTCCTTTTTGTTTaaacGAATTCctgcaReverse:	TGCAGGAATTCGTTTAAACAAAAAGGAGCCTCCCAGATGCTAATACTCGAGTATTAGCATCTGGGAGGCTCCAAACAAGGCTTTTCTForward:	AgaaaagccttgtttGCCGAAAGAGATTCCCAAGTTCTCGAGAACTTGGGAATCTCTTTCGGCTTTTTGTTTaaacGAATTCctgcaReverse:	TGCAGGAATTCGTTTAAACAAAAAGCCGAAAGAGATTCCCAAGTTCTCGAGAACTTGGGAATCTCTTTCGGCAAACAAGGCTTTTCT
SMPD1	shRNA2
SMPD1	shRNA3
CTSE	shRNA2
CTSE	shRNA3
GBA2	shRNA1
GBA2	shRNA2
GBA2	shRNA3
SMPD1	shRNA1
SU6EW Pme	I
CTSE	shRNA1
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c) Preparation	for	cloning	Linearised	 vector	 (200	ng)	 was	 mixed	 with	 insert	 (100	ng)	 and	 InFusion	cloning	reaction	enzyme	(2	µL)	(Clontech),	total	volume	was	made	up	to	10	µL	with	 water.	 The	 tubes	 were	 placed	 in	 a	 thermocycler	 (Mastercycler®	 nexus,	Eppendorf)	 and	 incubated	 at	 50	°C	 for	 15	minutes	 for	 the	 recombination	reaction.	
d) E.	coli	transformation	via	heat	shock		Diluted	In-fusion	reaction	solution	(1	µL)	(described	in	2.5.2c)	was	added	to	a	50	µL	aliquot	of	one-shot	Top10	competent	E.	coli	cells	and	incubated	on	ice	for	30	minutes.	The	tubes	were	placed	 into	a	ready	PTC-200	thermal	cycler	set	at	42	°C	and	held	for	exactly	30	sec	before	putting	them	back	on	ice	for	5	min.	Pre-warmed	 SOC	 media	 (950	µL)	 was	 added	 to	 the	 transformed	 cells	 before	incubating	in	a	shaking	heating	block	for	1	h	at	37	°C	at	250	rpm.	Transformed	bacteria	 were	 then	 plated	 on	 LB-Amp	 (pre-warmed	 to	 37	°C)	 plates	 and	incubated	overnight	at	37	°C.	
e) Colony	PCR	Colony	PCR	mix	was	prepared	by	adding	8.4	µL	Kappa	enzyme,	0.125	µL	each	primer	 (forward	 and	 reverse),	 and	 16.5	µL	 H2O.	 Selected	 colonies	 (14	per	plasmid)	were	 added	 to	 the	mix	 and	 PCR	 products	were	 synthesised	 using	 a	Mastercycler®	 nexus	 thermocycler	 (Eppendorf)	 under	 the	 following	parameters:	
1. Incubate	at	94	°C	for	2	minutes	2. Incubate	at	94	°C	for	15	seconds	3. Incubate	at	55	°C	for	30	seconds	4. Incubate	at	72	°C	for	3	minutes	5. Go	to	step	2	for	34	cycles	6. Incubate	at	4	°C	and	pause	
  
56 
The	PCR	product	was	then	run	on	a	1.5	%	agarose	gel	alongside	a	sample	of	100	bp	 DNA	 ladder	 (Promega)	 and	 visualised	 using	 a	 Fluoro-S	 Multimager	(Bio-	rad).	
f) E.	coli	culture		LB	broth	was	prepared	by	adding	LB	tablets	 to	water	 in	a	glass	bottle	and	autoclaving	it.	Selected	positive	E.coli	colonies	were	touched	with	the	end	of	a	pipette	 tip	 and	 placed	 into	 a	 50	mL	 Falcon	 tube	 with	 10	mL	 LB	 broth	 with	ampicillin	 (100	µg/mL).	The	culture	was	 then	 incubated	at	37	°C	 in	a	 shaking	incubator	(225	rpm)	for	18	h.	
g) Plasmid	DNA	extraction	Qiagen	Mini	and	Maxi	plasmid	prep	kits	were	used	to	extract	plasmid	DNA	from	E.coli.	 Bacterial	 cultures	were	 pelleted	 by	 centrifugation	 at	 6,800	x	g	 for	3	min	at	room	temperature.	The	cell	pellets	were	then	resuspended	in	lysis	buffer	to	 release	 plasmid	 DNA,	 and	 lysis	 was	 stopped	 after	 5	minutes	 to	 minimize	contamination	with	 bacterial	 DNA.	 The	 resulting	 solution	was	 centrifuged	 for	10	min	at	17,900	x	g.	The	supernatant	was	placed	onto	a	membrane	(provided	in	the	 Kit)	 to	 bind	 the	 DNA,	which	was	 then	washed	with	 ethanol.	 The	 purified	plasmid	DNA	was	eluted	with	elution	buffer.	DNA	concentrations	were	measured	using	a	Nanodrop	and	DNA	stored	at	-20	°C.		
h) DNA	sequencing	Plasmid	DNA	was	sent	for	sequencing	by	Eurofins	Genomics,	and	results	were	manually	checked.	Selected	plasmids	were	then	used	for	lentivirus	production.	
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2.5.3 	Lentivirus	production	
a) Transfection		
HEK293T	cells	(10	x106	cells)	were	seeded,	in	a	T175	flask	at	37	°C,	to	reach	70	–	90	%	 confluency	 after	 16	–	20	h.	 Cells	 were	 washed,	 taking	 care	 not	 to	disturb	the	monolayer.	And	then	12	mL	of	fresh	complete	media	added.	The	flask	was	placed	back	into	the	incubator	for	5	min	(37	°C).	Cells	were	transfected	using	the	Effectene	transfection	kit	(Qiagen).	Briefly,	2	µg	of	 lentiviral	plasmid	was	mixed	with	the	pCMVΔ8.91	(1.5	µg)	and	pMD2G	(1	µg)	 plasmids,	 and	 this	 solution	was	made	 up	 to	 600	µL	with	 condensation	buffer	EC.	The	Enhancer	(36	µL)	reagent	provided	in	the	kit	was	added	to	the	mix,	vortexed	 and	 incubated	 at	 RT	 for	 5	minutes	 to	 condense	 the	 DNA.	 Effectene	transfection	 reagent	 (120	µL)	 was	 added,	 vortexed	 and	 incubated	 at	 RT	 for	10	minutes,	to	form	micelle	complexes	around	the	condensed	DNA.	2.6	mL	D10	media	was	then	added	to	the	solution,	gently	mixed	and	poured	dropwise	into	the	cell	flask	directly	to	the	monolayer.	Cells	were	incubated	for	48	h	at	37	°C.	Cell	supernatant	was	collected	and	transferred	to	a	50	mL	falcon	tube	per	flask.	
b) Viral	particle	concentration	by	sucrose	gradient	The	supernatant	collected	from	the	transfection	step	was	filtered	through	a	0.45	µm	sterile	millex®GP	filter	(Millipore	Ireland	Ltd.)	into	a	sterile	50	mL	tube.	Filtered	medium	was	 then	 carefully	 overlaid	 on	 top	 of	 3	mL	 of	 20	%	 sucrose	(Sigma)	gradient	 in	Beckman	ultracentrifuge	conical	 tubes.	And	centrifuged	at	90,000	g	for	90	min	at	4	°.	The	pellet	was	resuspended	in	1	mL	AIM-V	media	and	aliquoted,	then	stored	at	-80	°C.	
2.5.4 Lentivirus	testing	Jurkat	cells	(0.2	x	106	cells	per	well)	were	seeded	into	a	24-well	plate	with	a	titrated	 volume	 (0	–	10	μL)	 of	 concentrated	 virus	 with	 R10	 kept	 constant	(200	µL).	 The	 plates	were	 incubated	 at	 37	°C	 in	 a	 humidified	 incubator.	 Cells	were	topped	up	with	500	μL	of	media	on	day	1	then	harvested	on	day	3,	washed	three	times	and	fixed	for	5	min	with	2	%	formaldehyde	(Sigma).	Cells	were	then	
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analysed	 using	 flow	 cytometry	 and	 the	 percentage	 of	 infected	 (GFP+)	 cells	calculated.	
2.5.5 Use	of	lentiviral	particles	in	culture		RAW	264.7	 cells	were	plated	 into	 a	12-well	 plate	 (0.4	x	106	cells	 in	400	µL	D10)	with	 a	 titrated	 volume	 (0	–	100	μL)	 of	 virus	 and	 the	 plate	 incubated	 for	5	days	at	37	°C.	Media	(500	μL)	was	added	to	wells	every	24	hours.		
2.5.6 Real-time	PCR	
a) Primer	design	Primers	used	for	real-time	PCR	were	designed	to	be	intron-spanning,	and	to	have	a	melting	temperature	55	-	65	°C.	The	intron-spanning	aspect	ensured	that	only	 mRNA	 and	 not	 genomic	 DNA	 were	 amplified.	 All	 primers	 and	oligonucleotides	were	obtained	from	Sigma	as	salt	free	purified	lyophilised	DNA.	The	sequences	of	the	real-time	PCR	primers	used	in	this	thesis	were:	
		 	
β-actin F:	GACCTCTATGCCAACACAGT R:	AGTACTTGCGCTCAGGAGGA
Gata6 F:	AAAGCTTGCTCCGGTAACAG R:	TCTCCCACTGCAGACATCAC
Ywhaz F:	TGCAAAAACAGCTTTCGATG R:	CCTGCTTCTGCTTCATCTCC
Ctse F:	GGGTCTGGGATACCCCTCAT R:	GTCTCCCACCTGGATTCCATC
Smpd1 F:	AGAGCACTCCTGTCAATGGC R:	AAGCCCCCAATTCTTAGGGTG
Gba2 F:	TCATGACTACCAGGACAGCAG R:	CGGAAGGGCTCATTCCACAA
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b) RNA	extraction	RNA	was	extracted	using	the	RNeasy	mini	kit	(Qiagen).	Briefly,	 lysis	buffer	was	added	to	cell	pellets	to	free	nucleic	acids,	which	were	brought	into	solution	with	 ethanol	 and	 bound	 to	 a	 membrane.	 The	 nucleic	 acids	 were	 washed	 to	remove	 chromatin	 contaminants,	 and	 contaminating	 salts	 removed	 using	ethanol.	Last,	the	ethanol	was	removed,	and	RNA	eluted	with	RNAse-free	dH2O	(Life	Technologies).	RNA	 concentration	was	measured	 using	 the	Nanodrop	 spectrophotometer	(Thermo	Scientific).	RNA	concentration	was	determined	based	on	the	equation:	optical	density	at	260	nm	×	40	ng/μL	(constant)	=	ng/μL	of	RNA.	
c) Reverse	transcription	Reverse	transcription	of	RNA	into	complementary	DNA	(cDNA)	was	carried-out	 using	 the	 High-Capacity	 cDNA	 Reverse	 Transcription	 Kit	 (Thermo	 Fisher	Scientific).	 Briefly,	 RNA	 obtained	 above	 (1000	ng	 per	 reaction)	 serves	 as	 the	template	 in	 the	 reverse	 transcription	 reaction,	where	 random	hexamers	were	used	to	synthesise	cDNA.		
d) Real-time	PCR	(qPCR)	Power	SYBR®	Green	PCR	Master	Mix	(Thermo	Fisher	scientific)	was	used	for	real-time	PCR.	Power	SYBR	Green	PCR	Master	Mix	(10	µL)	was	added	to	dH2O	(7.5	µL),	and	1	μl	primer	mix	(0.5	μg/mL	each	primer)	to	make	a	gene	specific	master	mix;	 cDNA	 (1.5	µL)	 from	 each	 sample	 was	 added	 to	 the	 reaction	mix	(17.5	µL)	 in	a	96-well	plate	well.	The	plate	was	 inserted	 into	a	QuantStudio	3	Real-Time	 PCR	 system	 and	 the	 PCR	 amplification	 started	 as	 per	 instrument	instruction:		
50°C	-	2min		95°C	-	10	min		95°C	-	15	sec		60°C	-	1	min		Repeat	3-	4	for	40	cycles		95°C	-	15	sec		4°C	¥	
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Ct	 values	were	 calculated	 for	 every	 gene	 specific	 reaction	 and	 normalised	against	 the	 housekeeping	 gene	 (Ywhaz	 and	 ß-actin).	 These	 values	 were	expressed	as	a	fold	change	(using	the	ΔΔ-Ct	method155).	
2.6 Mass	Spectrometry	
2.6.1 Chemicals		Lipid	 standards	 (Table	 2.5)	 were	 purchased	 from	 Cayman	 Chemical	(Cambridge,	UK).	HPLC	grade	solvents	and	acids	were	purchased	from	Thermo	Fisher	 Scientific	 Ltd	 (Newport,	 UK).	 All	 other	 reagents	 were	 obtained	 from	Sigma-Aldrich	unless	otherwise	stated.	
2.6.2 Lipid	Extraction	
a) 	Global	lipidomics	Arachidonic	 acid	 d8	 and	 PE	 ether	 (Table	 2.5)	 were	 added	 to	 each	 lavage	sample	before	extraction	(2.5	ng),	as	 internal	standards.	Lipids	were	extracted	by	 adding	 a	 solvent	mixture	 (1	M	 acetic	 acid/2-isopropanol/hexane	 (2:20:30,	v/v)	 to	 the	 sample	 at	 a	 ratio	 of	 2.5	mL	 of	 solvent	 mixture/1	 mL	 of	 sample,	vortexing	 for	1	min,	 and	 then	adding	2.5	mL	hexane.	 Following	vortexing	 and	centrifugation	(250	g	for	5	min),	lipids	were	recovered	in	the	upper	hexane	layer.	The	samples	were	then	re-extracted	by	addition	of	an	equal	volume	of	hexane,	followed	by	vortexing	and	centrifugation	(250	g	for	5	min).	The	bottom	layer	was	again	 re-extracted,	 using	 the	 Bligh	 and	 Dyer	 extraction	 method	 as	 follows:	3.75	mL	chloroform:MeOH	(1:2,	v/v)	was	added,	sample	was	vortexed	for	1min,	and	then	1.25	mL	chloroform	added.	Samples	were	vortexed	for	30	seconds	then	1.25	mL	water.	Following	vortexing	and	centrifugation	(250	g	for	5	min),	lipids	were	 recovered	 in	 the	 organic	 phase.	 The	 combined	 chloroform	 and	 hexane	phases	containing	lipids	were	dried	in	a	vacuum	drier,	then	redissolved	in	200	µL	methanol	and	stored	at	-80	°C	until	analysis.			 	
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Table	2.5	Lipid	standards.	
				 	
Standard Formal	Name Exact	Mass
PGE2-d4 prostaglandin	E2-d4	 356.2501
TxB2-d4 Thromboxane	B2-d4 374.2606
11-dehydro-TxB2-d4 11-dehydro-Thromboxane	B2-d4 372.245
13-HODE-d4 13S-	hydroxy-	9Z,	11E-	octadecadienoic-	9,	10,	12,	13-	d4	acid 300.2603
12-HETE-d8
12S- hydroxy- 5Z, 8Z, 10E, 14Z-eicosatetraenoic- 5, 6, 8, 9, 11, 12, 14, 15-d8	acid 328.2854
15-HETE-d8
15S- hydroxy- 5Z, 8Z, 11Z, 13E-eicosatetraenoic- 5, 6, 8, 9, 11, 12, 14, 15-d8	acid 328.2854
Arachidonic	acid-d8 5Z,8Z,11Z,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8	acid 312.29044
PE	Ether	(PEE	(40:1)) 1,2-di-(3,7,11,15-tetramethylhexadecyl)-sn-glycero-3-phosphoethanolamine 775.6819
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b) Sphingolipidomics	Lipid	 standards	 (Cer/Sph	 Mixture	 II,	 Avanti	 polar	 lipids,	 Table	 2.6)	 were	added	to	each	lavage	sample	before	extraction,	as	internal	standards.	Lipids	were	extracted	by	adding	a	 solvent	mixture	 (1	M	acetic	 acid/2-isopropanol/hexane	(2:20:30,	v/v)	to	the	sample	at	a	ratio	of	2.5	mL	solvent	mixture/1	mL	of	sample,	vortexing,	 and	 then	 adding	 2.5	mL	 hexane.	 Following	 vortexing	 and	centrifugation,	 lipids	were	 recovered	 in	 the	 upper	 hexane	 layer.	 The	 samples	were	then	re-extracted	by	addition	of	an	equal	volume	of	hexane,	 followed	by	vortexing	and	centrifugation.	The	bottom	layer	was	again	re-extracted,	using	the	Bligh	and	Dyer	method,	adding	3.75	mL	of	chloroform:MeOH	(1:2,	v/v),	vortexing	for	1	min,	and	added	1.25	mL	chloroform,	vortexing	 for	30	seconds	and	added	1.25	mL	water156.	Following	vortexing	and	centrifugation,	lipids	were	recovered	in	the	organic	phase.	The	combined	chloroform	and	hexane	phases	containing	lipids	were	dried	in	a	vacuum	drier	redissolved	in	200	µL	methanol	and	stored	at	-80	°C	until	analysis.	
2.6.3 Targeted	analysis	of	lipids	
a) Fatty	acids	and	eicosanoids	Lipids	extracts	were	separated	by	reverse	phase	HPLC	using	a	C18	Spherisorb	ODS2,	5	µm,	150	x	4.6	mm	column	 (Waters,	Hertfordshire,	UK).	With	a	mobile	phase	gradient	of	50	–	90	%	solvent	B	(60	%	methanol,	40	%	acetonitrile,	0.1	%	glacial	 acetic	 acid)	 in	 solvent	 A	 (75	%	 water,	 25	%	 acetonitrile,	 0.1	%	 glacial	acetic	acid)	over	20	min,	90	%	solvent	B	over	5	min,	90	–	50	%	solvent	B	from	25	–	25.1	min	 and	 50	%	 solvent	 B	 from	 25.1	–	30	min	 with	 a	 flow	 rate	 of	1	mL/min.	LC-MS/MS	was	performed	using	a	AB	Sciex	6500	Q-Trap,	monitoring	the	parent	to	daughter	m/z	as	listed	in	Table	2.7.	Peak	areas	were	then	used	to	calculate	extraction	efficiencies.			 	
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Table	2.6	SL	standards	(Cer/Sph	Mixture	II,	Avanti	polar	lipids).	
		
Table	 2.7	 Parent	 to	 daughter	 ion	 transitions	 used	 for	 measuring	 fatty	 acids	 and	
eicosanoid	in	murine	samples.	
			 	
Lipid Q1 Q3
C17	So 286.45 268.2
C17	Sa 288.44 270.2
C17	So-1-P 366.34 250.2
C17	Sa-1-P 368.41 270.29
C12	Cer 482.59 264.2
C25	Cer 664.83 646.7
C12	Cer-1-P 562.6 264.5
C12	SM 647.67 184.1
C12	GlucCer 644.68 264.5
C12	LacCer 806.69 264.4
Q1	Mass	(Da) Q3	Mass	(Da) Lipid
355.2 275.1 PGE2-d4
373.2 173.1 TxB2	d4
371.2 165.1 11	dehydro	TxB2	d4
299.2 198.1 13-HODE	d4
327.2 184.1 12-HETE	d8
327.2 226.1 15-HETE	d8
327.2 116.1 5-HETE-d8
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b) Sphingolipidomics	
i) Cer,	SM,	monohexosylceramides	(HexCer)	and	dihexosylceramides	
(LacCer)	Lipids	extracts	were	analysed	using	a	 reverse	phase	Accucore	C18	column	(150	x	2.1	mm,	2.6	µm)	using	an	isocratic	mobile	phase	A	(H2O:ACN	80:20	v/v)	and	a	phase	B	(IPA:ACN,	70:30	v/v)	at	a	flow	rate	of	0.4	mL/min	over	65	min,	with	4	mM	ammonium	acetate.	Samples	were	maintained	at	4	°C	and	the	column	at	25	°C.	LC-	MS/MS	was	performed	with	a	HPLC	(Shimadzu,	Japan)	and	6500	Q-Trap	(AB	Sciex,	Canada),	using	MRMs	in	positive	ionisation	mode	to	monitor	the	lipids	listed	in	Table	2.8,	in	Table	2.9,	and	Table	2.10.		
ii) Resolution	of	GlcCer	and	galactosylceramide	(GalCer)	These	 compounds	were	analysed	by	normal	phase	LC,	using	a	Supelco	2.1	(i.d.)	 ×	250	mm	LC-Si)	 and	 an	 isocratic	 elution	 with	 mobile	 phase	 A	(CH3CN/CH3OH/HCOOH,	 97/2/1,	 v/v/v,	with	 5	mM	 ammonium	 formate)	 at	 a	flow	 rate	 of	 1.5	mL/min	 over	 8	min.	 LC/MS/MS	was	 performed	with	 a	HPLC	(Shimadzu,	Japan)	and	6500	Q-Trap	(AB	Sciex,	Canada),	using	MRMs	in	positive	ionisation	mode	to	monitor	the	lipids	listed	Table	2.9.	
2.6.4 Untargeted/Global	lipid	analysis		Lipid	 extracts	were	 separated	 on	 an	 Accucore	 C18	 column	 (150	x	2.1	mm,	2.6	µm)	using	solvent	mixture	of	84	%	mobile	phase	A	(H2O:ACN	80:20	v/v)	and	16	%	phase	B	(IPA:	ACN,	70:30	v/v)	with	4	mM	ammonium	acetate.	The	A/B	ratio	was	maintained	at	84/16	for	12	min,	followed	by	a	linear	gradient	of	60	%	B	for	7	min,	72	%	B	 for	23	min,	84	%	B	 for	9	min,	 and	100	%	B	which	was	held	 for	6	min,	followed	by	an	8	min	wash	of	the	column	at	84/60	A/B	before	the	next	run.	Samples	were	maintained	at	4	°C	and	the	column	maintained	at	25	°C.	High	resolution	(60,000,	FWHM	at	400	amu)	full-scan	spectra	were	acquired	in	both	+ve	and	–ve	ESI	mode	over	100	–	1800	m/z	range	on	an	Orbitrap	(Elite)	MS.	The	MS	 conditions	were	 as	 follows:	 HESI-II	 temperature	 350	°C,	 N2	 as	 drying	 gas,	sheath	 gas	 flow	52	 arbitrary	 units,	 auxiliary	 gas	 flow	18	units,	 capillary	 temp	320	°C,	 spray	 voltage	 +/-	 3.5	kV	 and	 S-lens	 RF	 level	 65.60	%	 respectively	 for	
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negative	and	positive	ion	mode.	A	one-off	column	conditioning	at	the	beginning	was	done	with	two	runs	of	solvent	blank	followed	by	runs	of	solvent	blank	using	same	mobile	phase	gradient.		 	
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Table	2.8	Parent	to	daughter	ion	transitions	used	for	measuring	Cer	species.	
	 	
Lipid Q1	Mass	(Da) Q3	Mass	(Da)
C17:0 Sa 288.44 270.2
C17:0 Sa-1-P 368.4 252.2
C17:1 So 286.45 268.2
C17:1 So-1-P 366.3 250.2
C18:0 Sa 302.4 252.2
C18:0 Sa-1-P 382.4 266.4
C18:1 So 300.4 282.4
C18:1 So-1-P 380.4 264.4
Cer 18:1/12:0 482.6 264.2
Cer 18:1/16:0 538.7 264.4
Cer 18:1/18:0 566.5 264.4
Cer 18:1/18:1 564.5 264.4
Cer 18:1/20:0 594.6 264.4
Cer 18:1/20:1 592.6 264.4
Cer 18:1/22:0 622.6 264.4
Cer 18:1/22:1 620.6 264.4
Cer 18:1/24:0 650.6 264.4
Cer 18:1/24:1 648.6 264.4
Cer 18:1/25:0 664.8 264.4
Cer 18:1/26:0 678.7 264.4
Cer 18:1/26:1 676.7 264.4
CerP 18:0/24:0 732.9 266.4
CerP 18:0/24:1 650.6 266.4
CerP 18:1/12:0 562.5 264.5
CerP 18:1/16:0 618.7 264.4
CerP 18:1/24:0 730.9 264.4
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Table	 2.9	 Parent	 to	 daughter	 ion	 transitions	 used	 for	 measuring	
monohexosylceramides.	
	 	
Lipid Q1	Mass	(Da) Q3	Mass	(Da)
HexCer 18:0/14:0 674.5 266.4
HexCer 18:0/14:1 672.5 266.4
HexCer 18:0/16:0 702.6 266.4
HexCer 18:0/16:1 700.6 266.4
HexCer 18:0/18:0 730.6 266.4
HexCer 18:0/18:1 728.6 266.4
HexCer 18:0/20:0 758.6 266.4
HexCer 18:0/20:1 756.6 266.4
HexCer 18:0/22:0 786.7 266.4
HexCer 18:0/22:1 784.6 266.4
HexCer 18:0/24:0 814.9 266.4
HexCer 18:0/24:1 812.7 266.4
HexCer 18:0/26:0 842.7 266.4
HexCer 18:0/26:1 840.7 266.4
HexCer 18:1/12:0 644.7 264.5
HexCer 18:1/14:0 672.5 264.4
HexCer 18:1/16:0 700.6 264.4
Hexcer 18:1/16:1 698.5 264.4
Hexcer 18:1/18:0 728.6 264.4
Hexcer 18:1/18:1 726.6 264.4
HexCer 18:1/20:0 756.6 264.4
Hexcer 18:1/20:1 754.6 264.4
HexCer 18:1/22:0 784.6 264.4
Hexcer 18:1/22:1 782.6 264.4
HexCer 18:1/24:0 812.7 264.4
Hexcer 18:1/24:1 810.7 264.4
Hexcer 18:1/26:0 840.7 264.4
Hexcer 18:1/26:1 838.7 264.4
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Table	2.10	Parent	to	daughter	ion	transitions	used	for	measuring	LacCer	and	SM.	
	 	
Lipid Q1	Mass	(Da) Q3	Mass	(Da)
LacCer 18:1/12:0 806.7 264.4
LacCer 18:1/16:0 862.7 264.4
LacCer 18:1/18:0 890.7 264.4
LacCer 18:1/18:1 888.6 264.4
LacCer 18:1/20:0 918.7 264.4
LacCer 18:1/20:1 816.7 264.4
LacCer 18:1/22:0 946.8 264.4
LacCer 18:1/22:1 844.7 264.4
LacCer 18:1/24:0 974.8 264.4
LacCer 18:1/24:1 972.7 264.4
LacCer 18:1/26:0 1002.8 264.4
LacCer 18:1/26:1 1000.8 264.4
SM 18:0/12:0 649.7 184.1
SM 18:0/14:0 677.6 184.4
SM 18:0/16:0 705.6 184.4
SM 18:0/18:0 733.8 184.4
SM 18:0/20:0 761.6 184.4
SM 18:0/22:0 789.7 184.4
SM 18:0/24:0 817.9 184.4
SM 18:0/26:0 845.7 184.4
SM 18:1/12:0 647.7 184.1
SM 18:1/14:0 675.5 184.4
SM 18:1/16:0 703.6 184.4
SM 18:1/16:1 701.6 184.4
SM 18:1/18:0 731.8 184.4
SM 18:1/18:1 729.6 184.4
SM 18:1/20:0 759.6 184.4
SM 18:1/20:1 757.6 184.4
SM 18:1/22:0 787.6 184.4
SM 18:1/22:1 785.6 184.4
SM 18:1/24:0 815.9 184.4
SM 18:1/24:1 813.7 184.4
SM 18:1/26:0 843.7 184.4
SM 18:1/26:1 841.7 184.4
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2.6.5 Data	normalisation	by	DNA	content	
a) DNA	purification	
Genomic	DNA	from	pResMf	was	isolated	using	the	PureLink	Genomic	DNA	Mini	Kit	(Thermofisher)	according	to	supplier’s	specifications.	Briefly,	cell	lysates	from	pResMf	resuspended	in	PBS	were	prepared	by	adding	20	µL	proteinase	K	and	20	µL	RNase	A	to	the	sample	and	incubated	at	room	temperature	for	2	min;	added	200	µL	Purelink	Genomic	Lysis	(binding	buffer)	and	incubated	at	55	°C	for	10	minutes,	 followed	by	the	addition	of	200	µL	of	100	%	ethanol	to	the	 lysate.	The	sample	was	then	applied	to	a	PureLink	spin	column	and	washed	twice	with	wash	buffer	1	and	2,	before	DNA	was	eluted	using	elution	buffer.	
b) DNA	quantification		Genomic	DNA	from	pResMf	was	quantified	using	the	Quant-iT	dsDNA	Assay	Kit	 (ThermoFisher)	 according	 to	 supplier’s	 specifications.	 Briefly,	 assay	components	were	equilibrated	at	room	temperature,	and	working	solution	was	prepared	 by	 diluting	 the	 Quant-iT	 dsDNA	 reagent	 1:200	 in	 Quant-iT	 dsDNA	buffer.	Working	solution	was	loaded	(200	µL)	in	each	well,	10	µL	of	each	of	the	Quant-iT	dsDNA	standards	was	added,	and	unknown	DNA	sample	 to	 separate	wells	 in	 duplicate.	 Fluorescence	 was	 measured	 using	 a	 microplate	 reader	(excitation/emission	maxima	~502/503	nm)	 and	 standard	 curve	was	 used	 to	determine	DNA	concentration.	
2.7 Data	analysis		
2.7.1 Pathway	analysis	The	microarray	data	was	previously	published	by	Prof.	Phil	Taylor’s	lab69.	The	networks	and	functional	analyses	were	generated	through	the	use	of	QIAGEN’s	Ingenuity	 Pathway	 Analysis	 (IPAâ,	 QIAGEN	 Redwood	 City,	www.qiagen.com/ingenuity).		
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2.7.2 XCMS	processing	The	 .RAW	 files	 produced	 from	 the	 LC-MS	 runs	 were	 converted	 to	 .mzML	format	 applying	 ProteoWizard	 2.1157	 followed	 by	 deconvolution	 and	 peak	alignment	applying	XCMS	using	a	previously	described	method158;	Results	were	then	queried	against	two	databases,	Human	Metabolome	Database	(HMDB)	and	LIPID	MAPS	using	the	database	search	program	MS	search	with	mass	tolerance	of	 5	 ppm.	 MS	 search	 enables	 the	 query	 of	 a	 list	 of	 m/z	 values	 against	 MS	databases.	Thus,	providing	the	user	with	putative	identifications	for	the	features	whose	m/z	values	matched	entries	on	the	database.	
2.7.3 Statistical	analysis	XCMS-analysed	 data	 were	 processed	 using	 both	 an	 univariate	 and	multivariate	 approach.	 Significantly	 different	 lipids	 were	 identified	 using	 an	unpaired	 parametric	 t-test	 (Student	 t-test,	 unequal	 variances).	 P-values	 were	adjusted	 for	 multiple	 comparisons,	 using	 the	 Benjamini-Hochberg	 method.	Differential	expression	was	classified	as	significant	when	P	<	0.05	and	|FC|	>	1.5.	Unsupervised	 PCA	 and	 supervised	 OPLS	methods	were	 used	 to	 obtain	 group	clusters	using	the	program	Simca	(version	14.0.1.0,	Umetrics	AB,	Umeå,	Sweden,	2013).		Statistical	 analysis	 of	 differential	 lipid	 levels,	 from	 a	 targeted	 analysis,	consisted	of	a	univariate	model	to	detect	individual	lipids	known	to	be	present	in	Mf	that	are	significantly	different	in	abundance	in	two	sample	sets.	P-values	were	adjusted	 for	multiple	 comparisons,	 using	 the	 Benjamini-Hochberg	method.	 P-values	of	less	than	0.05	were	considered	statistically	significant.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD,	as	indicated	on	legends.	*	p<	0.05	was	considered	statistically	significant	and	**	indicated	p<	0.01.				 	
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Chapter	3 GATA6	transcription	factor	
regulates	the	expression	of	genes	related	
to	lipid	metabolism	
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3.1 Introduction	
3.1.1 Gata6	in	peritoneal	Mf	
As	described	in	Chapter	1,	the	functions	and	phenotypes	of	ResMf	are	highly	heterogeneous	and,	 in	most	cases,	 the	signals	and	molecular	mechanisms	 that	underlie	 their	 heterogeneity	 are	 poorly	 understood.	 In	 particular,	 the	transcription	 factor	 GATA6	 has	 a	 central	 role	 in	 promoting	 tissue-dependent	characteristics	of	pResMf	(e.g.	phenotype,	localization,	proliferative	renewal	and	function159),	 has	 previously	 been	 shown	 to	 be	 selectively	 expressed	 in	 these	cells51,69,	and	to	regulate	the	expression	of	‘pResMf-specific	genes’	(PMSGs)159.	Importantly,	 the	 transcriptional	 analysis	 of	 Gata6-KOmye	 and	 -WT	 pResMf	showed	 several	 differentially	 expressed	 genes	 involved	 in	 lipid	metabolism69.	Among	the	first	genes	identified	were	Abca,	Alox15,	Sptlc2,	Fabp4	and	Ldlr.	Such	changes	 in	 gene	 expression	 are	 presumably	 linked	 to	 alterations	 in	 lipid	metabolism	related	pathways.		
In	this	chapter	I	will	conduct	a	detailed	analysis	of	the	microarray	data	of	Mf	from	 Gata6-KOmye	 and	 -WT	mice	 to	 identify	 the	 gene	 networks	 regulated	 by	GATA6	associated	with	lipid	metabolic	processes69.	This	is	crucial	in	addressing	the	question	of	the	relevance	of	GATA6	in	regulating	lipid	biology	in	pResMf.		
I	will	begin	by	assessing	the	changes	in	gene	expression	that	occur	in	GATA6-deficient	 pResMf,	 which	 will	 result	 in	 a	 long	 list	 of	 genes	 with	 significantly	altered	transcript	levels.	Then,	I	will	characterise	the	mechanisms	that	underlie	the	observed	changes,	 in	order	 to	understand	 their	biological	 relevance160.	To	achieve	 this,	 I	 will	 use	 a	 combination	 of	 gene-ontology	 rankings,	 pathway	mappings	and	network	analysis.	
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3.1.2 Aims	The	studies	described	in	this	chapter	will:	
• Use	ingenuity	pathway	analysis	(IPA)	to	analyse	gene	pathways	and	networks	regulated	by	GATA6,	that	are	associated	with	lipid	metabolic	processes.	
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3.2 Results	
Microarray	 data	 generated	 as	 part	 of	 a	 previous	 study	 by	 the	 Taylor	 lab,	comparing	pResMf	from	Gata6-KOmye	and	-WT	naïve	mice	was	used	to	identify	genes	regulated	by	GATA669.	The	microarray	data	was	analysed	using	ingenuity	pathway	 analysis	 (IPA)	 software.	 IPA	 provides	 two	 powerful	 tools	 to	 help	determine	biological	mechanisms	behind	the	changes	in	transcript	levels,	termed	networks	 and	 canonical	 pathways,	which	will	 described	 in	more	 detail	 in	 the	following	sections.		The	 analysis	 of	 this	 high-throughput	 gene-expression	 data	 was	 greatly	facilitated	 by	 the	 availability	 of	 prior	 biological	 knowledge.	 Typically,	 such	analysis	 is	 done	 using	 statistical	 gene-set-enrichment	 methods	 where	differentially-expressed	 genes	 are	 interrogated	 using	 lists	 of	 genes	 associated	with	a	particular	biological	function	or	pathway.		
3.2.1 Canonical	Pathways		The	raw	microarray	data	files	were	processed	through	an	automated	feature	extraction	 and	 normalization	 pipeline	 developed	 at	 Cardiff	 University	 by	 Dr.	Robert	Andrews,	and	significantly-differentially	expressed	genes	(p-value<0.05	after	Benjamini-Hochberg	correction	and	fold	change³	1.5)	were	uploaded	and	analysed	 in	 IPA.	 The	 data	 analysis	 was	 performed	 in	 two	 primary	 steps,	identification	 of	 significantly	 altered	 (i)	 canonical	 pathways,	 and	 (ii)	functions/mechanisms	related	to	lipid	metabolism.	The	 first	 step	 of	 my	 analysis	 consisted	 of	 identifying	 which	 canonical	pathways	were	significantly	changed.	The	significance	of	the	association	between	the	 dataset	 and	 the	 canonical	 pathway	 was	 established	 based	 on	 two	considerations:	(i)	the	first	 is	the	ratio	between	the	number	of	genes	from	the	dataset	that	match	the	genes	in	the	pathway,	divided	by	the	total	number	of	genes	comprising	the	pathway;	(ii)	secondly	a	P-value,	calculated	using	Fisher’s	exact	test,	determining	the	likelihood	that	the	association	between	genes	in	the	dataset	and	the	canonical	pathway	is	a	random	occurrence160.		
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Using	 this	 analysis,	 I	 found	 that	 overall,	 the	 majority	 of	 dysregulated	pathways	 were	 	 related	 to	 metabolic	 processes	 and	 a	 high	 proportion	 of	pathways	 related	 to	 lipid	metabolism	were	 noted	 to	 be	 significantly	 enriched	(Table	 3.1.),	 either	 by	 affecting	 lipid	 pathways	 directly,	 or	 by	 altering	 lipid	catabolism	 and	 transport,	 both	 of	 which	 are	 essential	 in	 maintaining	 lipid	homeostasis	 (i.e.	 lysosomal	 metabolism).	 The	 most	 significant	 pathways	 are	compared	 in	 Table	 3.1.	 The	 ‘Macropinocytosis	 Signalling’,	 ‘Phospholipase	 C	Signalling’,	and	‘Sphingosine-1-phosphate	Signalling’	pathways	are	the	only	ones	for	which	 IPA	was	 able	 to	 calculate	 z-scores,	 and	 they	 are	 all	 predicted	 to	 be	activated	(positive	z-scores).	Thus,	going	forward,	the	goal	of	this	chapter	is	two-fold,	to	assess	which	lipid	classes	were	the	most	affected	by	GATA6	deficiency,	and	to	gauge	if	lysosomal	metabolism	related	genes	could	potentially	contribute	to	 alterations	 in	 lipid	metabolism.	 In	 the	next	 section	 the	pathways	 identified	above	will	be	divided	into	2	groups,	depending	on	their	function	and	expanded	to	categorise	the	biological/biochemical	effect	of	these	pathways.	The	first	group	will	be	based	on	 the	 regulation	of	different	 lipid	categories,	whilst	 the	second	comprises	 the	 pathways	 involved	 in	 lysosome	 fusion	 and	 function.	 The	 data	presented	in	the	next	2	sections	is	merely	descriptive	of	the	changes	observed,	but	following	that	I	will	continue	with	a	more	targeted	analysis,	focusing	on	SL	and	lysosomal	metabolism.					 	
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Table	3.1	-	The	most	significantly	enriched	lipid	metabolism	(ranked	by	log	p-value)	
related	pathways	in	Gata6-KOmye	pResMf	according	to	IPA1.	
		 	
																																																								
1 A positive z-score indicates a predicted activation, and a negative z-score 
indicates a predicted inactivation of the enriched pathway. NaN, a z-score cannot be 
calculated for all IPA canonical pathways.  
	
Ingenuity	Canonical	Pathways -log(p-value) Ratio z-scoreMacropinocytosis	Signalling 5.877 0.25 0.632Clathrin-mediated	Endocytosis	Signalling 4.94 0.157 NaNPhospholipase	C	Signalling 4.06 0.135 0.392Caveolar-mediated	Endocytosis	Signalling 3.18 0.183 NaNPhagosome	formation 3.13 0.156 NaNPhagosome	maturation 2.66 0.142 NaNSphingosine-1-phosphate	Signalling 2.29 0.138 0.258Prostanoid	Biosynthesis 1.75 0.333 NaNSuperpathway	of	D-myo-inositol	(1,4,5)-trisphosphate	Metabolism 1.74 0.208 NaN
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a) Regulation	of	specific	lipid	categories:	The	canonical	pathways	 identified	by	 the	 IPA	data	analysis	as	significantly	changed	 in	Gata6-KO	pResMf	 (Table	 3.1.),	were	 grouped	within	 specific	 lipid	categories	involved	in	lipid	metabolism	and	are	listed	below.		
i) Phospholipid	metabolism	Phospholipase	C	(PLC)	Signalling	-	PLC	selectively	catalyses	the	hydrolysis	of	the	phospholipid	phosphatidylinositol	4,5-bisphosphate	(PIP2)	on	the	glycerol	side	of	the	phosphodiester	bond.	This	reaction	leads	to	the	formation	of	inositol	1,2-cyclic	phosphodiester,	and	the	release	of	diacyl	glycerol	(DAG).	The	inositol	intermediate	is	then	hydrolyzed	to	inositol	1,4,5-trisphosphate	(IP3)92.	Superpathway	of	D-myo-inositol	(1,4,5)-trisphosphate	Metabolism	-	D-myo-inositol	(1,4,5)-trisphosphate	is	a	secondary	messenger	molecule	used	in	signal	transduction	 and	 lipid	 signaling.	 It	 is	 synthesized	 by	 hydrolysis	 of	phosphatidylinositol	4,5-bisphosphate	(PIP2),	a	phospholipid	that	is	 located	in	the	plasma	membrane,	by	the	action	of	phospholipase	C161.	
ii) Fatty	acid	metabolism	Prostanoid	Biosynthesis	-	Prostanoids	are	cyclic,	oxygenated	products	of	ω3	and	 ω6	 20-	 and	 22-carbon	 essential	 fatty	 acids	 (FAs)	 that	 are	 formed	enzymatically	through	cyclooxygenases162.		
iii) SL	metabolism	Sphingosine-1-phosphate	 (S1P)	 Signalling	 (Figure	 3.1)	 –	 S1P	 is	 a	 critical	regulator	 of	 many	 physiological	 and	 pathophysiological	 processes,	 including	cancer,	atherosclerosis,	diabetes	and	osteoporosis;	it	has	also	been	shown	that	S1P	 has	 important	 intracellular	 targets	 involved	 in	 inflammation,	 cancer	 and	Alzheimer’s	disease162.			
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Figure	3.1	Canonical	pathway	‘Sphingosine-1-phosphate	(S1P)	signalling’.		Significantly	enriched	for	genes	whose	expression	correlates	with	differentially	expressed	between	 Gata6-WT	 and	 -KOmye	 mice,	 defined	 by	 Ingenuity	 Pathway	 Analysis	 software.	Dysregulated	genes	outlined	 in	pink;	Up-	and	down-regulated	genes	shaded	 in	red	and	green,	respectively.	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	such	as	phosphatases	(△),	kinases	(▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	().			 	
20
Log2 FC
-20
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b) Lysosome	fusion	and	function:	The	 canonical	 pathways	 involved	 in	 lysosome	 fusion	 and	 function	 were	(Table	3.1.),	grouped	by	biological	processes,	and	listed	below.	
i) Endocytosis		Macropinocytosis	 Signalling	 (Figure	 3.2)-	 refers	 to	 the	 actin-dependent	formation	 of	 large	 endocytic	 vesicles	 of	 irregular	 size	 and	 shape	 called	macropinosomes163.		Clathrin-mediated	Endocytosis	Signalling	(Figure	3.3)-	is	the	major	pathway	for	 the	 internalization	 of	 nutrients,	 hormones	 and	 other	 signalling	molecules	from	the	plasma	membrane	into	intracellular	compartments164.	Caveolar-mediated	Endocytosis	Signalling	(Figure	3.4)-	plays	a	role	in	various	cellular	 processes	 such	 as	 endocytosis,	 cellular	 signalling	 and	 lipid	 recycling.	Caveolae	are	cholesterol-	and	SL-rich,	flask-shaped	invaginations	of	the	plasma	membrane,	which	are	involved	in	the	internalization	of	membrane	components,	extracellular	ligands,	viruses	and	bacterial	toxins165.		 	
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Figure	3.2	Canonical	pathway	‘Macropinocytosis	Signalling’.		Significantly	enriched	for	genes	whose	expression	correlates	with	differentially	expressed	between	 Gata6-WT	 and	 -KOmye	 mice,	 defined	 by	 Ingenuity	 Pathway	 Analysis	 software.	Dysregulated	genes	outlined	 in	pink;	Up-	and	down-regulated	genes	shaded	 in	red	and	green,	respectively.	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	such	as	phosphatases	(△),	kinases	(▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	().
20
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-20
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Figure	3.3	Canonical	pathway	‘Clathrin-mediated	Endocytosis	Signalling’.		Significantly	enriched	for	genes	whose	expression	correlates	with	differentially	expressed	between	 Gata6-WT	 and	 -KOmye	 mice,	 defined	 by	 Ingenuity	 Pathway	 Analysis	 software.	Dysregulated	genes	outlined	 in	pink;	Up-	and	down-regulated	genes	shaded	 in	red	and	green,	respectively.	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	such	as	phosphatases	(△),	kinases	(▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	().
20
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Figure	3.4	Canonical	pathway	‘Caveolar-mediated	Endocytosis	Signalling’.		Significantly	enriched	for	genes	whose	expression	correlates	with	differentially	expressed	between	 Gata6-WT	 and	 -KOmye	 mice,	 defined	 by	 Ingenuity	 Pathway	 Analysis	 software.	Dysregulated	genes	outlined	 in	pink;	Up-	and	down-regulated	genes	shaded	 in	red	and	green,	respectively.	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	such	as	phosphatases	(△),	kinases	(▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	().					 	
20
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ii) Phagocytosis	Phagosome	formation	(Figure	3.5)-	A	phagosome	is	formed	by	the	fusion	of	the	cell	membrane.	Phagosomes	have	membrane-bound	proteins	to	recruit	and	fuse	with	lysosomes	to	form	mature	phagolysosomes166.	Phagosome	maturation	(Figure	3.6)–	As	the	phagosome	matures,	it	becomes	more	acidic	 from	pH	6.5	to	pH	4	and	gains	characteristic	protein	markers	and	hydrolytic	 enzymes.	 The	 different	 enzymes	 function	 at	 different	 optimal	 pH,	forming	a	range	so	they	each	work	in	narrow	stages	of	the	maturation	process166.		 	
  
84 
	
	
Figure	3.5	Canonical	pathway	‘Phagosome	formation’.		Significantly	enriched	for	genes	whose	expression	correlates	with	differentially	expressed	between	 Gata6-WT	 and	 -KOmye	 mice,	 defined	 by	 Ingenuity	 Pathway	 Analysis	 software.	Dysregulated	genes	outlined	 in	pink;	Up-	and	down-regulated	genes	shaded	 in	red	and	green,	respectively.	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	such	as	phosphatases	(△),	kinases	(▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	().		
20
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Figure	3.6	Canonical	pathway	‘Phagosome	maturation’.		Significantly	enriched	for	genes	whose	expression	correlates	with	differentially	expressed	between	 Gata6-WT	 and	 -KOmye	 mice,	 defined	 by	 Ingenuity	 Pathway	 Analysis	 software.	Dysregulated	genes	outlined	 in	pink;	Up-	and	down-regulated	genes	shaded	 in	red	and	green,	respectively.	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	such	as	phosphatases	(△),	kinases	(▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	().		 	
20
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3.2.2 Mechanistic	Networks:	inferring	likely	causal	mechanisms	The	mechanistic	 networks	 algorithm	 in	 IPA	was	 used	 to	 determine	which	functions/mechanisms	directly	related	to	lipid	metabolism	had	been	altered	as	a	consequence	of	loss	of	GATA6.	The	algorithm	uses	the	network	edges	between	pre-determined	upstream	regulators	for	which	there	is	statistical	evidence	(P-value	<	0.05)	that	the	corresponding	relationship	is	likely	relevant	for	the	causal	mechanism	 behind	 the	 dataset.	 The	 most	 significant	 causal	 edges	 between	regulators	 are	 then	 used	 to	 construct	 networks	 downstream	 of	 a	 ‘master’	regulator	in	order	to	indicate	potential	causal	mechanisms	167.		The	 algorithm	 generated	 networks	 comprised	 of	 the	 genes	 present	 in	 the	dataset	and	assigned	a	Z-score.	The	score	is	a	numerical	value	that	considers	the	number	of	focus	genes	and	the	size	of	the	network.	It	is	used	to	rank	networks	according	to	their	relevance	in	regards	to	the	genes	in	the	input	dataset,	but	it	does	not	necessarily	correlate	with	the	biological	significance	of	the	network160.	Using	this	process,	I	found	68	causal	mechanistic	categories	with	p-values<0.05;	with	 the	 Lipid	 metabolism	 category	 (p-value	 =	 2.15	 x	 10-08	 -	 2.42	 x	 10-05),	including	14	networks	comprising	of	202	genes	(Table	3.2).	This	result	pointed	to	 the	 possibility	 that	 GATA6	 deficiency	 leads	 to	 dramatic	 changes	 in	 lipid	metabolism.	Thus,	the	next	step	was	to	pinpoint	which	particular	lipid	families	were	the	most	affected	by	GATA6	deficiency	by	identifying	causal	networks	that	infer	similar	mechanisms/effects.	In	the	next	section	I	will	select	genes	related	to	lysosomal	 metabolism	 and	 investigate	 whether	 the	 disruption	 of	 lysosomal	function	could	contribute	to	lipidomic	changes	in	GATA6-deficient	cells.	
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Table	 3.2	 Lipid	 metabolism	 related	 networks	 significantly	 altered	 by	 Gata6	
expression.	
		
Diseases or 
Functions 
Annotation 
p-Value 
Predicted 
Activation 
State 
Activation 
z-score Molecules # Molecules 
Fatty acid 
metabolism 2.17E-08  -0.579 
ABCA1,ABCC1,ABCG1,ACACA,ACAT1,ACOT9,ACSS1,ALOX15,AQP9,ARSA,ATP8A1,B4GALT6,C5AR1,CASP8,CAV1,CAV2,CD82,CD9,CERK,C
OL4A3BP,COTL1,CPT1A,CS,CSF1,CXCL12,DBI,FABP4,FAM213B,FAR1,FASN,FCGR1A,FGR,FPR1,FYN,GBA,GDF15,Gk,GLTP,HACD3,HMOX1,
HSD17B4,IGF1,ITGB3,KCNN4,KITLG,LAMTOR1,LDLR,LIPA,LPL,LTA4H,LTC4S,MAP3K8,MDH1,ME2,MECR,MIF,MITF,MYO5A,NCF1,NPC1,NPC
2,OLR1,OSBPL2,P2RX1,PARK7,PDHA1,PLTP,PRELID1,PRKCD,PTGIS,PTGR1,PTGS1,PTK2B,RAC1,RARB,RELA,RHOA,RTN4,SCARB1,SDHA,
SEC13,SGPP1,SLC36A1,SLC9A3R1,SLC9A3R2,SMPD1,SMPD2,SOD1,SPTLC2,ST3GAL5,TLR4,TRIAP1,TSPO 
93 
Concentration of 
phospholipid 5.85E-08  0.923 
ABCA1,ABCG1,ABHD12,ACACA,ANXA5,ARF6,BAX,BSCL2,CAV1,CD38,COL4A3BP,CSF1,DAB2IP,FASN,GNAQ,GOLPH3,HINT1,INPPL1,KITLG,
LDLR,LPL,LSR,MBOAT7,NPC1,PLTP,PRKCD,PSEN2,PTEN,RAB27A,RHOA,RILP,ROCK2,SCARB1,SIK3,SMPD1,SMPD2,SPTLC2,STARD4 
38 
Synthesis of lipid 3.84E-07 Decreased -2.297 
ABCA1,ABCC1,ABCG1,ACACA,ACAT1,ACAT2,ACSS1,ADORA2B,ALOX15,ARF6,ARSA,ASPA,B4GALT6,BSCL2,C5AR1,CASP8,CAV1,CAV2,CD8
2,CD9,CERK,CNBP,COTL1,CSF1,CXCL12,CYP26A1,CYP7B1,DBI,DENND1A,DPM2,FAM213B,FAR1,FASN,FCGR1A,FGR,FPR1,FYN,GBA,GDF1
5,HACD3,HDC,HMOX1,IGF1,IGFBP4,INPPL1,ITGA6,ITGB1,ITGB2,KITLG,LDLR,LPCAT1,LPCAT2,LPL,LTA4H,LTC4S,MAN2B1,MAP3K8,ME2,MG
AT2,MIF,MITF,MYO5A,NCF1,NPC1,NPC2,NR3C1,OLR1,P2RX1,PARK7,PDHA1,PLA2G16,PLTP,PRKCD,PTGIS,PTGS1,PTK2B,RAB27A,RAC1,R
ARB,RELA,RGS2,RGS3,RHOA,RHOQ,SCARB1,Sf1,SGPP1,SH3KBP1,SLC6A6,SLC9A3R1,SLC9A3R2,SMPD1,SMPD2,SOD1,SORBS1,SPTLC2,
ST3GAL5,STARD4,TAZ,TBXAS1,TCF7L2,TLR4,TSPO 
103 
Metabolism of 
membrane lipid 
derivative 
1.03E-06  -1.585 
ABCA1,ABCC1,ABCG1,ALOX15,APLP2,ARF6,ARSA,ASPA,B4GALT6,BAX,CASP8,CAV1,CD82,CD9,CERK,CLN8,CNBP,COL4A3BP,CREM,CYP7
B1,DBI,DPM2,FAR1,FASN,GATA6,GBA,HMOX1,IGF1,INPPL1,ITGB1,ITGB2,KITLG,LDLR,LIPA,LPCAT1,LPCAT2,LPL,MBOAT7,NPC1,ORMDL2,P
2RX1,PLA2G16,PLA2G7,PLEK,PLTP,PRKCD,PTEN,RAB27A,RAC1,RHOA,RHOQ,SCARB1,SERINC3,SGPP1,SH3KBP1,SLC6A6,SMPD1,SMPD2,
SPTLC2,ST3GAL5,TAZ 
61 
Accumulation of 
cholesterol 1.07E-06 Decreased -3.241 
ABCA1,ACAT1,ACAT2,ACP2,CAV1,CREM,FABP4,GSK3A,HMOX1,LAMP1,LAMP2,LDLR,NPC1,NPC2,PLTP,SMPD1 16 
Accumulation of 
sterol 1.33E-06 Decreased -3.313 
ABCA1,ACAT1,ACAT2,ACP2,CAV1,CREM,FABP4,GSK3A,HMOX1,LAMP1,LAMP2,LDLR,NPC1,NPC2,PLTP,SCARB1,SMPD1 17 
Concentration of 
lipid 1.97E-06  0.886 
ABCA1,ABCG1,ABHD12,ACACA,ACAT1,ACAT2,ACSS1,ADIPOR1,ADIPOR2,ADORA2B,ALOX15,ANXA5,AQP9,ARF6,ARNTL,BAX,BSCL2,CASP8
,CAV1,CCDC80,CD38,CDKN2C,CEACAM1,CERK,COL4A3BP,COMT,CPT1A,CSF1,CXCL12,CYP26A1,DAB2IP,DBI,FABP4,FASN,GATA6,GBA,G
FRA2,Gk,GNAQ,GOLPH3,GSTK1,H2AFY,HINT1,Hmgn3,HMOX1,HP,HSD17B4,IDH1,IGF1,IL18BP,INPPL1,ITGB3,KITLG,KPNA1,LDLR,LIPA,LPL,L
RPAP1,LSR,LTA4H,LTC4S,MAP3K8,MBOAT7,MGAT4A,MIF,MRC1,NCOA1,NEU1,NPC1,NPC2,NR3C1,OLR1,PDE10A,PDE3B,PEX11A,PHYH,PL
TP,PMP22,PPP3CA,PRKCD,PSEN2,PTEN,PTGIS,PTGS1,PTPN1,RAB27A,RAB7A,RAC1,RGCC,RHOA,RILP,ROCK2,SCARB1,SGPP1,SIK3,SLC4
A4,SLC9A3R1,SMPD1,SMPD2,SOD1,SOD2,SORBS1,SPTLC2,SRGAP3,ST3GAL5,STARD4,TAZ,TCF7L2,TGFBR2,TLR4,VAMP3,ZBTB16 
112 
Accumulation of 
lipid 4.48E-06 Decreased -2.884 
ABCA1,ABCC1,ACACA,ACAT1,ACAT2,ACP2,ADIPOR1,ADIPOR2,APOBR,ARSA,BAX,BRD8,CAV1,COL4A3BP,CPT1A,CREM,CSF2RB,CXCL12,
DBI,EPAS1,FABP4,FASN,FGR,GBA,GSK3A,H2AFZ,HCK,HMOX1,IDH1,IGF1,LAMP1,LAMP2,LDLR,LPL,MIF,NPC1,NPC2,PLTP,PTEN,PTPN1,RE
NBP,SCARB1,SCARB2,SHTN1,SLC36A1,SMPD1,SMPD2,TLR4 
48 
Accumulation of 
steroid 5.90E-06 Decreased -3.447 
ABCA1,ACAT1,ACAT2,ACP2,CAV1,CREM,FABP4,GSK3A,HMOX1,IGF1,LAMP1,LAMP2,LDLR,NPC1,NPC2,PLTP,SCARB1,SMPD1 18 
Quantity of 
sphingolipid 1.16E-05  0.981 
ARF6,CASP8,CAV1,CERK,COL4A3BP,CSF1,GBA,HINT1,IGF1,NPC1,PLTP,PMP22,PRKCD,PSEN2,RAC1,RHOA,SCARB1,SGPP1,SMPD1,SMPD
2,SPTLC2 
21 
Quantity of 
glycosphingolipid 1.46E-05  0.855 
ARF6,CASP8,CAV1,COL4A3BP,CSF1,GBA,HINT1,IGF1,NPC1,PLTP,PMP22,PRKCD,PSEN2,RAC1,RHOA,SCARB1,SGPP1,SMPD1,SMPD2,SPT
LC2 
20 
Storage of lipid 1.99E-05  -0.286 ABCA1,ABCG1,ARSA,BSCL2,CAV1,CISD1,EHD1,FABP4,ITGB3,LIPA,LPL,MGAT2,NPC1,NRIP1,OSBPL11,SCARB1,SMPD1 17 
Esterification of 
cholesterol 2.21E-05  -0.080 
ABCA1,ABCG1,ACAT1,ACAT2,CAV1,LAMTOR1,LDLR,LPL,OSBPL2,SCARB1,STARD4 11 
Concentration of 
sphingomyelin 2.49E-05  1.998 
ARF6,CAV1,COL4A3BP,HINT1,PLTP,PRKCD,PSEN2,SMPD1,SMPD2,SPTLC2 10 
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3.2.3 Lysosomal	Pathways	and	genes		Regulation	 of	 lipid	 metabolism	 is	 key	 to	 the	 homeostasis	 of	 cells	 and	organisms,	and	the	lysosome	is	an	important	element	of	this	network,	due	to	its	capacity	 to	 process	 and	 sort	 exogenous	 and	 endogenous	 lipids152.	 The	 results	obtained	in	section	3.2.1	Identified	four	canonical	pathways	involved	in	lysosome	fusion	 and	 function,	 therefore	 supporting	 the	 hypothesis	 that	 the	 lysosomal	function	is	regulated	by	the	GATA6	transcription	factor	in	pResMf.		
In	order	to	explore	the	possibility	that	GATA6	regulates	lysosomal	function,	I	first	selected	a	group	of	566	genes	known	to	be	involved	in	lysosome	biology	(	which	I	names	LBG	dataset).	Next,	I	used	the	expression	values	for	these	genes	to	perform	 a	 guided	 analysis	 of	 the	 changes	 occurring	 in	 Gata6-KOmye	 pResMf.	Given	 the	 impact	 of	 sample	 size	 in	 p-value	 adjustment,	 it	 was	 necessary	 to	reassess	the	significance	of	this	data	subset,	by	correcting	the	p-values	using	the	Benjamini-Hochberg	method.	Thus,	I	found	that	of	the	LBG	dataset,	101	genes	are	statistically	 different	 (p	value<0.05).	 Compared	 to	 the	 values	 used	 in	 section	3.2.1	there	were	now	31	new	genes	considered	relevant	to	use	in	the	analysis	of	lysosomal	mechanisms	and	pathways.	The	volcano	plot	depicted	 in	Figure	3.7	shows	how	the	genes	from	the	LBG	dataset	are	regulated	in	Gata6-KOmye	pResMf.	A	 total	of	33	genes	with	significantly	altered	expression	 levels	were	 found	(at	least	2-fold	difference	and	with	p-value	<	0.05),	with	12	and	21	genes	either	down	or	up	regulated,	respectively.			The	LBG	dataset	was	analysed	using	statistical	gene-set-enrichment	methods	where	 differentially-expressed	 genes	 are	 interrogated	 using	 lists	 of	 genes	associated	 with	 a	 particular	 biological	 function	 or	 pathway.	 Significantly	differentially	 expressed	 genes	 (corrected	 p-value<0.05	 and	 fold	 change³	 1.5)	were	uploaded	and	analysed	in	IPA.	I	first	determined	which	canonical	pathways	were	relevantly	changed,	and	I	found	that	the	results	obtained	via	this	approach	supported	those	 in	Section	3.2.1,	where	the	combination	of	 the	most	enriched	canonical	 pathways,	 related	 to	 lipid	metabolism,	 suggested	 a	 dysregulation	of	lysosome	 function,	 but	 also	 provided	 further	 insight	 regarding	 which	 lipid	pathways/classes	could	be	the	most	sensitive	to	the	deletion	of	Gata6.	Table	3.3	
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lists	the	canonical	pathways	related	to	lipid	metabolism	of	the	LBG	dataset	that	were	 significantly	 enriched	 in	 Gata6-KOmye	 pResMf.	 Interestingly,	 five	 of	 the	eight	pathways	were	directly	 linked	to	SL	metabolism-related	genes.	Thus,	my	results	suggested	that	GATA6	deficiency	may	lead	to	dramatic	dysregulation	of	SL	metabolism.	
3.2.4 SL	metabolism	A	closer	inspection	into	which	functions/mechanisms,	directly	related	to	lipid	metabolism,	were	altered	as	a	consequence	of	GATA6	deficiency,	revealed	that	the	 networks	 ‘quantity	 of	 sphingolipid’,	 ‘concentration	 of	 sphingomyelin’	 and	‘quantity	 of	 glycosphingolipid’,	 (Figure	 3.8)	 were	 all	 activated,	 suggesting	 a	pattern	 of	 network	 alterations	 that	 led	 to	 accumulation	 of	 SL.	 The	 generated	networks	 are	 presented	 as	 a	 graph	 indicating	 the	 molecular	 relationships	between	 genes	 and	 gene	 products.	 Genes	 are	 depicted	 as	 nodes,	 and	 the	biological	relationship	between	two	nodes	is	represented	as	an	edge	(line).	The	intensity	of	 the	node	colour	 indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	 (◇),	 such	as	phosphatases	 (△),	kinases	 (▽);	transmembrane	receptor	(0);	cytokines	(☐	);	and	other	(○).	
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Figure	3.7	GATA6	deficiency	leads	to	dysregulation	of	lysosomal	metabolism	related	
genes.		‘Volcano	plot’	of	statistical	significance	against	fold-change	between	Gata6-WT	and	Gata6-KOmye	pResMj,	demonstrating	the	most	significantly	differentially	expressed	genes.	Notably	2-fold	down-regulated	and	up-	regulated	genes	with	p-value<0.05	are	indicated.	A	total	of	36	genes	with	significantly	altered	(red	dots)	expression	levels	were	found	(at	least	2-fold	altered	and	with	p-value	 <	 0.05),	 with	 12	 and	 24	 genes	 either	 down	 or	 up	 regulated,	 respectively.	 Statistical	significance	was	assessed	using	Benjamini-Hochberg	method.		 	
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Table	3.3	-	The	most	significantly	enriched	lipid	metabolism	related	pathways	in	the	
LBG	dataset	for	Gata6-KO	pResMf	according	to	IPA2.	
		 	
																																																								
2 A positive z-score indicates a predicted activation, and a negative z-score 
indicates a predicted inactivation of the enriched pathway. NaN, a z-score cannot be 
calculated for all Ingenuity canonical pathways.  
	
Ingenuity	Canonical	Pathways -log(p-value) Ratio z-scorePhagosome	maturation 33.6 0.25 NaNAutophagy 23.2 0.35 NaNCeramide	Degradation 4.23 0.5 NaNClathrin-mediated	Endocytosis	Signaling 3.8 0.0558 NaNSphingosine	and	Sphingosine-1-phosphate	Metabolism 3.79 0.375 NaNSphingomyelin	Metabolism 3.79 0.375 NaNSphingosine-1-phosphate	Signaling 3.37 0.0656 -1.342Ceramide	Signaling 1.93 0.0538 NaN
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Figure	3.8	Causal	networks	infer	SL	accumulation	in	GATA	deficient	ResMf.		Predicted	regulatory	networks	from	Causal	Network	Analysis	and	the	impact	on	biological	function.	 The	 network	 is	 graphically	 represented	 as	 nodes	 (genes)	 and	 edges	 (the	 biological	relationship	 between	 genes).	 Genes	 are	 depicted	 as	 nodes,	 and	 the	 biological	 relationship	between	two	nodes	is	represented	as	an	edge	(line).	The	intensity	of	the	node	colour	indicates	the	degree	of	regulation	(-up	or	-down).	The	node	shapes	depict	enzymes	(◇),	phosphatases	(△),	kinases	(▽),	transmembrane	receptor	(0),	cytokines	(☐),	and	other	(○).	Red	and	green	shaded	nodes	 represent	 up-	 and	 downregulated	 genes,	 respectively.	 Orange	 lines	 indicate	 that	 the	regulation	of	that	gene	leads	to	activation,	Yellow	lines	indicate	that	the	regulation	observed	is	inconsistent	with	expectations,	while	grey	arrows	indicate	lack	of	pre-existing	data	to	formulate	expectations.			 	
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3.3 Discussion	
The	 purpose	 of	 this	 chapter	was	 to	 investigate	whether	 the	 expression	 of	genes	 related	 to	 lipid	 metabolism	 was	 regulated	 by	 the	 transcription	 factor	GATA6	 in	pResMf.	First,	 the	microarray	data	 from	WT	and	Gata6-KOmye	mice,	obtained	by	Prof.	Phil	Taylor’s	group	was	analysed	by	employing	the	canonical	pathways	feature	in	IPA	in	order	to	ascertain	the	probable	downstream	effects	of	
Gata6	 KO	 on	 cellular	 biology.	 This	 analysis	 was	 carried	 out	 with	 particular	emphasis	on	lipid	related	pathways	by	focusing	not	only	on	pathways	and	causal	networks	that	could	be	involved	in	lipid	metabolism,	but	also	on	those	that	could	affect	lipid	levels	by	altering	lipid	catabolism,	transport,	and	storage.		Using	this	method,	I	identified	eight	canonical	pathways	that	suggested	how	lipid	metabolism	was	regulated	by	GATA6	in	pResMf.	These	can	be	divided	into	two	main	sets,	(i)	regulation	of	specific	lipid	categories,	and	(ii)	lysosome	fusion	and	 function.	 The	 first	 comprised	 three	 lipid	 categories,	 phospholipids,	 fatty	acids	and	SL,	whilst	the	latter	covered	the	different	routes	of	endocytosis	as	well	as	crucial	steps	in	phagosome	formation.	This	indicates	that	Gata6	expression	is	critical	 for	 lipid	biosynthesis	and	accumulation,	 in	particular,	by	regulating	SL	degradation	 by	 lysosomes.	 That	 in	 turn	 could	 lead	 to	 lysosomal	 storage	disorders.	Thus,	my	results	provide	possible	link	between	Gata6	expression	and	downstream	signalling	related	to	lysosomal	dysfunction.		There	 are	 over	 40	 lysosomal	 storage	 disorders	 known,	 including	 several	sphindolipidoses	where	an	intra-lysosomal	accumulation	of	SL	occurs,	with	the	most	well	studied	of	 these	being	Niemann-Pick	disease125.	Additionally,	 it	was	recently	 shown	 that	 a	 marked	 decrease	 in	 cathepsin	 E	 (CTSE),	 a	 proteinase	mainly	 localized	 on	 the	 endosomal	 compartment	 in	 Mf168,	 and	 highly	 down-regulated	in	GATA6-deficient	cells,	can	lead	to	a	novel	form	of	lysosome	storage	disorder169	 and	 lead	 to	 abnormal	 lipid	 metabolism170.	 Interestingly,	 the	microarray	data	showed	a	downregulation	of	the	Ctse	gene,	indicating	that	CTSE	could	be	involved	in	maintaining	lipid	homeostasis	in	Mf.		
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The	mechanistic	network	algorithm	from	IPA	was	then	used	to	infer	which	functions/mechanisms	were	 likely	 to	 lead	 to	changes	 in	 lipid	metabolism	as	a	consequence	of	GATA6	deficiency.	Thus,	only	the	hypotheses	that	added	relevant	information	 were	 considered	 (i.e.	 lipid	 metabolism	 related	 causal	 networks),	revealing	 14	mechanistic	 networks	 of	 interest	 (Table	 3.2).	 However,	 some	 of	these	data	were	puzzling,	for	instance,	‘quantity	of	glycosphingolipid’,	‘quantity	of	sphingolipid’	and	‘quantity	of	sphingomyelin’	had	positive	z-scores,	indicating	network	activation;	whilst	at	the	same	time,	‘accumulation	of	lipid’,	‘lipid	storage’	and	‘synthesis	of	lipid’	had	negative	z-scores,	suggesting	a	decreased	activation	state.	It	is	possible	though	that	this	could	indicate	an	increase	in	SL,	combined	with	 a	 decrease	 of	 overall	 lipid	 levels.	 Thus,	 taken	 together	 these	 analyses	indicated	 that	 GATA6	 signalling	was	 involved	 in	 lipid	metabolism	 in	 pResMf.	These	observations	led	to	a	further	in-depth	analysis	of	a	data	subset	comprising	of	genes	involved	in	lysosomal	metabolism.	Through	this	approach	I	found	five	canonical	pathways	involved	in	SL	metabolism	that	were	significantly	enriched	in	GATA6-deficient	pResMf	(Table	3.3).	The	analysis	of	this	data	subset	using	the	causal	 analysis	 algorithm	 revealed	 a	 particular	 pattern	 in	 gene	regulation/network	 activation	 that	 ultimately	 could	 lead	 to	 an	 increase	 in	 SL	levels	 (e.g.	 down-regulation	 of	 genes	 that	 lead	 to	 lipid	 consumption,	 up-regulation	of	genes	that	lead	to	lipid	synthesis).	SL	are	located	in	the	outer	leaflet	of	 the	 plasma	 membrane	 and	 interact	 with	 cholesterol-containing	 specific	membrane	domains	known	as	‘lipid	rafts’.	These	are	small	regions	(10-200	nm)	that	 play	 a	 key	 role	 in	 the	 compartmentalisation	 of	 cellular	 processes	 by	stabilising	protein-protein	or	protein-lipid	interactions.	Further	analysis	of	IPA	data	 showed	 a	 dysregulation	 of	 other	 genes	 involved	 in	 Caveolin-mediated	endocytosis.	The	presence	of	Caveolin-1	in	a	lipid	raft	creates	an	invagination	of	the	 membrane	 recognised	 as	 ‘caveolae’171.	 This	 is	 of	 particular	 relevance	 as	caveolae-mediated	endocytosis	functions	as	a	‘true	uptake	mechanism’	parallel	to	 the	 clathrin	 mediated	 pathway.	 However,	 caveolar	 endocytosis	 provides	 a	more	selective	and	highly	regulated	way	for	uptake	of	specified	substances172.	Caveolae	are	well-studied	in	certain	cell	types	(e.g.,	endothelial	cells,	fibroblasts),	it	is	thought	to	be	absent	in	others	(e.g.,	lymphocytes).	The	presence	of	caveolae	in	Mf	is	less	well-defined	and	indeed	controversial,	varying	by	Mf	type173.	Even	
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though,	the	precise	function	of	caveolins	in	Mf	lipid	metabolism	is	still	unclear,	studies	suggest	their	involvement	in	cholesterol	transport	to	the	membrane174.	Additionally,	caveolins	may	also	be	 involved	 in	 the	modulation	of	Mf	 immune	responses,	as	well	as,	in	the	clearance	of	apoptotic	cells	in	lesions174.		In	 this	 Chapter,	 I	 performed	 analysis	 of	 gene	 expression	 in	 Gata6-KOmye	pResMf.	I	found	dysregulated	gene	networks	directly	linked	to	lipid	metabolism	that	can	potentially	 impact	 the	regulation	of	pResMf	phenotype.	 In	particular,	the	 IPA	 analyses	 indicated	 enrichment	 in	 gene	 networks	 associated	 with	 an	increase	in	the	levels	of	SL.	This	class	of	lipids	has	key	roles	in	the	regulation	of	both	trafficking	and	functions	of	immune	cells175,	and	their	accumulation	leads	to	sphingolipidoses,	a	group	of	inherited	human	diseases	in	which	SL	accumulate	in	one	or	more	organs	due	to	a	degradation	disorder176.	The	activation	of	gene	networks	 indicating	 SL	 accumulation	 can	 potentially	 lead	 to	 changes	 in	 lipid	levels	not	only	in	SL	but	in	the	other	classes	as	well.	It	has	previously	been	shown	that	perturbations	in	genes	involved	in	SL	metabolism,	can	lead	to	a	remarkable	heterogeneity	 in	 lipid	 states,	 affecting	 both	 SL	 and	 GPL98.	 Thus,	 my	 analysis	identified	one	specific	class	of	lipids	to	be	directly	linked	to	Gata6	expression	in	pResMf	(SL).	
In	 conclusion,	 the	 findings	 in	 this	 Chapter	 showed	 that:	 1)	 GATA6	transcription	factor	regulates	the	expression	of	lipid	metabolism	related	genes	in	pResMf;	 2)	 in	particular,	 SL	metabolism-related	 genes	 are	 affected	by	GATA6	deficiency,	 as	 evidenced	 by	 the	 suggested	 dysregulation	 of	 SL	 metabolism-related	pathways	and	causal	mechanisms;	3)	a	wide	range	of	genes	with	roles	in	lysosomal	 function	 have	 been	 found	 to	 be	 dysregulated	 as	 a	 consequence	 of	GATA6	loss.	Hence,	the	first	step	in	answering	the	question	of	how	GATA6	affects	lipid	 levels	 in	 pResMf,	 will	 be	 to	 establish	 an	 untargeted	 LC-MS	 lipidomics	workflow.	This	will	enable	me	to	perform	a	global	lipidomics	analysis	in	Gata6-KOmye	 and	 WT	 pResMf,	 and	 thoroughly	 characterise	 the	 impact	 of	 gene	dysregulation	on	global	lipid	levels.			 	
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Chapter	4 Optimisation	of	LC-MS	
conditions	for	untargeted	lipidomics	of	
Mf-like	cells		
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4.1 Introduction	
4.1.1 Untargeted	lipidomics	Studies	conducted	in	Chapter	3	demonstrated	that	the	GATA6	transcription	factor	regulates	lipid	metabolism	related	genes	in	pResMf.		This	work	now	needs	to	be	extended	through	characterising	how	GATA6	regulates	the	levels	of	lipid	metabolites	themselves.	Herein	I	will	optimise	and	validate	an	untargeted	LC-MS	lipidomics	 workflow,	 that	 will	 later	 be	 used	 to	 characterise	 the	 lipidomic	differences	between	Gata6-WT	and	-KOmye	pResMf.		
Lipids	are	important	structural	components	of	cells,	that	also	act	as	sources	of	energy	and	signalling	mediators.	Alterations	in	lipid	metabolism	are	involved	in	 the	 onset	 and	 progression	 of	 a	 variety	 of	 diseases	 such	 as	 cancer,	cardiovascular	disorders,	neurodegenerative	diseases,	obesity	and	diabetes177–181.	Hence	the	increasing	interest	in	the	comprehensive	characterisation	of	the	lipidome	 (lipidomics),	 using	 high-resolution	 mass	 spectrometry.	 There	 are	numerous	 lipidomics	 methods	 available.	 However,	 the	 structural	 diversity	 of	lipids	makes	 getting	 a	 complete	 overview	 of	 all	 lipids	 in	 a	 system	 extremely	challenging182.	High-resolution	lipidomics	approaches	able	to	profile	lipids	in	a	complex	matrix,	and	remove	artefacts	(i.e.	adducts	and	isotopes),	are	not	widely	available,	thus	estimating	the	total	lipidome	is	extremely	difficult93.		The	 most	 common	 approach	 to	 this	 problem	 until	 recently	 was	 a	comprehensive	 lipidomic	 analysis	 by	 ‘separation	 simplification’153.	 This	approach	uses	 several	different	methods	 that	 each	address	 the	 structural	 and	biophysical	 diversity	 of	 lipid	 categories.	 	 In	 that	 way,	 the	 extraction,	 LC	separations	 and	MS	protocols	 are	 separately	 optimised	 to	 obtain	 quantitative	information	about	the	compounds	in	each	lipid	category	separately,	in	a	targeted	fashion182.	The	drawback	of	 targeted	 lipidomics	 is	 that	only	known	species	of	lipids	are	measured93.	Conversely,	untargeted	approaches	are	used	for	global	profiling	of	 lipids	in	biological	systems	without	bias.	While	several	analytical	approaches	can	be	used	to	 perform	 untargeted	 lipidomics,	 liquid	 chromatography/mass	 spectrometry	
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(LC/MS)	is	often	the	technique	of	choice,	due	to	the	large	number	of	metabolites	that	can	be	measured	in	a	single	analysis183.	Using	LC/MS,	tens	of	thousands	of	“features”	can	be	analysed	in	a	single	lipid	extract	(where	a	feature	is	defined	as	an	ion	with	a	unique	m/z	and	retention	time).	At	the	cost	of	increased	run	time,	LC	 separation	 reduces	 the	 complexity	 of	 the	matrix	 introduced	 into	 the	mass	spectrometer,	thus	decreasing	ion-suppression	during	ionization.	As	a	result,	low	abundance	species	are	more	readily	detected184.	With	untargeted	lipidomics	the	aim	is	often	to	determine	which	of	these	features	are	dysregulated	between	two	or	more	sample	sets.		Recently,	 an	 untargeted	 method	 for	 mapping	 the	 platelet	 lipidome	 was	published	using	 a	 lipidomic	workflow	 that	maximizes	 coverage,	 ensuring	 that	low-abundance	lipids	were	detected	and	verified,	essential	step	for	the	discovery	of	 signalling	 lipids93.	 For	 these	 reasons,	 this	method	was	 chosen	 as	 a	 starting	point	 for	 the	 lipidomic	 analysis	 of	 Mf	 populations	 of	 interest	 in	 my	 project.	However,	 this	workflow	had	been	optimised	 for	 the	 analysis	 of	 platelet	 lipids	where	a	higher	number	of	cells	was	available,	 than	I	could	easily	obtain	using	
Gata6-WT	and	-KOmye	pResMf.	Thus,	herein	I	will	use	Mf-like	cells	to	optimise	and	validate	an	untargeted	lipidomics	approach	that	can	later	be	used	to	analyse	pResMf.	
Studies	 in	 the	 past	 2	 decades	 have	 provided	 remarkable	 insight	 into	 the	functional	and	phenotypic	diversity	of	Mf,	which	reflects	their	vital	role	in	innate	immunity,	homeostasis	and	pathogenesis185.	The	majority	of	Mf	ex	vivo	studies	utilize	only	a	few	Mf	phenotypes	for	practical	reasons111	(as	discussed	below).	
The	peritoneal	cavity	provides	an	easy-access	source	of	pResMf,	which	can	be	 isolated	 through	 lavage	with	PBS,	yielding	c.a.	1	million	cells	per	mouse186.	This	is	a	relatively	low	yield	that	makes	large	scale	experiments	quite	difficult.	Alternatively,	 thioglycollate-elicited	 Mf	 (TGEM)	 can	 be	 isolated	 with	 much	higher	 yields	 (30-40	 million	 cells/mouse),	 however	 their	 phenotype	 is	significantly	different	from	that	of	pResMf	as	they	are	inflammatory	Mf	derived	from	 monocytes187.	 BMDM	 are	 another	 source	 of	 primary	 Mf.	 Nevertheless,	BMDMs	require	isolation	of	stem	cells	that	are	further	cultured	for	1	week	in	the	
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presence	 of	 M-CSF	 for	 differentiation,	 which	 represents	 a	 fairly	 artificial	environment111.	 Lastly,	 RAW	264.7	 cells	 are	 one	 of	 the	most	 widely	 used	Mf	phenotypes	used	in	cell	culture	due	to	their	ability	to	replicate	rapidly.	RAW	cells	represent	an	immortalized	phenotype	derived	from	peritoneal	tumours	induced	in	BALB/c	male	mice	by	the	Abelson	murine	leukaemia	virus111.	These	cells	have	been	passaged	for	over	20	years	ex	vivo,	thus	relating	information	from	RAW	cells	to	a	biological	context	requires	some	direct	comparison	with	primary	Mf111.		
A	previous	attempt	at	characterizing	the	global	murine	Mf	 lipidome	relied	solely	on	the	use	of	RAW	cells95	and	did	not	address	the	issue	of	the	different	Mf	phenotypes	 and	 how	 their	 lipid	metabolism	might	 be	 differentially	 regulated.	Additionally,	 studies	 where	 the	 different	 Mf	 phenotypes	 were	 considered	focused	 solely	 on	 FA	 metabolism111,188.	 In	 this	 Chapter	 I	 will	 optimise	 and	validate	an	untargeted	lipidomics	approach,	for	global	lipid	profiling	of	murine	pResMf	and	RAW	cells,	ensuring	that	the	occurrence	of	false	positive	features	is	minimised.	This	 Chapter	 describes	 the	modifications	 implemented	 to	 the	workflow	 in	order	to	adapt	it	to	the	samples/questions	of	interest	for	the	lipidomics	analysis	of	Gata6-	WT	and	-KOmye	pResMf.	I	will	use	this	workflow	to	profile	the	lipidome	of	murine	 pResMf	 and	 RAW	 cells	 to	 uncover	 cell-type	 specific	 differences	 in	order	 to	 ensure	 that	 the	methods	 employed	 are	 optimised	 for	 the	untargeted	lipidomic	analysis	of	Mf.		
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4.1.2 Aims	
• Studies	described	in	this	Chapter	will	establish	an	untargeted	LC-MS	method	for	the	lipidomic	analysis	of	Mf.	Here,	I	will:	
o Evaluate	the	sensitivity	of	the	untargeted	lipidomics	approach.	
o Check	possible	artefacts	in	data	analysis.	
o Optimize	the	LTQ	Orbitrap	settings	for	optimal	performance.	
o Analyse	differences	in	lipid	molecular	species	between	primary	and	immortalised	Mf	cells	used	for	ex	vivo	studies.	
o Establish	 a	 lipidomic	 analysis	 workflow	 that	 minimizes	 the	occurrence	 of	 false	 positive	 and	 false	 negative	 features,	providing	a	more	manageable	and	comprehensive	dataset.	
o Characterise	the	lipidomic	differences	between	Mf-like	cells.	
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4.2 Results	
An	untargeted	 lipidomics	approach	based	on	LC-MS	will	be	used	 to	profile	lipid	differences	in	murine	Mf.	However,	there	is	no	standardised	workflow	and	researchers	use	a	wide	variety	of	high-resolution	mass	spectrometers,	operating	under	different	operating	conditions.	To	this	end,	I	first	investigated	the	quality	of	lipidomics	data	obtained	from	control	samples	(peritoneal	lavages)	analysed	under	several	conditions.	LC-MS	conditions	and	data	processing	methods	were	optimised	 in	 a	 systematic	manner,	 in	 order	 to	 achieve	 a	workflow	 capable	 of	profiling	lipidomic	changes	in	murine	Mf,	and	will	be	described	in	detail	in	the	following	sections.	
4.2.1 Optimisation	of	LC-MS	conditions	
a) Mass	range	In	previous	studies	using	similar	conditions,	two	LC-MS	runs	were	combined	for	untargeted	lipidomics,	providing	coverage	of	both	high	and	low	m/z	values	(m/z	100	-	900	 and	m/z	800	-	1600)93.	 This	 ensured	 that	 the	 sensitivity	 of	 the	method	was	not	compromised.	However,	being	able	to	combine	these	two	ranges	into	 one	 would	 mean	 reducing	 by	 half	 the	 number	 of	 runs	 needed	 and	consequently	the	amount	of	sample	required,	which	is	paramount	when	dealing	with	animal	samples,	in	particular	with	samples	from	Gata6-WT-KOmye	pResMf,	due	to	their	low	cell	yield.		To	determine	whether	combination	of	both	high	and	low	mass	ranges	would	result	 in	 loss	of	 features/sensitivity,	 I	analysed	a	 lipid	extract	 from	Raw	264.7	cells	in	negative	mode	using	m/z	range	from	100	–	1600	amu	(“Full”	range)	and	a	combined	range	from	100	-	900	and	800	-	1600	m/z	(“combined”	range),	where	the	same	sample	was	run	twice,	scanning	from	100	–	900	m/z	and	a	second	time	with	a	800	–	1600	m/z	 range.	 Following	 the	LC-MS	analysis	 the	data	 from	 the	100	-	900	and	800	–	1600	m/z	runs	were	combined.	It	is	important	to	note	that	the	data	comparison	was	done	using	pre-processed	data	from	an	initial	step	in	the	data	analysis	and	therefore,	both	the	number	of	frames	and	peaks	obtained	was	compared.	
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Results	showed	that	the	number	of	features	was	similar	to	both	mass	ranges	(“combined”	and	“full”),	2281	and	2323	 features	 for	 the	“combined”	and	“full”	ranges,	respectively,	revealing	a	2	%	increase	in	the	number	of	features	found	in	the	 full	 range,	 of	which	 73	%	were	 common	 to	 both	 approaches	 (Figure	 4.1).	Thus,	 the	 data	 indicates	 that	 there	 is	 no	 significant	 loss	 of	 information,	when	comparing	the	two	approaches.	
a) Improvement	of	mass	accuracy	of	high-resolution	LC-MS	data	using	
background	ions			Mass	 accuracy	 and	 mass	 reproducibility	 are	 key	 parameters	 of	 mass	spectrometric	 performance	 and	 lipid	 species	 identification.	 Mass	 accuracy	 is	commonly	specified	as	the	ratio	of	the	m/z	measurement	error	(Dm/z)	to	the	true	
m/z.	 The	mass	 accuracy	 is	 typically	 reported	 in	 parts	 per	million	 (ppm,	 10-6)	(Equation	 4.1).	 Mass	 reproducibility	 is	 the	 standard	 error	 of	 the	 m/z	measurement189.		
Equation	4.1	Mass	accuracy	!"##	"%%&'"%(	(++,) = ;3#0'405	,/= − >ℎ0;'0>@%"A	,/=>ℎ0;'0>@%"A	,/= × 109	Mass	 accuracy	 and	 mass	 reproducibility	 are	 linked	 to	 both	 the	 resolving	power	 and	 the	 mass	 spectrometer	 hardware.	 Essentially,	 a	 relative	 mass	reproducibility	of	±	1	ppm	means	that	the	measurement	error	of	a	lipid	ion	with	
m/z	304.4669	will	be	within	±	0.0003	amu.	Hence,	the	measured	m/z	value	of	the	lipid	 ion	 will	 be	 in	 the	 range	 of	 m/z	304.4970	±	0.0003	amu.	 Thus,	 the	identification	of	lipid	ions	is	usually	performed	using	a	“m/z	tolerance	window”	(5	ppm	max),	 set	 according	 to	 the	 mass	 resolution,	 mass	 accuracy	 and	 mass	reproducibility	of	the	acquired	data.	In	order	to	obtain	a	high	mass	accuracy	–	and	specific	lipid	identification	–	it	is	necessary	to	accurately	calibrate	the	mass	spectrometer.	However,	large	lipidomic	experiments	with	data	acquisition	over	several	days	will	be	influenced	by	drifts	of	mass	analyser	accuracy,	leading	to	a	calibration	m/z	 offset	 that	 will	 affect	 the	 mass	 calibration	 but	 not	 the	 mass	reproducibility.	 One	way	 of	minimizing	 the	 adverse	 effects	 of	m/z	 calibration	drift	 is	 by	 internal	 calibration,	 using	 internal	 lipid	 standards	 or	 sample	
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contaminants	with	known	m/z	value	that	are	present	in	all	samples.	This	latter	approach	is	called	“lock	mass”	190,191.		While	the	concept	of	a	lock	mass	is	well	known	it	is	not	frequently	employed.	This	is	due,	in	part,	to	the	effort	of	introducing	a	lock	mass	into	the	samples	being	analysed.	However,	herein	the	lock-masses	used	for	positive	and	negative	mode	were	 from	stable	contaminants	 found	 in	all	 samples.	Before	each	analysis,	 the	instrument	was	externally	calibrated	and	at	 least	 three	methanol	blanks	were	analysed	by	LC-MS.	Internal	mass	calibrants	(lock-masses)	were	used	in	positive	and	negative	ion	mode	and	consisted	of	diisooctyl	phthalate	(m/z	391.2842	[M-H]-)	and	sodium	dodecyl	sulfate	(m/z	265.1479)	respectively.	Implementing	this	strategy	 resulted	 in	 a	 significant	 improvement	 in	 mass	 accuracy	 and	reproducibility	 (Figure	4.2).	Several	 lipid	standards	were	analysed	 in	order	 to	assess	 the	mass	accuracy	values	obtained	with	and	without	 lock-mass	(Figure	4.3).		Having	successfully	optimised	the	LC-MS	conditions,	in	the	next	section	I	will	establish	 methods	 for	 data	 analysis	 and	 validate	 the	 untargeted	 lipidomics	workflow	using	lipid	extracts	from	Mf-like	cells.			 	
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Figure	4.1	Comparison	between	“full”	and	“combined”	mass	ranges.		Venn	diagram	depicting	total	features	found	for	“combined”	and	“full”	m/z	ranges	as	well	as	features	common	to	found	in	both	analysis	types.	A	total	of	1659	(73	%)	features	were	common	to	both	m/z	ranges,	with	2281	being	found	only	in	the	combined	range	and	2323	in	the	full	range.			 	
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Figure	 4.2	 Increasing	 the	 mass	 accuracy	 of	 high-resolution	 LC-MS	 data	 using	
background	ions.		Diisooctyl	 phthalate	 (m/z	391.2842)	 and	 sodium	 dodecyl	 sulphate	 (m/z	265.1479)	 were	used	as	internal	mass	calibrants	(lock-masses).	Resulting	in	a	significant	improvement	in	mass	accuracy.	Bars	represent	 the	combination	of	all	m/z	values	analysed	 in	negative	 ion	mode	for	samples	analysed	with	and	without	 lock	mass	with	the	respective	SEM.	Statistical	significance	determined	 using	 the	 Holm-Sidak	 method,	 with	 alpha=5.000%.	 Each	 row	 was	 analysed	individually,	without	assuming	a	consistent	SD,	 the	graphs	depict	 the	mean	and	SEM.	p-value,	*<0.05,	**<0.01.							
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Figure	 4.3	 Increasing	 the	 mass	 accuracy	 of	 high-resolution	 LC-MS	 data	 using	
background	ions.		Diisooctyl	phthalate	(m/z	391.2842)	and	sodium	dodecyl	sulfate	(m/z	265.1479)	were	used	as	 internal	 mass	 calibrants	 (lock-masses).	 Resulting	 in	 a	 significant	 improvement	 in	 mass	accuracy.	Bars	represent	the	mass	accuracy	in	negative	ion	mode,	for	samples	analysed	with	and	without	lock	mass,	for	different	lipid	standards.	Individual	deuterated	internal	standard	Dppm	values.	
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Figure	4.4	Increasing	the	mass	accuracy	and	reproducibility	of	high-resolution	LC-MS	
data	using	background	ions.		A-	 scatter	 plot	 representation	 of	 mass	 accuracy	 variation	 for	 two	 deuterated	 internal	standards	 with	 time	 (23	h).	 B-	 Mass	 reproducibility	 of	 samples	 depicted	 in	 panel	 A.	 Grey	 –	Arachidonic	acid	d8,	Black	-	PE	ether.		 	
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4.2.2 Validation	of	LC-MS	workflow	
To	compare	the	lipidomes	of	pResMf	and	RAW		264.7	cells,	high-resolution	LC-	MS	 was	 used	 to	 maximize	 detection	 of	 lipids	 with	 close	m/z	 values,	 and	extensive	 chromatography	 was	 used	 to	 separate	 isobaric	 species	 and	 enable	detection	of	low-abundance	lipids.		
pResMf	 were	 obtained	 from	 C57BL/6	 mice	 aged	 between	 10	–	13	weeks,	through	 peritoneal	 lavage	 followed	 by	 Mf	 isolation	 using	 FACS	 sorting.	RAW	264.7	cells	were	cultured	as	described	in	Chapter	2.	Independent	triplicates	were	collected	for	both	cell	types.	Total	lipids	from	these	samples	were	extracted	using	 a	 double	 extraction	 (Isopropanol/hexane/acetic	 acid	 followed	 by	chloroform/methanol).	The	lipid	extracts	were	then	separated	on	an	Accucore	C18	column	(150	x	2.1	mm,	2.6	µm)	using	an	isocratic	mobile	phase	A	(H2O:ACN	80:20	v/v)	and	a	phase	B	(IPA:	ACN,	70:30	v/v)	at	a	flow	rate	of	0.425	mL/min	over	60	min,	with	4	mM	ammonium	acetate.	High	resolution	(60,000,	FWHM	at	400	amu)	 full-scan	 spectra	were	acquired	 in	both	+ve	and	–ve	ESI	mode	over	100	-	1800	m/z	range	on	an	Orbitrap	(Elite).	Chromatographic	alignment,	peak	integration	 and	 isotope	 removal	was	 done	using	XCMS.	 The	dataset	was	 then	further	 processed	 using	 the	 software	 recently	 developed	 by	 the	 Cardiff	Lipidomics	 group,	 LipidFinder192.	 Results	 were	 then	 queried	 against	 a	 lipid	database,	 LIPID	 MAPS	 using	 the	 database	 search	 module	 integrated	 with	LipidFinder	with	mass	tolerance	of	5	ppm.		
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4.2.3 Identification	of	Mf	lipids	using	XCMS	online	
The	processing	of	metabolomic	data	by	XCMS	Online	 is	organized	 in	 three	steps:	 data	 upload,	 parameter	 selection,	 and	 result	 interpretation183.	 The	samples	for	both	groups	(pResMf	and	RAW	cells)	and	extracted	blanks	(samples	containing	only	PBS	that	went	through	the	same	extraction	procedure	as	the	cell	samples)	were	uploaded	through	a	specific	Java	applet,	which	allows	the	user	to	drag	and	drop	the	into	the	upload	area	of	the	program.	During	the	file	upload,	parameters	were	 selected	matching	 the	 instrument	 setup	used	 to	 analyse	 the	samples	(Methods).	Once	the	files	were	uploaded	and	correct	parameters	were	selected	the	‘job’	was	then	submitted	to	the	system.		XCMS	Online	uses	nonlinear	methods	to	compensate	for	retention	time	drifts	between	 samples193,194.	 An	 overlay	 of	 all	 total	 ion	 chromatograms	 is	 shown	before	 and	 after	 retention	 time	 correction,	 in	 addition	 to	 the	 retention	 time	correction	curves	(Figure	4.5).	After	retention	time	correction,	all	TICs	should	be	in	alignment,	allowing	the	differential	analysis	of	lipids	present	in	the	3	samples.	The	“mirror	plots”183	in	Figure	4.5D	are	part	of	the	output	from	XCMS,	show	the	dysregulated	features,	ions	whose	intensities	are	altered	between	the	two	Mf	sample	 groups,	 according	 to	 the	 statistical	 threshold	 selected	 (P	<	0.1	 and	|FC|	>	1.5).	Down-regulated	features	are	represented	as	circles	on	the	bottom	of	the	plot,	whilst	up-regulated	features	are	represented	as	circles	on	the	top	of	the	plot.	The	size	of	each	circle	 corresponds	 to	 the	 fold	change	 (up-regulated	and	down-regulated	 features	 are	 represented	 in	 green	 and	 red	 respectively);	whereas	 the	 shade	 of	 the	 colour	 represents	 the	 p-value,	with	 brighter	 circles	having	lower	p-values.	The	retention	time	corrected	TICs	are	also	overlaid	in	the	background	of	the	figure.				 	
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Figure	4.5	XCMS	RT	correction	and	“mirror	plots”.		Mf	 lipid	extracts	from	RAW	cells	and	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Overlay	of	all	total	ion	chromatograms	is	shown	before	(A)	and	after	retention	time	correction	(B),	retention	time	correction	curves	(C).	“Mirror	plots”	show	the	dysregulated	features,	ions	whose	intensities	are	altered	between	the	2	Mf	sample	groups,	according	to	the	statistical	threshold	selected	(P	<	0.1	and	|FC|	>	1.5).	Down-regulated	 features	 are	 represented	 as	 circles	 on	 the	 bottom	 of	 the	 plot,	 whilst	 up-regulated	features	are	represented	as	circles	on	the	bottom	of	the	plot.	The	size	of	each	circle	corresponds	to	the	(log)	fold	change	(up-regulated	and	down-regulated	features	are	represented	in	green	and	red	respectively);	shade	of	the	colour	represents	the	p-value,	with	brighter	circles	having	lower	p-values.	The	retention	time	corrected	TIC	are	also	overlaid	in	the	background	of	the	figure.			 	
10 20 30 40 50
Retention time (minutes)
m
/z
15
00
10
00
50
0
0
50
0
10
00
15
00
Cloud Plot    10391 features with p-value  0.05 , fold change  1.5
0 10 20 30 40 50 60
0.
0e
+0
0
2.
0e
+0
8
4.
0e
+0
8
6.
0e
+0
8
8.
0e
+0
8
1.
0e
+0
9
1.
2e
+0
9 Total Ion Chromatograms (original)
Retention Time (minutes)
TI
C
1_GATA6_WT_1
3_GATA6_WT_1
4_GATA6_WT_1
1_RAW
3_RAW
4_RAW
0 10 20 30 40 50 60
0.
0e
+0
0
2.
0e
+0
8
4.
0e
+0
8
6.
0e
+0
8
8.
0e
+0
8
1.
0e
+0
9
1.
2e
+0
9 Total Ion Chromatograms (corrected)
Retention Time (minutes)
TI
C
3_RAW
1_RAW
4_RAW
4_GATA6_WT_1
3_GATA6_WT_1
1_GATA6_WT_1
1_PBS
4_PBS
3_PBS
0 10 20 30 40 50 60
−1
0
1
2
Retention Time Deviation vs. Retention Time
Retention Time (minutes)
Re
te
nt
ion
 T
im
e 
De
via
tio
n 
(m
inu
te
s)
3_RAW
1_RAW
4_RAW
4_GATA6_WT_1
3_GATA6_WT_1
1_GATA6_WT_1
1_PBS
4_PBS
3_PBS
Retention time (minutes)
Retention time (minutes) Retention time (minutes)
Retention time (minutes)
TI
C
TI
C
m
/z
R
et
en
tio
n 
tim
e 
co
rr
ec
tio
n 
(m
in
ut
es
)
A
C
B
D
  
111 
A	table	with	details	for	all	the	identified	lipid	features	is	generated	by	XCMS	(diffreport),	as	well	as	an	overlay	of	the	extracted	ion	chromatograms	from	each	sample	for	all	lipid	features.	This	feature	of	XCMS	is	particularly	important	and	it	will	be	useful	in	further	sections,	as	it	was	critical	in	the	validation	of	the	peak	integration	of	the	dataset.		XCMS	 provides	 putative	 identifications	 based	 on	 a	 METLIN	 search	 of	 the	accurate	 mass,	 ordered	 by	 mass	 difference	 (ppm).	 However,	 METLIN	 is	 a	computational	database	including	over	a	million	molecules	ranging	from	lipids,	steroids,	plant	&	bacteria	metabolites,	small	peptides,	carbohydrates,	exogenous	drugs/metabolites,	central	carbon	metabolites	and	toxicants;	and	whilst	a	large	number	of	entries	 in	a	database	 is	a	positive	 factor,	 it	can	also	be	detrimental	when	 there	 is	no	option	 to	select	a	category	such	as	 lipids	 for	a	more	concise	search	 which	 often	 leads	 to	 incorrect	 putative	 identifications.	 Additionally,	diffreport	does	not	provide	a	reliable	approximation	of	metabolites	detected	due	to	 adducts,	 fragments,	 and	 artefacts.	 Indeed,	 depending	 on	 experimental	conditions,	more	 than	 50	%	 of	 the	 features	 on	 a	 diffreport	 can	 be	 a	 result	 of	fragments	and	artefacts195.		Isotopic	interferences	arise	when	an	isotope	from	one	species	occurs	at	the	same	 nominal	 mass	 as	 the	 monoisotopic	 mass	 of	 another	 species189.	 This	situation	is	very	common	in	untargeted	lipidomics	approaches,	which	makes	it	essential	 to	 implement	 an	 accurate	 method	 of	 isotope	 correction	(deisotoping)196.	A	 final	 optional	 isotope	 removal	 step	 is	 done	 to	 identify	 and	remove	features,	thus	simplifying	considerably	the	dataset.	This	step	reduced	the	Mf	 lipidomics	dataset	size	by	ca.	33	%	(Negative	ion	mode	before	deisotoping	3295,	 after	 2216;	 Positive	 ion	 mode	 before	 deisotoping	 10327,	 after	 6849),	Figure	4.6.		 	
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Figure	4.6	Isotope	detection	by	XCMS	on	dataset	containing	ions	present	in	both	RAW	
cells	and	pResMf.		Mf	 lipid	extracts	from	RAW	cells	and	pResMf	were	analyzed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Scatter	diagrams	showing	elution	of	lipids	and	 isotopes	 identified	by	XCMS,	 in	either	negative-	or	positive-ion	mode.	A	–	Mf	 removal	of	isotopes	 from	 the	dataset	processed	with	XCMS;	B-	Mf	 lipids	after	 isotope	 removal.	Red	dots	indicate	m/z	 ions	 identified	as	 isotopes	 removed	during	 the	 isotope	 removal	 step;	Black	dots	represent	remaining	m/z	ions.	Isotope	removal	reduced	the	Mf	lipidomics	dataset	size	by	ca.	33%	(Negative	ion	mode	before	deisotoping	3295,	after	2216;	Positive	ion	mode	before	deisotoping	10327,	after	6849).	 	
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4.2.4 Computational	workflow	for	discovery	of	lipids	identifies	significant	
differences	in	the	lipidome	of	RAW	264.7	cells	and	pResMf	
a) LipidFinder	clean-up	Accurate	and	high-quality	curation	of	lipidomic	datasets	is	essential	for	cell	biology	studies	and	biomarker	discovery.	Nevertheless,	a	major	challenge	lies	in	removing	 artefacts	 otherwise	mistakenly	 interpreted	 as	 real	 lipids	 from	 large	LC-	MS	datasets,	while	 retaining	genuine	 ions	 in	 the	dataset.	Herein	 I	used	an	approach	specifically	tailored	for	lipidomics,	particularly	discovery	research,	on	the	data	obtained	after	XCMS	processing.	LipidFinder	is	an	open-source	Python	workflow	 that	 screens	 the	 data	 for	 possible	 artefacts,	 and	 the	 outputs	 are	assessed	against	online	databases	and	categorized	into	LIPID	MAPS	categories192.		A	major	issue	with	ESI,	is	the	generation	of	ions	arising	from	either	common	contaminating	ions,	in-source	fragments	of	lipids,	multiple	noncovalent	adducts,	or	 solvent	 background192.	 The	 PeakFilter	 program	 is	 the	 main	 peak-finding	algorithm	in	LipidFinder,	and	 it	 includes	contaminant/adduct	removal	and	RT	correction.	The	Mf	lipid	dataset	was	subjected	to	PeakFilter,	resulting	in	a	39	%	reduction	 of	 features,	 from	 9065	 to	 5529	 (Figure	 4.7):	 21	%	 solvent	contaminants,	0.3	%	mass	contaminants	and	low	intensity	ions,	8.8	%	adducts,	7.5	%	outliers,	1.7	%	RT	exclusion	ions.			 	
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Figure	4.7	LipidFinder	greatly	reduces	the	number	of	features.		Mf	 lipid	extracts	from	RAW	cells	and	pResMf	were	analyzed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS	followed	by	LipidFinder.	Scatter	diagrams	showing	elution	of	lipids	identified	by	XCMS,	in	either	negative-	or	positive-ion	mode,	highlighting	the	m/z	ions	removed	by	LipidFinder,	resulting	in	a	39	%	reduction	of	lipid	features:	21	%	solvent	contaminants,	0.3	%	mass	contaminants	and	 low	 intensity	 ions,	8.8	%	adducts,	7.5	%	outliers,	1.7	%	RT	exclusion	ions.	Red	dots	indicate	m/z	ions	identified	as	artefacts	and	removed	during	PeakFilter;	Black	dots	represent	remaining	m/z	ions.		 	
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b) Putative	identification	of	positively	and	negatively	charged	lipids	by	
LipidFinder	The	positive	and	negative	ion	mode	data	resulting	from	PeakFilter	was	then	combined	using	 the	Amalgamator,	 an	optional	program	used	 to	 combine	data	sets	from	positive	and	negative	runs.	The	program	found	matches	for	402	m/z	ions	resulting	 in	a	 further	reduction	of	 the	number	of	 features	by	3.7	%,	 from	5529	to	5324.		The	MSSearch	program	in	LipidFinder	uses	 the	 list	of	m/z	values	resulting	from	the	Amalgamator	for	putative	identification	based	on	accurate	mass	using	the	LIPID	MAPS	database3	(Figure	4.8).	However,	there	is	still	a	large	number	of	lipids	missing	from	online	databases	and	the	results	coming	back	as	unknown	is	spread	through	the	whole	m/z	 range,	accounting	 for	about	24	%	of	 the	values	searched.	The	putative	identification	process	returned	classifications	for	76	%	of	
m/z	 ions	 matching	 5	 of	 the	 8	 Lipid	 Maps	 categories,	 Fatty	 acyls	 (FA)	 10	%;	Glycerolipids	(GL)	17	%;	(GPL)	37	%;	SL	12	%;	Sterol	 lipids	0.36	%.	Moreover,	the	lipids	identified	seem	to	overall	match	the	m/z	and	retention	times	expected	for	the	respective	lipid	categories.		
4.2.5 Lipid	levels	and	species	vary	greatly	between	pResMf	and	RAW	cells	
a) Global	lipidomic	differences	between	pResMf	and	RAW	cells	
Next,	 I	 examined	 the	 global	 differences	 between	 pResMf	 and	 RAW	 cells,	analysing	lipids	whose	levels	are	significantly	different	in	both	cell	types	(Figure	4.9).	 Of	 the	 5265	 features	 comprising	 the	 dataset,	 69.4	%	 were	 significantly	dysregulated.	However,	of	the	dysregulated	features	the	number	of	significantly	increased	 is	 surprisingly	 similar	 between	 the	 2	 samples.	 With	 RAW	 cells	presenting	a	slightly	higher	percentage	of	upregulated,	55	%	vs.	the	45	%	found	in	pResMf.		 	
																																																								
(1) 3	COMP_DB:	a	computationally	generated	database	composed	of	over	30,000	bulk	(isobaric)	species	covering	30	lipid	classes	which	is	customized	for	precursor	ion	searching.		
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Figure	 4.8	 Putative	 identification	 of	 positively	 and	 negatively	 charged	 lipids	 by	
LipidFinder.		Mf	 lipid	extracts	from	RAW	cells	and	pResMf	were	analyzed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS	followed	by	LipidFinder.	Scatter	diagram	showing	Mf	 lipids	 present	 in	 pResMf	 and	 RAW	 cells	 putatively	 identified	 using	 LipidFinder	(MSSearch).	 Fatty	 acyls	 -	 178	 lipids	 (10	%);	 Glycerolipids	 –	 1487	 lipids	 (17	%);	Glycerophospholipids	-1974	lipids	(37	%);	Sphingolipids	–	669	lipids	(12	%);	Sterol	lipids	–	17	lipids	(0.36	%);	Unknown	–	940	lipids	(24	%).		
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Figure	4.9	Lipid	levels	and	species	vary	greatly	between	pResMf	and	RAW	cells.		Mf	 lipid	extracts	from	RAW	cells	and	pResMf	were	analyzed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	 then	processed	using	XCMS	followed	by	LipidFinder.	Volcano	plots	representing	 fold-change	 and	 p-value	 of	 lipids	 in	 pResMf	 relative	 RAW	 cells.	 Significantly	changed	 lipid	 levels	 are	 indicated	 by	 black	 (69.4	%),	 and	 unchanged	 levels	 by	 grey	 (30.6	%).	Statistical	 significance	was	determined	using	 the	Holm-Sidak	method,	with	alpha=5.0	%.	Each	row	was	analysed	 individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P	<	0.1	and	|FC|	>	1.5	(depicted	in	black).			 	
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b) Lipid	dysregulation	by	lipid	category	in	Mf	
Mapping	 the	distribution	of	 the	upregulated	 features	 in	pResMf	 and	RAW	cells	by	lipid	category	gave	some	insight	into	how	these	differ	in	the	2	cell	types,	leading	me	to	take	a	closer	look	at	how	significant	these	differences	are4.		
Volcano	 plots	 representing	 fold-change	 and	 p-value	 of	 lipids	 in	 pResMf	relative	RAW	cells	by	 lipid	category,	show	that	GL	(73	%),	GPL	(68	%)	and	SL	(66	%)	 are	 the	 categories	 with	 highest	 percentage	 of	 dysregulated	 lipids.	Interestingly,	FA	(51	%)	and	GL	(51	%)	are	the	only	categories	where	most	of	the	significantly	 dysregulated	 lipids	 are	 upregulated	 in	 pResMf.	 However,	 even	though	not	all	the	lipids	were	detected	in	both	cell	types,	the	percentage	of	lipids	present	 only	 in	 one	 cell	 type	 remains	 below	 10	%	 for	 most	 lipid	 categories	(percentage	 of	 unique	 lipids	 calculated	 considering	 the	 significant	m/z	 ions	upregulated	 for	 pResMf	 and	 RAW	cells).	 With	 the	 exception	 being	 the	 FA	category,	where	29	%	of	lipids	upregulated	in	RAW	cells	are	absent	in	pResMf.			
Next,	I	will	look	into	which	lipid	classes	accounted	for	the	highest	percentages	of	molecules	within	the	significantly	changed	lipid	categories.					 	
																																																								
4	Due	to	the	low	number	of	features	identified	as	sterol	lipids	(17)	it	is	not	possible	to	assume	significance	of	percentages.	
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Figure	 4.10	 Volcano	 plot	 of	 significantly	 increased	 lipids	 in	 both	 pResMf	 and	
RAW	264.7	cells	by	lipid	category.		Mf	 lipid	extracts	from	RAW	cells	and	pResMf	were	analyzed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	 then	processed	using	XCMS	followed	by	LipidFinder.	Volcano	plots	representing	fold-change	and	p-value	of	lipids	in	pResMf	relative	RAW	cells	by	lipid	category.	Significantly	changed	 lipid	 levels	are	 indicated	by	black,	and	unchanged	 levels	by	grey.	Lipids	found	 only	 in	 pResMf	 or	 RAW	 cells	 are	 coloured	 in	 blue	 and	 red,	 respectively.	 Statistical	significance	was	determined	using	 the	Holm-Sidak	method,	with	alpha=5.00%.	Each	 row	was	analysed	individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P	<	0.1	and	|FC|	>	1.5	(depicted	in	black).					 	
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c) Significantly	different	lipid	classes	in	Mf-like	cells	
Here	 I	 selected	 the	 significantly	different	 lipids	 in	pResMf	 and	RAW	264.7	cells	 and	 found	 that	 the	majority	 (44.4	%)	were	 putatively	 identified	 as	 GPL,	followed	 by	 GL	 (19.3	%)	 and	 SL	 (9.1	%)	 (Figure	 4.11	 inner	 ring).	 I	 then	subdivided	each	lipid	category	into	their	respective	lipid	classes,	which	revealed	that	 glycerophosphoethanolamines	 (PE)	 and	 glycerophosphocholines	 (PC)	represented	20.7	%	of	all	molecules,	whilst	triradylglycerols	accounted	for	8.3	%.	Due	to	the	structural	similarities	between	PE	and	PC	classes	it	is	not	possible	to	accurately	distinguish	them	using	this	approach.		Next,	 I	 looked	into	the	significantly	changed	lipid	classes,	searching	for	the	ones	that	were	particularly	enriched	in	one	cell	type	by	plotting	the	ratio	of	the	number	 of	 lipids	 significantly	 increased	 in	 RAW	264.7/pResMf	 (Figure	 4.12).	Thus,	 I	 found	 that	 only	 putatively	 identified	 bile	 acids	 and	 acidic	 GSL	 are	increased	in	pResMf,	whilst	steroids,	isoprenoids,	diradylglycerols	and	Cer	are	mainly	increased	in	RAW	264.7	cells.								 	
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Figure	 4.11	 Global	 view	 of	 the	 lipidomic	 differences	 between	 of	 pResMf	 and	 RAW	
264.7	cells.	The	pie	chart	shows	the	percentage	of	 the	different	 lipid	categories	(inner	ring)	and	 lipid	classes	 (outer	 ring)	 significantly	 altered	between	pResMf	 and	RAW	264.7	 cells,	 values	 below	each	category	represents	the	percentage	of	lipids	putatively	identified	for	each	category.		 	
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Figure	4.12	Lipid	class	enrichment	in	pResMf	and	RAW	264.7	cells.	The	graph	shows	the	enrichment	of	different	lipid	classes	in	pResMf	and	RAW	264.7	cells.	The	abscissa	represents	the	Log2	of	the	ratio	of	the	number	of	lipids	increased	in	RAW	264.7	and	pResMf.	Negative	values-	increased	in	pResMf;	Positive	values-	increased	in	RAW	264.7.			 	
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4.3 Discussion	
In	this	Chapter	the	aim	was	to	optimise	the	high-resolution	untargeted	LC-MS	lipidomics	workflow,	previously	implemented	in	platelet	studies,	for	the	analysis	of	Mf	 extracts.	Due	 to	 the	different	nature	and	 low	abundance	of	 the	samples	analysed,	it	was	necessary	to	optimise	the	different	steps	of	the	workflow,	such	as	LC-MS	conditions	and	data	analysis.		
In	order	to	efficiently	profile	the	lipidome	of	Mf-like	cells,	it	is	necessary	to	reach	the	lowest	mass	accuracy	possible189.	To	this	end,	I	employed	the	lock	mass	feature,	which	successfully	improved	the	Dppm	to	2	ppm.	However,	one	of	the	drawbacks	 of	 using	 the	 untargeted	 approach	 is	 that	 the	 methods	 are	 often	associated	with	relatively	long	runtimes,	as	is	the	case	of	the	LC-MS	runs	in	this	thesis	 (60	min).	 Herein	 I	 combined	 2	mass	 ranges,	 previously	 used	 for	 other	studies,	 into	 a	 single	mass	 range	 (from	100	–	1800	m/z),	 described	 in	 section	4.2.1a),	thus	reducing	the	number	of	chromatographic	runs	and	the	amount	of	sample	necessary	to	be	cut	in	half.		One	of	 the	main	challenges	 for	 lipidomics,	 in	particular	 for	high-resolution	untargeted	 LC-MS-based	 approaches,	 resides	 in	 the	 computational	 and	bioinformatics	difficulties	of	handling	 the	 large	amount	of	data	obtained	 from	such	experiments.	Specifically,	high-resolution	untargeted	LC-MS	data	collection	requires	 substantial	 efforts	 in	 chromatographic	 alignment	 and	 statistical	appraisal	of	variations	in	signal	intensity.	These	fluctuations	can	have	different	origins,	such	as	biological	variations,	sample	handling	and	analytical	accuracy104.	Subsequently,	several	replicates	are	usually	required	for	accurate	determination	of	lipid	changes	in	complex	matrixes	by	high-resolution	untargeted	LC-MS.		
Since	 their	 discovery	Mf	 have	 one	 of	 the	most	 studied	 immune	 cell	 types	because	 of	 their	 central	 role	 in	 immune	 processes	 and	 disease.	 However,	 the	technical	 expertise	 required	 to	 process	 LC-MS-based	 untargeted	metabolomic	data	has	caused	 lipidomics	 to	 lag	behind	metabolomics	because	 it	was	mainly	undertaken	by	specialists,	such	as	biologists	or	chemists	with	primary	interests	in	the	biology	or	chemistry	of	lipids,	who	did	not	have	an	analytical	background.	
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Nevertheless,	lipids	make	up	about	a	third	of	the	metabolome,	so	the	field	is	now	catching	 up.	 One	 of	 the	 drawbacks	 of	 high-resolution	 LC-MS	 analysis,	 as	 the	method	I	performed	in	this	Chapter,	is	the	number	of	artefacts	and	contaminants	contained	in	the	raw	data.	In	order	to	‘clean-up’	my	data-set	and	minimise	the	number	of	false-	positive	lipid	features	I	took	advantage	of	the	XCMS	Online	peak	filtering	and	deisotoping	capabilities	and	LipidFinder’s	clean-up	and	MSSearch	capabilities,	which	 lead	 to	 a	 reduction	 39	%	 reduction	 of	 lipid	 features.	 Thus,	providing	me	with	a	more	comprehensive	and	biologically	relevant	dataset.			
The	results	presented	herein	hint	at	the	fact	that	distinct	Mf	phenotypes	are	significantly	 different	metabolically,	 69.4%	of	 lipid	 features	were	 found	 to	 be	significantly	 dysregulated.	 The	 categories	 with	 highest	 percentage	 of	dysregulated	lipids	were	GL	(73	%),	GPL	(68	%)	and	SL	(66	%).	Interestingly,	FA	(51	%)	and	GL	 (51	%)	are	 the	only	 categories	where	most	of	 the	 significantly	dysregulated	lipids	are	upregulated	in	pResMf.	A	closer	analysis	of	which	lipid	putatively	identified	classes	were	enriched	in	the	different	Mf	subsets	revealed	that:	 (i)	 bile	 acids	 and	 derivates	 are	 significantly	 increased	 in	 pResMf.	 These	lipids	 act	 as	 signalling	 molecules,	 affecting	 lipopolysaccharide	 (LPS)-induced	cytokine	expression	in	Mf,	and	are	able	to	reprogram	pro-inflammatory	Mf	to	an	anti-inflammatory	phenotype197,198.	(ii)	the	steroid	class	is	significantly	increased	in	 RAW	264.7	 when	 compared	 to	 pResMf.	 Steroids	 are	 synthesized	 from	cholesterol	and	have	long	been	known	to	stimulate	phagocytic	activity	in	Mf,	and	are	 able	 to	 downregulate	 pro-inflammatory	 cytokine	 production199,200.	 These	two	 findings	 suggest	 that	 RAW	264.7	 might	 have	 a	 more	 pro-inflammatory	phenotype,	while	pResMf	may	have	an	increased	phagocytic	activity	and	a	more	anti-inflammatory/pro-resolving	phenotype.	Overall	the	work	developed	in	this	Chapter	was	extremely	important	for	the	development	of	an	adequate	workflow	for	the	lipidomics	analysis	of	pResMf.	It	enlightened	which	features,	processes,	and	conditions	are	useful	in	a	differential	analysis	of	two	Mf	samples.	The	conditions	optimised	herein	will	be	carried	on	to	 the	 next	 Chapter	 where	 this	 workflow	 will	 be	 used	 to	 characterise	 the	lipidomic	differences	in	Gata6-WT	and	-KOmye	pResMf.			 	
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Chapter	5 Global	lipidomic	
characterisation	of	Gata6-WT	and	-KOmye	
pResMf	
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5.1 Introduction	
To	address	the	question	of	whether	myeloid	deficiency	of	GATA6	is	associated	with	significant	changes	in	lipid	metabolism,	at	a	transcriptional	and	molecular	level,	 I	 conducted	 experiments	 to	 establish	 a	 connection	 between	 Gata6	expression	 and	 alterations	 in	 lipid	 metabolism-related	 pathways/networks	(Chapter	3).	Thus,	I	confirmed	that	the	knockdown	of	Gata6	expression	leads	to	significant	changes	at	a	transcriptional	level,	with	emphasis	on	SL	related	causal	networks.	In	this	Chapter	I	will	extend	my	transcriptional	analysis,	by	characterising	the	global	lipidome	of	Gata6-WT	and	-KOmye	pResMf.	This	will	allow	me	to	determine	(in	conjunction	with	Chapters	4)	the	fundamental	changes	both	in	lipid	levels	and	potential	signalling	deficits	associated	with	the	myeloid	deficiency	of	GATA6,	as	well	as	which	lipid	categories	are	the	most	influenced	by	Gata6.	
I	 will	 begin	 by	 isolating	 pResMf	 from	 Gata6-WT	 and	 -KOmye.	 Then	 I	 will	perform	an	untargeted	lipidomic	characterisation,	using	the	workflow	developed	in	Chapters	4,	which	uses	high-resolution	mass	spectrometry	coupled	to	ultra-high	pressure	liquid	chromatography	(UPLC-MS).	The	data	will	then	be	analysed	using	computational	methodologies	combined	with	bioinformatics	tools	in	order	to	remove	artefact	signals,	search	databases,	and	provide	putative	classification	for	 lipids	 found.	 Last,	multi-	 and	univariate	data	 analysis	will	 be	 employed	 to	determine	statistical	significance.	
5.1.1 	Aim	
• To	 characterise	 the	 global	 lipidome	 of	 Gata6-KOmye	 and	 –WT	pResMf.	
• To	 determine	 the	 effect	 of	 GATA6	 deficiency	 on	 lipid	molecular	species	in	peritoneal	Mf.		 	
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5.2 Results	
5.2.1 GATA6	regulates	lipid	profiles	in	pResMf		
Lipid	extracts	were	analysed	by	UPLC-MS	(as	described	in	Chapter	2).	Briefly,	peritoneal	 lavages	 collected	 from	 Gata6-WT	 and	 -KOmye	 female	 mice	 were	phenotyped	and	pooled5	(details	in	Materials	and	Methods,	Chapter	2).	pResMf	were	 isolated	by	FACS	 (pooled	 to	provide	2	x	106	cells/replicate),	 centrifuged,	and	 cell	 pellets	 stored	 at	 -80°C,	 until	 ready	 for	 extraction.	 When	 all	 three	biological	 replicates	 were	 collected,	 lipids	 were	 extracted	 using	 a	 double	extraction	 method	 (Hexane/Isopropanol;	 Bligh	 and	 Dyer).	 I	 then	 used	 a	lipidomics	platform,	consisting	of	a	Nexera	UPLC	coupled	with	an	Orbitrap	Elite,	to	profile	the	lipid	extracts	from	Gata6-WT	and	-KOmye	(Figure	5.1A).			The	 raw	 data	 obtained	 from	 the	 UPLC-MS	 analysis,	 was	 processed	 using	chromatographic	alignment,	peak	integration	and	isotope	removal	by	XCMS.	The	dataset	was	then	manually	inspected,	and	incorrectly	integrated	features	were	removed.	A	table	with	details	for	all	identified	lipid	features	is	generated	by	XCMS	(diffreport),	as	well	as	an	overlay	of	the	extracted	ion	chromatograms	from	each	sample	for	all	lipid	features.	This	feature	of	XCMS	is	particularly	important	and	it	was	 critical	 in	 the	 validation	 of	 the	 peak	 integration	 of	 the	 dataset	 (First	 and	second	stages	Figure	5.1B).	The	positive	and	negative	ion	mode	data	resulting	from	XCMS	was	submitted	to	 a	 program	 that	 combines	 data	 sets	 from	 positive	 and	 negative	 runs	(LipidFinder,	described	in	the	previous	Chapter).	This	program	found	matches	for	4.4	%	of	ions,	causing	a	further	reduction	of	the	number	of	features.	The	final	number	of	features	was	14988.			 	
																																																								
5	Due	to	the	low	recovery	of	pResMf	in	GATA6	deficient	mice,	it	was	necessary	to	combine	peritoneal	lavages	from		~15	mice.	In	order	to	obtain	2	x	106	cells/replicate.	
  
128 
	
Figure	5.1	From	sample	collection	to	statistical	significance	workflow.		The	 figure	 depicts	 the	 different	 stages	 of	 the	 untargeted	 lipidomics	 workflow	 described	herein.	 Top	 panel-	 describes	 the	 steps	 involved	 from	 sample	 preparation	 to	 data	 collection,	including	sample	collection,	cell	isolation,	lipid	extraction	and	analysis	by	LC-MS,	which	is	then	followed	 by	 the	 steps	 described	 in	 the	 bottom	 panel,	 From	 Raw	 data	 analysis	 to	 statistical	significance.	 This	 comprises	 alignment	 and	 feature	 discovery,	 data	 clean-up,	 putative	identification	and	statistical	analysis.			 	
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a) Power	analysis	Power	analysis	is	performed	to	determine	the	minimum	sample	size	used	to	detect	an	effect	size	of	interest,	with	power	defined	as	the	probability	of	detecting	an	effect,	given	that	the	effect	is	really	there.	For	example,	if	a	study	comparing	two	groups	(e.g.	WT	vs	KO)	has	power	of	0.8,	then	80	%	of	the	time,	the	analysis	was	performed,	it	would	deliver	a	statistically	significant	difference	between	the	two	groups.		This	calculation	can	be	affected	by	three	main	factors:		
• Effect	size	which	 is	usually	defined	as	 the	difference	of	 the	 two	group	means	divided	by	the	pooled	standards	deviation.	
• Degree	of	confidence	for	statistical	significance	(a).	
• Sample	size,	more	samples	will	increase	power.	
Ideally	this	analysis	would	have	been	performed	using	pilot	data201.	However,	due	 to	 the	 limitations	 encountered	 when	 working	 with	 primary	 cells,	 in	particular	Gata6-KOmye	and	–WT	pResMf,	where	the	yield	of	cells	is	~50	%	lower	than	with	WT	animals,	I	was	limited	to	3	biological	replicates	per	group.	Thus,	I	used	 the	 full	 dataset	 for	 the	 calculations.	 Nevertheless,	 it	 is	 important	 to	investigate	the	power	of	my	experimental	design,	as	it	will	help	me	calculate	the	magnitude	of	the	effect	of	interest	in	the	population	(effect	size).		As	 metabolomics	 evolves,	 and	 becomes	 more	 widely	 used,	 careful	consideration	of	methods,	to	ensure	proper	experimental	design	are	essential	for	an	accurate	and	robust	identification	of	metabolites.	Traditional	power	analysis	tools	 have	 become	 unsuitable	 for	 high-throughput	 metabolomics	 data.	 The	nature	 of	 this	 data	 means	 that	 it	 is	 highly	 dimensional	 and	 often	 correlated.	Moreover,	the	number	of	metabolites	identified	greatly	outnumbers	the	sample	size201.	 This	 data	 will	 be	 used	 as	 a	 screen,	 that	 will	 serve	 to	 select	 the	most	significantly	altered	lipid	categories.	The	changes	observed	will	then	be	validated	in	the	next	Chapter	using	a	targeted	approach.	
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In	order	to	assess	the	power	of	the	Gata6-WT	and	-KOmye	dataset,	I	used	both	a	traditional	analysis	tool	as	well	as	a	modified	method	of	power	analysis,	that	uses	 the	 average	power	of	 all	metabolites,	 and	 corrects	 it	 for	multiple	 testing	using	false	discovery	rate	(FDR)	instead	of	raw	p-values.	First,	I	chose	10	lipid	features	at	random,	and	calculated	the	sample	size	(for	an	a	of	0.05	and	power	of	80	%)	for	each	lipid.	Resulting	in	a	sample	size	larger	than	 3	 samples/group	 for	 7	 of	 the	 selected	 features,	 Table	 5.1.	 Extrapolating	these	results	to	the	entire	dataset	would	suggest	that	a	sample	size	of	3	will	result	in	30	%	of	lipid	features	being	significantly	different.	Next,	I	used	the	entire	untargeted	lipidomics	dataset	and	processed	it	using	the	 power	 analysis	module	 in	Metaboanalyst202.	 The	 output	 consisted	 of	 four	diagnostic	plots	(Figure	5.2),	where	it	is	possible	to	evaluate	whether	or	not	the	calculations	were	successful.	The	analysis	is	based	on	the	assumptions	that	the	effect	is	present	in	the	data,	and	that	test	statistic	follows	a	normal	or	near	normal	(Students’t	t-test)	distribution		
The	 FDR	 selected,	 or	 significance	 criterion	 selected	 was	 a=	0.1,	 which	resulted	 in	 a	 predicted	 power	 of	 34	%	 for	 a	 sample	 size	 of	 3	 (Figure	 5.2A),	suggesting	that	my	experimental	design	is	underpowered,	but	it	will	still	be	able	to	detect	significant	differences	between	the	2	groups.	In	order	to	achieve	80	%	power,	the	sample	size	would	have	to	be	16,	which	would	correspond	to	culling	approximately	 480	 animals	 (15	 animals/sample).	 The	majority	 of	 p-values	 is	close	to	zero	(Figure	5.2B	and	D),	indicating	a	strong	effect,	whilst	the	QQ	plot	confirms	that	the	data	follows	a	normal	distribution	(the	data	points	follow	the	straight	line)	(Figure	5.2C).	
  
131 
					
Table	5.1	Power	calculations	for	Gata6-WT	and	-KOmye	untargeted	lipidomics	data.	
		
Peaks	(mz/RT) Mean	WT Mean	KO Stdev	WT Stdev	KO Sample	size788.544/29.14 8.95E+07 1.56E+08 1.64E+07 1.02E+07 2431.379/24.33 6.26E+03 4.50E+04 5.85E+03 1.80E+04 5932.5859/19.75 5.85E+04 7.30E+04 2.89E+04 3.95E+03 30789.5471/21.55 1.03E+05 6.55E+05 1.63E+04 4.11E+04 2964.6236/48.02 2.28E+04 4.22E+04 9.51E+03 8.75E+03 5405.2654/16.11 4.11E+03 1.95E+04 6.52E+02 2.22E+04 30854.4816/36.99 4.37E+05 3.18E+05 8.32E+04 2.12E+05 301625.132/35.23 4.76E+05 5.86E+05 8.44E+04 1.65E+05 30789.686/52.81 1.52E+05 2.06E+05 5.01E+04 9.55E+04 30680.5441/27.27 2.56E+06 6.87E+04 1.66E+04 1.57E+04 2
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Figure	5.2	Power	statistics	of	untargeted	lipidomics	data	comparing	Gata6-WT	and	-
KOmye.		Mf	 lipid	extracts	 from	Gata6-WT	and	-KOmye	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Various	plots	overviewing	the	test-statistics	and	p-values	calculated	from	the	data	to	evaluate	if	it	follows	a	normal	distribution.	A-	Plot	of	the	predicted	power	curve.	B-	shows	the	distribution	of	the	p-values,	where	the	majority	of	p-values	hover	around	0.	C	&	D-	Quantile-Quantile	plots	(QQ	plots),	the	test-statistics	and	the	p-values	follow	a	standard	normal	distribution	(the	data	points	follow	the	straight	line).	For	the	qq-plot,	the	p-values	are	sorted	against	their	ranks.		 	
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b) Statistical	and	Machine	Learning	Data	Analysis		
i) Univariate	analysis	methods	Once	 the	 dataset	 was	 processed	 by	 XCMS	 (as	 described	 in	 the	 previous	Chapter),	 I	 performed	 a	 statistical	 analysis	 to	 identify	 lipid	 features	 that	comprehend	 the	 bulk	 of	 the	 variance	 within	 the	 dataset.	 The	 selection	 of	 an	suitable	statistical	method	is	dependent	on	the	sample	size	and	distribution	or	the	ability	to	evaluate	the	normality	of	the	distribution.	Univariate	 analysis	 methods	 are	 the	 most	 common	 methods	 used	 for	exploratory	data	analysis.	Herein	I	did	a	Fold	Change	(FC)	analysis,	t-tests,	Mirror	plot,	 and	 volcano	 plot,	 which	 is	 a	 combination	 of	 the	 first	 two	methods.	 The	univariate	 analyses	 provide	 a	 preliminary	 overview	 about	 features	 that	 are	potentially	significant	in	discriminating	the	conditions	under	study.			
 Fold	Change	Analysis	For	paired	FC	analysis,	 the	algorithm	used	 first	counts	 the	total	number	of	pairs	 with	 fold	 changes	 that	 are	 consistently	 above/below	 the	 specified	 FC	threshold	(|FC|	>	1.5)	for	each	variable.	A	variable	is	reported	as	significant	if	this	number	is	above	a	given	count	threshold	(	>	75	%	of	pairs/variable)	(Figure	5.3).		Of	note,	the	purpose	of	FC	is	to	compare	absolute	value	changes	between	two	group	means.	 Therefore,	 the	 result	 is	 plotted	 in	 log2	 scale,	 so	 that	 same	 fold	change	(up/down	regulated)	will	have	the	same	distance	to	the	zero	baseline.	Figure	5.3A	shows	the	3062	features	identified	as	significant	by	fold	change	analysis,	 which	 represents	 20.3	%	 of	 the	 dataset.	 The	 putative	 identification	column	shows	the	results	obtained	using	the	LIPID	MAPS	database.	The	LIPID	MAPS	database	enabled	a	 lipid	category	to	be	assigned,	with	a	putative	match	generated,	where	possible,	using	an	in-house	database.	The	results	show	that	15	of	the	20	features	with	the	highest	FC	are	GPL	(5),	SL	(2),	FA	(2),	and	GL	(1).	For	the	remaining	5	lipid	features	it	was	not	possible	to	find	a	match	in	the	database.		 	
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 T-tests	The	second	univariate	method	used	was	a	Student	t-test,	or	unequal	variances	t-test,	which	is	a	is	a	two-sample	location	test.	The	purpose	of	t-test	analysis	is	to	test	whether	two	distributions	come	from	the	same	population203.		Figure	5.3B	shows	the	1897	features	identified	by	t-tests	(P-value	<	0.1)	(P-values	 were	 corrected	 for	 multiple-testing	 using	 Benjamini-Hochberg).	 The	details	 of	 the	 20	 features	 with	 the	 lowest	 P-value	 are	 shown	 Table	 5.3.	 The	method	used	for	putative	identification	of	lipid	features	was	as	described	in	the	previous	section.	The	results	show	that	17	of	the	20	features	with	the	smallest	P-values	are	GPL	(11),	SL	(2),	FA	(2),	and	ST	(2).	For	the	remaining	3	lipid	features	it	was	not	possible	to	find	a	match	in	the	database.	Of	note,	none	of	the	features	selected	are	present	in	both	the	FC	and	the	t-test	analysis	(top	20	features).		In	 the	 next	 section	 I	will	 provide	 further	 insight	 about	which	 features	 are	potentially	significant	 in	discriminating	Gata6-WT	and	-KOmye	pResMf	using	a	“mirror	plot”	analysis.		
 Mirror	plots	The	 “mirror	 plots”183	 in	 Figure	 5.4,	 show	 the	 dysregulated	 features,	 ions	whose	intensities	are	significantly	altered	between	Gata6-WT	and	-KO	pResMf,	according	 to	 the	 statistical	 threshold	 selected	 (p-value	<	0.1	 and	 |FC|	>	1.5).	Down-regulated	features	are	represented	as	red	circles	on	the	bottom	of	the	plot,	whilst	up-regulated	features	are	represented	as	green	circles	on	the	top	of	the	plot.	The	size	of	each	circle	 corresponds	 to	 the	 fold	change	 (up-regulated	and	down-regulated	 features	 are	 represented	 in	 green	 and	 red	 respectively);	whereas	 the	 shade	 of	 the	 colour	 represents	 the	 p-value,	with	 brighter	 circles	having	 lower	 p-values.	 The	 retention	 time	 corrected	 TIC	 are	 overlaid	 in	 the	background	of	the	figure.	This	analysis	revealed	an	even	spread	of	lipid	features	throughout	the	5	and	50	min	RT	range,	with	more	features	presenting	increases	in	intensity	(upper	part	of	the	plot).		 	
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Figure	 5.3	 Fold-change	 and	 t-test	 analysis	 displays	 evidence	 of	 lipid	 regulation	 by	
GATA6.	
Mf	 lipid	 extracts	 from	Gata6-WT	 and	 -KOmye	 pResMf	 were	 analysed	 by	 LC-FTMS	 on	 the	Orbitrap	 Elite,	 at	 60,000	 resolution,	 then	 processed	 using	 XCMS.	 Figure	 A	 shows	 important	features	selected	by	fold-change	analysis	with	threshold	2.	The	pink	circles	represent	features	above	 the	 threshold.	 Note	 the	 values	 are	 on	 log	 scale,	 so	 that	 both	 up-regulated	 and	 down-	regulated	 features	 can	 be	 plotted	 in	 a	 symmetrical	 way.	 Figure	 B	 shows	 important	 features	selected	by	t-tests	with	threshold	0.1.	The	pink	circles	represent	features	above	the	threshold.	Note	the	p	values	are	transformed	by	-log10	so	that	the	more	significant	features	(with	smaller	p	values)	are	plotted	higher	on	the	graph.				 	
A- Fold change
B- T-test
Lipid	features	
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Figure	5.4	“Mirror	plots”	show	evidence	of	lipid	regulation	by	GATA6.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	 at	 60,000	 resolution,	 then	processed	using	XCMS.	 “Mirror	plots”	 show	 the	dysregulated	features,	ions	whose	intensities	are	altered	between	the	2	Mf	sample	groups,	according	to	the	statistical	 threshold	 selected	 (p-value	 <	 0.1	 and	 |FC|	>	1.5).	 Down-regulated	 features	 are	represented	as	circles	on	the	bottom	of	the	plot,	whilst	up-regulated	features	are	represented	as	circles	on	the	bottom	of	the	plot.	The	size	of	each	circle	corresponds	to	the	(log)	FC	(up-regulated	and	down-regulated	features	are	represented	in	green	and	red	respectively);	shade	of	the	colour	represents	the	p-value,	with	brighter	circles	having	lower	p-values.	The	retention	time	corrected	TIC	 are	 also	overlaid	 in	 the	background	of	 the	 figure.	 (A)Positive	 ion	mode;	 (B)	Negative	 ion	mode.	
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 Volcano	Plot	Volcano	plots	use	a	combination	of	FC	and	t-test	analysis,	where	important	features	 are	 selected	 based	 on	 the	 fold	 change	 threshold	 (x)	 2	 and	 t-tests	threshold	 (y)	 0.1.	 The	 further	 its	 position	 away	 from	 the	 (0,0),	 the	 more	significant	the	feature	is.	Figure	5.5	shows	the	important	features	identified	by	volcano	 plot,	 8.4	%	 of	 the	 whole	 dataset,	 of	 which	 91.2	%	were	 increased	 in	GATA6	 deficient	 cells.	 Table	 4	 shows	 the	 details	 of	 the	 20	most	 significantly	altered	features.	These	features	match	exactly	with	the	ones	identified	by	t-test.			 	
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Figure	5.5	Lipid	levels	vary	significantly	between	Gata6-WT	and	-KO	pResMf.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Volcano	plots	representing	fold-change	and	p-value	of	lipids	in	Gata6-WT	relative	to	-KO	pResMf.	Significantly	changed	lipid	levels	are	indicated	 by	 red	 (8.4	%)	 (of	 which	 91.2	%	 were	 increased	 in	 GATA6	 deficient	 cells),	 and	unchanged	levels	by	grey	(87.4	%).	Statistical	significance	was	determined	using	the	student	t-test,	 with	 alpha=	10.00	%,	 P-values	 were	 corrected	 for	 multiple-testing	 using	 Benjamini-Hochberg.	Each	row	was	analysed	 individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P<	0.1	and	|FC|	>	1.5	(depicted	in	red).	Note	both	fold	changes	and	p-values	are	log	transformed.	The	further	its	position	away	from	the	(0,0),	the	more	significant	the	feature	is.				 	
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i) Multivariate	analysis	methods:	Data	 reduction	approaches	 such	as	principle	 component	 analysis	 (PCA)	or	supervised	approaches,	including	orthogonal	partial	least	squares	discriminant	analysis	 (OPLS-DA),	 can	 help	 to	 reduce	 complex	 data	 to	 a	 manageable	 form,	identify	associations	within	datasets	and	identify	key	metabolites	contributing	to	the	variance204.		Multivariate	 data	 analysis	 (MDA)	 by	 PCA	 provided	 an	 overview	 of	 the	contribution	of	GATA6	to	the	different	lipid	classes	and	further	complements	the	results	 from	 section	 5.2.1c).	 MDA	 methods	 are	 typically	 used	 for	 group	differentiation	 in	 lipidomics,	 using	 either	 supervised	 or	 unsupervised	approaches.	PCA	reduces	primary	variables	(peaks)	to	the	latent	variables,	which	are	called	principal	components,	due	to	the	decreasing	model	dimensionality205.	
 Data	scaling		The	first	step	before	performing	an	MDA	is	to	scale	the	data,	in	particular	in	cases	where	the	variables	being	compared	have	different	response	units.	For	LC-MS	data,	all	of	the	responses	correspond	to	peak	areas	and	hence	have	the	same	units,	so	scaling	is	not	absolutely	essential,	but	is	still	useful.	If	the	original	data	is	 not	 scaled	 in	 any	way	 the	 variables	with	 the	 largest	 response	will	 tend	 to	dominate	 the	 PCA	 analysis.	 For	 example,	 a	 very	 large	 variable	 which	 is	approximately	constant	for	all	samples	may	dominate	PC1,	or	as	is	the	case	with	this	dataset,	peaks	measured	in	positive	ion	mode	tend	to	be	more	intense	than	those	detected	in	negative	mode,	thus	skewing	the	MDA	results.	For	this	reason,	I	used	the	Pareto	scaling	method,	where	the	data	is	first	mean	centered	and	then	divided	by	 the	 square	 root	of	 the	 standard	deviation	 for	 the	variable.	The	net	effect	is	that	larger	variables	receive	more	importance	than	with	autoscaling,	but	less	than	with	mean	centering	alone,	Figure	5.6.					
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Figure	5.6	Untargeted	lipidomics	data	of	Gata6-WT	and	-KOmye	pResMf	scaled	using	
the	Pareto	method.		Mf	 lipid	 extracts	 from	Gata6-WT	 and	 -KOmye	 pResMf	 were	 analysed	 by	 LC-FTMS	 on	 the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	The	boxplots	show	13	features	due	to	space	limit.	The	density	plots	are	based	on	all	samples.		 	
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ii) Principal	Component	Analysis	(PCA)		PCA	 is	 an	 unsupervised	method	 that	 aims	 to	 find	 the	 directions	 that	 best	explain	the	variance	in	a	data	set	(X)	without	considering	class	 labels	(Y).	The	data	are	summarized	into	less	variables	called	scores	(one	variable	per	sample)	which	are	weighted	average	of	the	original	variables.	The	weighting	profiles	are	called	 loadings.	Herein,	 the	PCA	analysis	was	performed	using	Metaboanalyst,	and	the	calculations	are	based	on	singular	value	decomposition.	Figure	5.7	shows	pairwise	score	plots	providing	an	overview	of	the	various	separation	patterns	among	the	most	significant	principal	components	(PC)	(from	1	to	5),	where	PC1	explains	62.1%	of	the	variance	between	Gata6-KOmye	and	-WT.	The	PCA	scree	plot	of	the	variance	explained	by	PC1-PC5	showed	that	the	other	significant	components	are	given	by	PC2-PC5,	with	percentages	of	contribution	of	 19	%,	 8.2	%,	 6.1	%,	 and	 4.7	%,	 respectively.	 By	 removing	 the	 PCs	 that	contribute	little	to	the	variance	(PC3-5),	I	can	project	the	entire	dataset	to	a	lower	dimensional	space	but	retain	most	of	the	information	(Figure	5.8),	and	allow	for	the	clustering	of	the	two	sample	groups	(Figure	5.9).	Because	the	PCA	is	a	transformation	of	the	old	coordinate	system	(peaks)	into	a	new	coordinate	structure	(PC),	 it	can	be	assessed	how	much	each	of	 the	old	coordinates	 (peaks)	 contribute	 to	 each	of	 the	new	ones	 (PCs).	The	higher	 the	loading	(further	away	from	the	cluster)	of	a	particular	peak	onto	a	PC,	the	more	impact	 they	have	on	 the	variance	between	Gata6-KOmye	and	 -WT.	Similarly,	 to	what	was	found	during	the	univariate	analysis,	the	majority	of	the	features	were	identified	as	GPL	(13)	and	SL	(6).		In	 the	 next	 section	 I	will	 look	 into	 how	Gata6-KOmye	 affects	 lipid	 levels	 in	different	categories,	which	will	allow	me	to	direct	my	studies	to	a	particular	lipid	category.	 	
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Figure	5.7	PC	1	explains	62.1	%	of	the	variability	between	Gata6-KOmye	and	-WT.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	 then	processed	using	XCMS.	The	figure	shows	pairwise	score	plots	between	 the	 selected	 PCs.	 The	 explained	 variance	 of	 each	 PC	 is	 shown	 in	 the	 corresponding	diagonal	 cell.	 Green	 and	 red	 symbols	 represent	 individual	 samples,	 Gata6-WT	 and	 -KOmye	respectively.		 	
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Figure	5.8	PCA	analysis	shows	a	clear	separation	between	Gata6-KOmye	and	-WT.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	 then	processed	using	XCMS.	The	figure	shows	pairwise	score	plots	between	the	PC1	and	PC2.	Green	and	red	symbols	represent	individual	samples,	Gata6-WT	and	-KOmye	respectively.	And	shaded	areas	represent	the	95%	confidence	intervals	corresponding	to	each	group.	The	explained	variances	are	shown	in	brackets.		 	
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Figure	 5.9	 Unsupervised	 MDA	 clusters	 Gata6-WT	 and	 -KOmye	 samples	 into	 their	
respective	groups.		Untargeted	lipidomics	data	was	submitted	to	PCA	analysis	and	clustering.	Result	shown	as	dendrogram	(distance	measure	using	euclidean,	and	clustering	algorithm	using	ward.D).				 	
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c) GATA6	 deficiency	 leads	 to	 significant	 changes	 in	 lipid	 levels	 in	
various	lipid	categories	in	pResMf	
As	previously	mentioned	(Chapter	4),	the	MSSearch	program	in	LipidFinder	uses	 the	 list	 of	 m/z	 values	 resulting	 from	 the	 Amalgamator	 for	 putative	identification	based	on	accurate	mass	using	 the	classification	system	from	the	LIPID	MAPS	 database	 (Figure	 5.10).	 Herein	 I	 used	 the	 MSSearch	 program	 to	putatively	identify	all	the	features	in	the	dataset,	Figure	5.11.	However,	there	is	still	 a	 large	 number	 of	 lipids	missing	 from	 online	 databases	 and	 as	 such	 the	number	 of	 results	 coming	 back	 as	 unknown	 is	 higher	 than	 what	 would	 be	desirable,	and	spread	through	the	whole	m/z	range,	accounting	for	about	24.1	%	of	 the	 values	 searched.	 The	 putative	 identification	 process	 returned	classifications	for	75.9	%	of	m/z	ions	matching	the	8	Lipid	Maps	categories.	The	categories	with	 the	most	matches	were	 FA	13	%,	GL	9	%,	GPL	32	%;	 SL	 10	%	(Figure	5.11).	Moreover,	the	lipids	identified	seem	to	overall	match	the	m/z	and	retention	 times	 expected	 for	 the	 respective	 lipid	 categories.	 However,	 this	analysis	gives	no	information	regarding	the	molecular	abundance	of	the	different	categories,	 or	 their	 differences	 in	 Gata6-WT	 and	 KOmye	 cells.	 These	 will	 be	analysed	in	further	detail	in	the	following	sections.		 	
  
146 
	
	
Figure	5.10	Representative	lipid	structures	from	the	LIPID	MAPS	structure	database	
for	different	lipid	categories.		Lipid	category	and	name	are	shown	under	each	structure.		
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Figure	5.11	Global	view	of	the	lipidome	of	pRes	Mf.		The	pie	chart	shows	the	contribution	of	the	different	lipid	categories	to	the	total	lipidome	(number	 of	 lipid	 species	 putatively	 identified),	 values	 below	 each	 category	 represents	 the	number	of	lipids	putatively	identified	for	each	category,	according	to	the	classification	on	figure	6.4.			 	
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d) MDA	with	 putative	 identifications	 reveals	 that	 lipid	 regulation	 by	
GATA6	varies	depending	on	lipid	category	Following	the	putative	identification	of	the	entire	dataset,	I	mapped	the	lipid	categories	onto	the	results	obtained	in	section	5.2.1b)i),	 in	an	effort	to	discern	which	 lipid	 categories	 were	 responsible	 for	 the	 lipidomic	 variance	 between	
Gata6-WT	 and	 -KOmye	 pResMf.	 The	 loadings	 in	 Figure	 5.12	 indicate	 that	 the	observed	separation	between	the	two	groups	is	mostly	due	to	an	increase	in	lipid	levels,	from	different	categories,	in	Gata6-WT	and	-KOmye	pResMf,	evidenced	by	the	higher	numbers	of	features	on	the	2nd	and	4th	quadrant	of	the	plot	(positive	PC1	 values).	 Overall	 the	 results	 from	 the	 univariate	 and	multivariate	 analysis	seem	to	match,	with	the	lipids	identified	as	significantly	altered	being	positioned	on	opposite	ends	on	PC1.	Of	 interest	 8.4	%	 of	 total	 identified	 lipids	 showed	 significant	 differences,	however,	in	2	of	the	8	lipid	categories	(SL	and	GPL)	the	percentage	of	significantly	altered	lipids,	in	Gata6-KOmye,	was	considerably	higher	(9	–	15	%).	The	lipid	class	where	percentage	change	was	lowest	was	FA	(3	%),	Figure	5.13.		Next,	 I	will	 analyse	 the	 lipidomic	 differences	 by	 lipid	 category,	which	will	allow	 me	 to	 investigate	 if	 which	 lipid	 species	 and	 pathways	 have	 been	significantly	altered	by	GATA6	deficiency.					
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Figure	5.12	Mapping	of	multivariate	data	analysis	with	putative	identifications	reveals	
that	lipid	regulation	by	GATA6	varies	depending	on	lipid	category.		Figure	shows	loadings	plots	for	PCA	models	by	lipid	category.	Significantly	altered	lipids	in	
Gata6-KOmye	pResMf	are	represented	 in	red.	Statistical	significance	was	determined	using	the	student	t-test	on	log	transformed	data,	with	alpha=5.00	%.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD,	and	P-values	were	adjusted	using	B.H	correction.	Differential	expression	was	classified	as	significant	when	P<	0.1	and	|FC|	>	1.5	(depicted	in	red).	Note	both	fold	changes	and	p-values	are	log	transformed.	The	further	its	position	away	from	the	(0,0),	the	more	significant	the	feature	is.		 	
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Figure	5.13	Interrelationships	between	cellular	metabolic	pathways.		Blue	arrows	denote	multistep	transformations	among	the	major	lipid	categories	and	acetyl	CoA.	 Values	 in	 yellow	 circles	 represent	 the	 percentage	 of	 analytes,	 putatively	 identified	 as	belonging	 to	 each	 lipid	 category	 that	 were	 significantly	 changed	 in	 Gata6-KOmye	 cells.	 Green	rectangles	represent	the	lipid	categories	that	changes	the	most.			
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5.2.2 Untargeted	analysis	of	lipid	by	category	
The	 pResMf	 lipidome	 is	 comprised	 of	 hundreds	 of	 thousands	 of	 unique	molecular	species	of	lipids	and	metabolism	in	a	given	mammalian	cell	involves	many	thousands	of	these.	In	my	attempt	to	define	the	differences	between	Gata6-
WT	 and	 -KOmye	 pResMf,	 I	 have	 focused	 on	 the	 putatively	 identified	 lipid	categories	that	changed	the	most	between	the	two	cell	types.	A	global	overview	of	the	changes	in	the	murine	Mf	lipidome	upon	Gata6-KOmye	is	depicted	in	Figure	5.13	which	illustrates	the	interrelationships	between	major	lipid	categories,	the	percentage	of	analytes	and	those	putatively	identified	as	belonging	to	each	lipid	category,	that	were	significantly	changed	in	Gata6-KOmye	vs	-WT	cells.	Based	on	the	 analysis	 peformed	 in	 the	 previous	 section,	 the	 2	 lipid	 categories	with	 the	highest	percentages	of	significantly	altered	lipids,	were	selected	for	an	in-depth	look	 into	 which	 species	 are	 being	 altered	 as	 a	 consequence	 of	Gata6	 KO	 (SL	(15	%)	and	GPL	(10%);	represented	in	green,	Figure	5.13).		Acetyl	 CoA	 is	 converted	 into	 fatty	 acids,	 sterols,	 and	 other	 intermediary	metabolites	 in	 the	 six	major	 lipid	 categories.	 Fatty	 acids	 (a	 subset	 of	 FA)	 are	converted	 into	 bioactive	 eicosanoids	 (also	 a	 subset	 of	 FA)	 and	more	 complex	lipids	such	as	GL,	GPL,	and	SL.		Additionally,	due	to	the	central	role	of	fatty	acids	in	lipid	metabolism	(Figure	5.13),	I	will	also	investigate	what	molecular	species	of	this	class	were	affected	by	the	downregulation	of	Gata6.	
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a) FA		The	analysis	performed	in	the	previous	section	revealed	that	only	4	%	of	FA	were	significantly	changed	in	in	Gata6-KOmye	vs	control	cells.	FA	(including	fatty	acids)	are	a	lipid	category	comprising	a	diverse	group	of	molecules	synthesized	by	 chain-elongation	 of	 an	 acetyl-CoA	 primer	 with	 malonyl-CoA	 or	methylmalonyl-CoA	 groups,	 and	 therefore	 is	 one	 of	 the	 most	 fundamental	categories	of	biological	 lipids	(see	Chapter	1,	Table	1.2	for	the	complete	 list	of	lipid	classes).		First,	 I	selected	the	 features	 identified	by	the	volcano	(Figure	5.14)	plot	as	significant	 and	 used	 an	 in-house	 generated	 retention	 time	 and	m/z	 database	which	identifies	around	1,000	lipids	known	to	be	present	in	mammalian	cells	for	putative	identification	(level	three	identification	according	to	the	metabolomics	standard	initiative206)	(Figure	5.15).	This	analysis	revealed	that	the	main	class	with	 the	 higher	 percentage	 of	 significantly	 changed	 lipid	 levels	was	 fatty	 acyl	glycosides,	simple	glycolipids	generally	constituted	of	a	glycosyl	moiety	(one	or	several	 units)	 linked	 to	 the	 hydroxyl	 group	 of	 a	 hydroxy	 fatty	 acid	 or	 to	 one	carboxyl	 group	 of	 a	 normal	 fatty	 acid	 (ester	 linkage).	 Several	 more	 complex	glycosides	are	also	 formed	by	amide	 linkage	between	a	glycosyl	moiety	and	a	fatty	acid.	
Next,	I	considered	free	fatty	acids	known	to	be	present	in	pResMf,	due	to	their	relevance	for	other	lipid	categories.								
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Figure	5.14	3%	of	FA	vary	significantly	between	Gata6-WT	and	-KO	pResMf.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Volcano	plots	representing	fold-change	and	p-value	of	lipids	in	Gata6-WT	relative	to	-KO	pResMf.	Lipids	were	putatively	identified	using	the	MSSearch	program,	which	used	the	LIPIDMAPS	database	to	attribute	a	lipid	category	to	each	lipid.	Significantly	changed	lipid	levels	are	indicated	by	red	(3	%)	(of	which	87	%	were	increased	in	 GATA6	 deficient	 cells),	 and	 unchanged	 levels	 by	 grey	 (97	%).	 Statistical	 significance	 was	determined	using	the	student	t-test	on	log	transformed	data,	with	alpha=5.00%.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD,	and	P-values	were	adjusted	using	B.H	correction.	 Differential	 expression	 was	 classified	 as	 significant	 when	 P<	0.1	 and	 |FC|	>	1.5	(depicted	 in	 red).	 Note	 both	 fold	 changes	 and	 p-values	 are	 log	 transformed.	 The	 further	 its	position	away	from	the	(0,0),	the	more	significant	the	feature	is.			 	
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Figure	5.15	9%	of	fatty	acyl	glycosides	increase	significantly	in	Gata6-KOmye	pResMf.		Histogram	shows	the	number	of	FA	species	by	lipid	class.	Grey	corresponds	to	the	number	of	lipids	that	did	not	change	significantly;	magenta,	lipids	that	decreased	significantly;	green,	lipids	that	 increased	 significantly.	 Significance	 was	 determined	 using	 the	 student	 t-test	 on	 log	transformed	 data,	 corrected	 using	 B.H.	 with	 alpha=10.00	%.	 Differential	 expression	 was	classified	as	significant	when	P	<	0.1	and	|FC|	>	1.5.		
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i) Free	fatty	acids	Knowledge	of	the	fatty	acid	composition	of	lipid	classes	is	an	important	factor	in	 the	 investigation	 of	 metabolism.	 Thus,	 I	 compiled	 a	 list	 of	 32	 putatively	identified	fatty	acids,	known	to	be	present	in	Mf-like	cells95,	and	split	them	into	four	groups,	based	on	the	degree	of	saturation	and	position	of	the	double	bonds.	These	lipids	were	identified	based	on	their	accurate	m/z	and	retention	time.	The	four	 groups	 were	 saturated	 fatty	 acids	 and	 ω-3,	 -6,	 and	 -9	 mono-	 and	polyunsaturated	fatty	acids	(Table	5.2).	The	designation	ω-fatty	acid	refers	to	the	position	 of	 the	 first	 double	 counted	 from	 the	 ω	 carbon	 (or	 n	 position),	 for	example,	 the	first	double	bond	(counted	from	the	ω	carbon)	 in	alpha	linolenic	acid	 (ALA)	 (18:3	 (n-3)),	 represented	 in	 Figure	 5.16	 is	 positioned	 on	 the	 3rd	carbon,	thus	ALA	is	an	ω-3	polyunsaturated	fatty	acid.	Fatty	 acids	 changed	as	 a	 consequence	of	Gata6-KO.	 Levels	 of	ω-6	 and	ω-9	unsaturated	free	fatty	acids	were	 increased	 in	Gata6-KOmye	pResMf.	Out	of	31	molecular	species,	4	were	significantly	 increased	 in	Gata6-KOmye.	Additionally,	there	was	a	trend	for	the	fatty	acids	with	a	higher	FC	corresponded	to	lipids	with	a	higher	degree	of	unsaturation,	which	can	be	seen	more	clearly	in	the	pathways	depicted	in	Figure	5.18	and	Figure	5.19.				 	
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Figure	5.16	Chemical	 structure	of	 alpha-linolenic	 acid	 (ALA),	 an	essential	 omega−3	
fatty	acid.		18:3Δ9c,12c,15c,	 which	 means	 a	 chain	 of	 18	 carbons	 with	 3	 double	 bonds	 on	 carbons	numbered	9,	12,	and	15.			 	
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Table	5.2	List	of	putative	fatty	acids	found	in	pResMf.		
		
Saturated	fatty	acids
Common	name Lipid	name Chemical	nameLauric	acid C12:0 dodecanoic	acidMyristic	acid C14:0 tetradecanoic	acidPentadecylic	acid C15:0 pentadecanoic	acidPalmitic	acid C16:0 hexadecanoic	acidcis-9-palmitoleic	acid C16:1n-7 9Z-hexadecenoic	acidMargaric	acid C17:0 heptadecanoic	acid10Z-heptadecenoic	acid C17:1n-7 10Z-heptadecenoic	acidStearic	acid C18:0 octadecanoic	acidArachidic	acid C20:0 eicosanoic	acidBehenic	acid C22:0 docosanoic	acidTricosanoic	acid C23:0 tricosanoic	acidLignoceric	acid C24:0 tetracosanoic	acidCerotic	acid C26:0 hexacosanoic	acid
Common	name Lipid	name Chemical	nameHexadecatrienoic	acid	(HTA) 16:3	(n-3) all-cis 	7,10,13-hexadecatrienoic	acidAlpha-linolenic	acid	(ALA) 18:3	(n-3) all-cis -9,12,15-octadecatrienoic	acidStearidonic	acid	(SDA) 18:4	(n-3) all-cis -6,9,12,15,-octadecatetraenoic	acidEicosatrienoic	acid	(ETE) 20:3	(n-3) all-cis -11,14,17-eicosatrienoic	acidEicosapentaenoic	acid	(EPA,	Timnodonic	acid) 20:5	(n-3) all-cis -5,8,11,14,17-eicosapentaenoic	acidDTrE 22:3	(n-3) all-cis -3,6,9-docosatrienoic	acidDocosapentaenoic	acid	(DPA,	Clupanodonic	acid)22:5	(n-3) all-cis -7,10,13,16,19-docosapentaenoic	acidDocosahexaenoic	acid	(DHA,	Cervonic	acid) 22:6	(n-3) all-cis -4,7,10,13,16,19-docosahexaenoic	acid
Common	name Lipid	name Chemical	nameLinoleic	acid 18:2	(n-6) all-cis -9,12-octadecadienoic	acidGamma-linolenic	acid	(GLA) 18:3	(n-6) all-cis -6,9,12-octadecatrienoic	acidEicosadienoic	acid 20:2	(n-6) all-cis -11,14-eicosadienoic	acidDihomo-gamma-linolenic	acid	(DGLA) 20:3	(n-6) all-cis -8,11,14-eicosatrienoic	acidArachidonic	acid	(AA) 20:4	(n-6) all-cis -5,8,11,14-eicosatetraenoic	acidDocosadienoic	acid 22:2	(n-6) all-cis -13,16-docosadienoic	acidAdrenic	acid 22:4	(n-6) all-cis -7,10,13,16-docosatetraenoic	acidDocosapentaenoic	acid	(Osbond	acid) 22:5	(n-6) all-cis -4,7,10,13,16-docosapentaenoic	acid
Common	name Lipid	name Chemical	nameOleic	acid 18:1	(n-9) cis -9-octadecenoic	acidMead	acid 20:3	(n-9) all-cis -5,8,11-eicosatrienoic	acidErucic	acid 22:1	(n-9) cis -13-docosenoic	acidNervonic	acid 24:1	(n-9) cis -15-tetracosenoic	acid
Omega-3	fatty	acids,	polyunsaturated
Omega-6	fatty	acids,	polyunsaturated
Omega-9	fatty	acids,	mono-	and	polyunsaturated
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Figure	5.17	ω-6	and	-9	FA	increase	significantly	between	Gata6-WT	and	-KO	pResMf.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Volcano	plots	representing	fold-change	and	p-value	of	 free	FA	 in	Gata6-WT	relative	 to	 -KO	pResMf.	Lipids	were	putatively	 identified	using	an	inhouse	database,	which	used	the	m/z	and	RT	to	attribute	a	putative	identification	to	each	 lipid.	Statistical	significance	was	determined	using	the	student	t-test,	with	alpha=10.0	%.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P	<	0.05	and	|FC|	>	1.5	(depicted	in	red).	Note	both	fold	changes	and	 p-values	 are	 log	 transformed.	 The	 further	 its	 position	 away	 from	 the	 (0,0),	 the	 more	significant	the	feature	is.		 	
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 Pathway	analysis	The	pathway	analysis	in	in	Figure	5.18	and	Figure	5.19	illustrates	the	changes	in	metabolites	and	transcripts	leading	from	alpha-linolenic	acid	and	linoleic	acid	to	the	ω-3	and	ω-6	unsaturated	fatty	acids	(Figure	5.18),	and	from	lauric	acid	to	the	 saturated	 and	 ω-9	 unsaturated	 fatty	 acids	 in	 response	 to	Gata6-KOmye	 in	pResMf.	
Multiple	genes	encoding	fatty	acid	elongases	(Elovl)	and	desaturases	(Fads)	were	 down-regulated	 in	 to	 Gata6-KOmye.	 However,	 these	 decreases	 did	 not	correlate	with	a	higher	abundance	of	free	fatty	acid	levels.	 	The	levels	of	these	lipids	can	also	be	related	to	the	activity	of	acyl	transferases,	which	remodel	them	into	complex	lipids	(these	will	be	discussed	in	the	next	sections).		
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Figure	5.18	Changes	in	metabolites	and	transcripts	leading	from	alpha-linolenic	acid	and	linoleic	acid	to	the	ω-3	and	ω-6	unsaturated	fatty	acids	in	
response	to	Gata6-KOmye	in	pResMf.		Rectangular	boxes	represent	genes	coding	for	enzymes	that	catalyse	the	indicated	conversion,	while	boxes	with	rounded	edged	represent	lipid	metabolites.	The	colour	in	each	lipid	and	gene	represent	the	Log2(FC).	Lipid	and	mRNA	levels	were	obtained	as	described	in	Chapter	2.	
  
161 
	
	
Figure	 5.19	 Changes	 in	metabolites	 and	 transcripts	 leading	 from	 lauric	 acid	 to	 the	
saturated	and	ω-9	unsaturated	fatty	acids	in	response	to	Gata6-KOmye	in	pResMf.		Rectangular	 boxes	 represent	 genes	 coding	 for	 enzymes	 that	 catalyse	 the	 indicated	conversion,	while	boxes	with	rounded	edged	represent	lipid	metabolites.	The	colour	in	each	lipid	and	gene	represent	the	Log2(FC).	Lipid	and	mRNA	levels	were	obtained	as	described	in	Chapter	2.	 			 	
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b) SL	Putatively	 identified	 SL	 (Figure	5.20),	 presented	 the	highest	 percentage	of	significantly	altered	lipids	(15	%),	of	which	94%	were	increased	(Figure	5.21).	Complex	SL	are	comprised	of	a	sphingoid	long-chain	base	(LCB)	linked	via	the	amide	bond	to	an	N-acylated	fatty	acid	to	yield	Cer	(the	basic	unit	of	all	SL)	and	a	polar	 head	 group	 (Figure	 5.20)128,130,207,208.	 As	 shown	 in	 Figure	 5.20,	 the	 high	structural	multiplicity	of	SL	is	attributed	to	(a)	the	length	of	the	sphingoid	LCB	(the	most	common	chain	being	18	carbon	atoms)	and	the	N-acylated	fatty	acid	chain	 (often	 ranging	 from	 14	 to	 36	 carbon	 atoms)128,130,	 (b)	 the	 degree	 of	hydroxylation,	 and	 number	 and	 position	 of	 double	 bond	 in	 the	 LCB,	 (c)	 the	saturation	and	hydroxylation	status	of	the	fatty	acid,	and	(d)	the	substituent	as	the	head	group	at	position	1	of	the	basic	Cer	(which	contains	a	simple	hydroxyl	group)	128,130.	Consequently,	the	resulting	sphingolipidome	is	extremely	complex,	encompassing	up	to	thousands	of	sphingoid	bases	and	their	derivatives.	It	is	the	structural	diversity	of	SL	that	is	believed	to	enable	their	diverse	cellular	functions	including	 those	 related	 to	 immunity.	 There	 is	 a	 convenient	 short-hand	nomenclature	 to	 describe	 SL	 with	 structural	 features128.	 For	 example,	d18:1/C16:0	refers	to	a	Cer	consisting	of	So,	which	has	an	18	carbon	chain	with	1	double	bond	(d18:1),	and	an	amide-linked	C16	fatty	acid	chain	with	0	double	bond	(C16:0)	(Figure	5.20).	Here,	I	selected	the	significantly	changed	features	putatively	identified	as	SL	and	attributed	classes	to	each	of	the	lipid	features,	as	described	in	the	previous	section.	This	 analysis	 revealed	 that	 the	 classes	with	 the	highest	percentage	of	matches	were	also	the	ones	that	changed	the	most	upon	Gata6	KO,	neutral	SL,	Cer	 and	 phosphosphingolipids	 (Figure	 5.22).	 These	 classes	 showed	 increased	lipid	levels	in	9	–	28	%	of	all	putatively	identified	features	(phosphosphingolipids	9%,	Cer	13	%,	and	neutral	SL	28	%)	and	I	will	look	into	them	in	more	detail	in	the	next	section.		 	
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Figure	5.20	SL	structure	and	nomenclature.		All	 the	 structural	 variables	 are	highlighted.	 Ceramide	 (Cer)	 is	 the	 fundamental	 unit	 of	 all	complex	SL.	The	Cer	 consists	of	 two	structural	moieties:	 the	 sphingoid	 long-chain	base	 (LCB)	depicted	in	black,	and	the	fatty	acid	chain	linked	via	an	amide	bond,	blue.	The	typical	LCB	has	a	chain	length	of	18	carbons,	which	may	be	hydroxylated	at	4-position,	or	have	a	double	bond	at	the	4	or	8	 carbon.	The	 fatty	acid	chain	may	be	hydroxylated	at	 the	α-position,	and/or	have	a	double	bond	at	ω9-position.	The	 fatty	 acid	 chain	 length	may	vary	 from	14	 to	36	 (if	 >20,	 it	 is	referred	to	as	very	long-chain	fatty	acid,	i.e.,	VLCFA).	The	structurally	diverse	Cer	species	can	be	converted	to	more	complex	SL	via	substitution	of	the	hydroxyl	group	at	the	1-position	of	the	LCB.	Additional	sugar	residues	may	be	further	added,	resulting	in	more	complex	SL.		
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Figure	5.21	15	%	of	SL	vary	significantly	between	Gata6-WT	and	-KO	pResMf.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Volcano	plots	representing	fold-change	and	p-value	of	lipids	in	Gata6-WT	relative	to	-KO	pResMf.	Lipids	were	putatively	identified	using	the	MSSearch	program,	which	used	the	LIPIDMAPS	database	to	attribute	a	lipid	category	to	each	lipid.	Significantly	changed	lipid	levels	are	indicated	by	red	(15	%)	(of	which	94	%	were	increased	in	 GATA6	 deficient	 cells),	 and	 unchanged	 levels	 by	 grey	 (85	%).	 Statistical	 significance	 was	determined	using	the	student	t-test	on	log	transformed	data,	with	alpha=10.00	%.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD,	and	P-values	were	adjusted	using	B.H	correction.	 Differential	 expression	 was	 classified	 as	 significant	 when	 P	<	0.1	 and	 |FC|	>	1.5	(depicted	 in	 red).	 Note	 both	 fold	 changes	 and	 p-values	 are	 log	 transformed.	 The	 further	 its	position	away	from	the	(0,0),	the	more	significant	the	feature	is.		 	
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Figure	5.22	28	%	of	neutral	SL	increase	significantly	in	Gata6-KOmye	pResMf.		Histogram	shows	the	number	of	SL	species	by	lipid	class.	Grey	corresponds	to	the	number	of	lipids	that	did	not	change	significantly;	magenta,	lipids	that	decreased	significantly;	green,	lipids	that	 increased	 significantly.	 Significance	 was	 determined	 using	 the	 student	 t-test	 on	 log	transformed	 data,	 corrected	 using	 B.H.	 with	 alpha=10.00	%.	 Differential	 expression	 was	classified	as	significant	when	P	<	0.1	and	-|FC|	>	1.5.		
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i) Neutral	SL,	Cer	and	phosphosphingolipids	I	 considered	 a	 group	 of	 50	 putatively	 identified	 neutral	 SL,	 Cer	 and	phosphosphingolipids	 known	 to	 be	 present	 in	 pResMf,	 in	 order	 to	 establish	common	structural	 features	amongst	 the	significantly	 increased	 lipids.	 I	 found	that	 out	 of	 the	 50,	 30	 were	 significantly	 increased	 in	 the	 Gata6-KO	 pResMf	(Figure	 5.23).	 Of	 these,	 the	 highest	 fold	 changes	 corresponded	 to	 long	 chain	HexCer	and	SM	(Figure	5.24).					 	
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Figure	5.23	SM	and	HexCer	increase	significantly	in	Gata6-KOmye	pResMf.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Volcano	plot	represents	the	fold-change	and	p-value	of	SL	in	Gata6-WT	relative	to	-KO	pResMf.	Lipids	were	putatively	identified	using	an	inhouse	database,	which	used	the	m/z	and	RT	to	attribute	a	putative	identification	to	each	lipid.	Statistical	significance	was	determined	using	the	student	t-test,	with	alpha=10.00	%.	Each	row	was	 analysed	 individually,	 without	 assuming	 a	 consistent	 SD.	 Differential	 expression	 was	classified	as	significant	when	P	<	0.05	and	|FC|	>	1.5	(depicted	in	red).	Note	both	fold	changes	and	p-values	are	log	transformed.	The	further	its	position	away	from	the	(0,0),	the	more	significant	the	feature	is.	
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Figure	5.24	Effect	of	Gata6-KO	on	SL	composition	in	pResMf.		Heatmaps	 were	 generated	 with	 intensity	 values	 using	 the	 pheatmap	 package	 in	 R.	Hierarchical	cluster	analysis	for	SL	present	in	Gata6-KOmye	and	–WT	pResMf.	Intensity	levels	are	represented	by	a	colour	gradient	ranging	from	blue	(decrease	in	response)	to	white	(no	change)	to	red	(increase	 in	response).	Each	 lipid	was	annotated,	using	a	colour	code,	according	 to	 the	number	of	double	bonds	and	chain	length;	the	variations	in	signal	intensity	are	represented	in	colour	 range,	 from	blue	 to	 red	 (from	 the	 least	 to	 the	most	 intense	 signals),	 and	 clustered	 by	similarity	in	overall	response	to	Gata6-KO.					 	
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c) GPL	GPL	was	the	lipid	category	with	the	most	lipid	species	putatively	identified	(37%	of	all	lipid	features).	With	10	%	of	these	molecules	significantly	altered	by	
Gata6	KO.	GPL,	are	ubiquitous	in	nature	and	are	key	structural	components	of	cell	membranes.	They	are	precursors	of	 intracellular	signalling	molecules	 that	modulate	membrane	trafficking	and	signal	transduction.	The	GPL	lipid	category	can	be	subdivided	into	several	distinct	classes,	based	on	the	nature	of	the	polar	headgroups	(Figure	5.25).		I	selected	the	features	identified	as	GPL	and	subdivided	them	into	lipid	classes	(Figure	5.26).	This	analysis	revealed	that	the	class	with	the	highest	percentage	of	significantly	 changed	 lipid	 levels	 was	 glycerophosphoglycerols6,	 with	 16%	 of	lipids	significantly	increased.	Next,	I	selected	a	group	of	26	PG	with	increasing	chain	lengths	and	degrees	of	saturation,	 in	 order	 to	 establish	 common	 structural	 features	 amongst	 the	significantly	 increased	 lipids.	 I	 found	 that	 out	 of	 the	26,	 19	were	 significantly	increased	in	the	Gata6-KO	pResMf	(Figure	5.28)	with	a	clear	trend	for	the	levels	of	shorter	chain	PG	to	be	more	increased	than	longer	chain	PG.				 	
																																																								
6	There	were	two	other	lipid	classes	with	higher	percentages	of	significantly	increased	lipids,	however	there	were	less	than	10	lipids	in	each	class	and	thus	they	were	not	considered	for	further	analysis.	
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Figure	5.25	Structures	of	major	GPL.		Head	groups	legend:	PA	=	Phosphate,	PPA	=	Pyrophosphate,	PE	=	Phosphoethanolamine,	PC	=	Phosphocholine,	PS	=	Phosphoserine,	PG	=	Phosphoglycerol,	and	PI	=	Phosphoinositol.	
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Figure	5.26	10	%	of	GPL	vary	significantly	between	Gata6-WT	and	-KO	pResMf.		Mf	lipid	extracts	from	Gata6-WT	and	-KO	pResMf	were	analysed	by	LC-FTMS	on	the	Orbitrap	Elite,	at	60,000	resolution,	then	processed	using	XCMS.	Volcano	plots	representing	fold-change	and	p-value	of	GPL	in	Gata6-WT	relative	to	-KO	pResMf.	Lipids	were	putatively	identified	using	the	MSSearch	program,	which	used	the	LIPIDMAPS	database	to	attribute	a	lipid	category	to	each	lipid.	Significantly	changed	lipid	levels	are	indicated	by	red	(10	%)	(of	which	92	%	were	increased	in	 GATA6	 deficient	 cells),	 and	 unchanged	 levels	 by	 grey	 (90	%).	 Statistical	 significance	 was	determined	using	the	student	t-test	on	log	transformed	data,	with	alpha=5.00	%.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD,	and	P-values	were	adjusted	using	B.H	correction.	 Differential	 expression	 was	 classified	 as	 significant	 when	 P	<	0.1	 and	 |FC|	>	1.5	(depicted	 in	 red).	 Note	 both	 fold	 changes	 and	 p-values	 are	 log	 transformed.	 The	 further	 its	position	away	from	the	(0,0),	the	more	significant	the	feature	is.		 	
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Figure	5.27	16	%	of	PG	increase	significantly	in	Gata6-KOmye	pResMf.		Histogram	shows	the	number	of	GPL	species	by	lipid	class.	Grey	corresponds	to	the	number	of	 lipids	 that	 did	not	 change	 significantly;	magenta,	 lipids	 that	 decreased	 significantly;	 green,	lipids	 that	 increased	significantly.	Significance	was	determined	using	 the	student	 t-test	on	 log	transformed	 data,	 corrected	 using	 B.H.	 with	 alpha=10.00	%.	 Differential	 expression	 was	classified	as	significant	when	P	<	0.1	and	|FC|	>	1.5.		
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Figure	5.28	Alterations	in	the	levels	of	PG	during	GATA	KO.		The	colour	code	mirrors	the	log2(FC),	the	colour	gradient	from	white	to	blue	represents	an	increase	 in	 the	 lipid	 levels.	The	significances	of	 the	differences	(*p	<	0.05,	**p	<	0.005,	***p	<	0.0005;	t-test)	are	marked.			 	
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5.3 Discussion	
In	this	Chapter,	an	LC-MS	based	lipidomics	approach	was	used	in	an	effort	to	elucidate	if	the	transcription	factor	GATA6	regulates	lipid	metabolism	in	murine	pResMf.		
My	lipid	analysis	strategy	greatly	facilitated	interpretation	of	Gata6-WT	and	-KOmye	pResMf	 lipidomic	profiles	allowing	me	to	identify	several	trends	in	the	regulation	of	lipid	levels.	The	power	analysis	performed	in	the	beginning	of	this	Chapter	revealed	that	my	experimental	design	is	underpowered,	however,	it	will	still	be	able	to	detect	significant	lipidomic	differences	between	the	Gata6-WT	and	-KOmye	 pResMf,	 and	 importantly	 direct	 me	 to	 decide	 which	 lipids	 should	 be	analysed	using	targeted	MS/MS	methods	in	order	to	validate	my	findings.	Lipids	from	GATA6-deficient	cells	were	compared	to	those	obtained	from	WT	pResMf.	 The	 statistical	 analysis	 performed	 on	 the	 untargeted	 lipidomics	 data	showed	 that	 the	 lipidome	 of	 Gata6-WT	 and	 -KOmye	 pResMf	 was	 significantly	different.	8%	of	putatively	identified	lipids	increased	significantly	in	Gata6-KOmye	pResMf.	However,	when	looking	at	one	of	the	most	 important	 lipid	categories	(FA),	 which	 comprises	 a	 diverse	 group	 of	 molecules,	 it	 was	 one	 of	 the	 lipid	categories	that	changed	the	least	(3%),	and	the	changes	in	lipid	levels	were	not	consistent	throughout	the	different	lipid	classes,	thus	suggesting	that	GATA6	has	a	 regulatory	 effect	 on	 some,	 but	 not	 all,	 of	 the	 enzymes	 involved	 in	 FA	metabolism.		The	analysis	of	free	fatty	acids	revealed	a	trend	for	longer	chain	unsaturated	fatty	acid	levels	to	increase	with	GATA6	deficiency.	Increases	in	unsaturated	fatty	acids	has	been	shown	to	suppressed	ABCA1	and	ABCG1	transcripts	and	protein	levels	 in	 human	 Mf209.	 However,	 I	 could	 find	 no	 evidence	 of	 transcriptional	suppression	of	Abca1	and	Abcg1	in	Gata6-KOmye	pResMf,	which	could	be	due	to	different	regulatory	mechanisms	found	in	humans	and	mice,	or	the	fact	that	the	increase	 in	unsaturated	fatty	acid	 levels	as	not	enough	to	elicit	 transcriptional	changes.			
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Out	of	the	8	classes	analysed,	2	showed	significant	changes	in	over	10	%	of	lipids,	most	of	which	were	 increased	 in	Gata6-KOmye	pResMf.	 These	2	 classes	were	SL	and	GPL,	and	they	will	be	further	discussed	in	the	following	sections.		
5.3.1 SL	SL	are	located	in	the	outer	leaflet	of	the	plasma	membrane	and	interact	with	cholesterol-containing	specific	membrane	domains	known	as	‘lipid	rafts’.	These	are	small	regions	(10-200	nm)	that	play	a	key	role	in	the	compartmentalisation	of	cellular	processes	by	stabilising	protein-protein	or	protein-lipid	interactions.	SL	 are	 known	 for	 playing	 important	 roles	 in	 inflammation,	 activation	 of	 pro-inflammatory	 transcription	 factors	 in	 different	 cell	 types	 and	 induction	 of	cyclooxygenase-2,	leading	to	production	of	pro-inflammatory	prostaglandins210.	The	 presence	 of	 Caveolin-1	 in	 a	 lipid	 raft	 creates	 an	 invagination	 of	 the	membrane	recognised	as	‘caveolae’.	The	data	from	section	5.2.2b)	shows	that	the	most	significantly	altered	SL	were	long	chain	HexCer	and	SM,	commonly	found	in	the	 caveolar	 membrane	 fraction171.	 This	 could	 potentially	 contribute	 to	 a	disturbance	 in	 caveolae	 leading	 to	 a	 less	 effective	 endocytosis.	 In	 the	 next	Chapter	 I	 will	 validate	 the	 changes	 observed	 in	 SL	 using	 a	 targeted	 MS/MS	approach.	
5.3.2 GPL	Over	50%	of	all	GPL	were	putatively	identified	as	PC	or	PE.	The	host-defence	process	 performed	 by	 Mf	 starts	 with	 the	 attachment,	 recognition	 and	endocytosis	of	particles	by	the	plasma	membrane,	 the	sealing	vacuole	and	the	digestion	by	the	lysosome211.	These	events	are	accompanied	by	the	secretion	of	various	 factors,	 and	 also	 by	 the	 induction	 of	 changes	 in	 the	 metabolism	 of	membrane	 components,	 in	 particular	 GPL212.	 PG	 was	 the	 lipid	 category	 that	presented	the	highest	percentage	of	significantly	increased	GPL,	with	a	trend	for	the	shorter	chain	lipids	to	increase	the	most.	Previous	studies	in	alveolar	Mf	have	shown	 that	 phosphatidylglycerol	 stimulates	 the	 phagocytosis	 by	 resMf	 but	hardly	affects	the	uptake	by	alveolar	type	II	cells213.	High	concentrations	of	PG	reduce	the	number	of	resMf	in	the	alveolar	space	and	deteriorate	lung	function.	
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However,	further	study	is	needed	to	clarify	if	PG	has	the	same	effects	in	resMf	in	the	peritoneal	cavity.		
5.3.3 Conclusion	In	summary,	the	data	presented	herein	indicates	that	the	transcription	factor	GATA6	might	play	an	important	role	in	the	regulation	of	lipid	metabolism	in	Mf	causing	an	increase	in	lipid	levels	of	different	classes,	however	it	is	still	unclear	if	this	 could	be	due	 to	an	 increase	 in	production	or	 failure	 to	degrade	or	utilize	certain	 lipids.	 It	 is	 possible	 that	 the	 increase	 in	 lipid	 levels	 is	 caused	 by	dysregulation	of	the	lysosomes	where	lipids	could	accumulate.	There	are	over	40	lysosome	storage	disorders	known,	including	several	sphindolipidoses	where	an	intra-lysosomal	 accumulation	 of	 SL	 occurs125.	 Additionally,	 it	 has	 been	 shown	that	 a	 marked	 decrease	 in	 Cathepsin	 E,	 a	 proteinase	mainly	 localized	 on	 the	endosomal	compartment	in	Mf168,	can	lead	to	a	novel	form	of	lysosome	storage	disorder169.	 Interestingly,	 the	 microarray	 data	 (Chapter	 3)	 showed	 a	downregulation	of	the	cathepsin	E	gene	(Ctse),	indicating	that	cathepsin	E	could	be	 involved	 in	 maintaining	 lipid	 homeostasis	 in	 Mf	 by	 preventing	 lipid	degradation	and	consequently	promoting	an	increase	in	lipid	levels,	such	as	the	ones	observed	during	the	lipidomic	analysis	of	Gata6-WT	and	-KOmye	ResMf.		
Thus,	it	is	imperative	that	a	more	in-depth	analysis	is	performed,	in	order	to	validate	the	findings	from	this	Chapter.	Hence,	in	the	next	Chapter	I	will	perform	a	 targeted	analysis	of	 the	sphingolipidome,	using	an	LC-MS/MS	analysis	using	lipid	standards	for	the	different	SL	classes.	The	advantage	of	this	approach	is	that	it	will	 allow	me	 to	accurately	 identify	and	quantify	 individual	 lipid	species,	 as	opposed	to	using	only	accurate	m/z	and	RT	(untargeted	approach).	
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Chapter	6 Gata6	deficiency	leads	to	
sphingolipid	accumulation	in	pResMf	
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6.1 Introduction	
In	Chapters	3	and	6,	I	presented	transcriptomics	and	lipidomics	data	showing	that	GATA6	deficiency	leads	to	lipid	accumulation	in	pResMf,	in	particular	SL.	In	order	to	further	investigate	this,	here	I	will	perform	a	targeted	sphingolipidomic	analysis	of	Gata6-WT	and	-KOmye	pResMf.	
SL	are	a	highly	diverse	family	of	bioactive	lipids	that	contribute	to	numerous	aspects	of	cell	structure	and	signaling118,127,214.	Numerous	 functions	have	been	associated	with	all	SL	classes,	such	as	sphingoid	bases215,	Cer215,	SM216,	and	both	simple217	 and	 complex	 GSL,	 in	 Mf218–220.	 Furthermore,	 inhibition	 of	 de	 novo	biosynthesis	of	SL,	can	modify	Mf	behaviour,	i.e.	cell	cycle,	apoptosis,	autophagy	and	senescence	221–225.	The	 discovery	 and	 analysis	 of	 SL	 has	 benefited	 significantly	 from	technological	advances	in	lipid	detection,	analysis	and	quantitation	using	mass	spectrometry.	 However,	 to	 date	 no	 method	 has	 been	 developed	 that	 can	encompass	 all	 SL	 compounds	 in	 a	 structurally	 specific	 and	 quantitative	manner226.	The	need	for	diverse	methodologies	arises	from	the	fact	that	different	SL	classes	dissociate	into	structurally	different	fragments	corresponding	to	their	sphingoid	 bases,	 N-acyl	 chains	 and	 polar	 headgroups156,227.	 Hence,	 a	 range	 of	sample	 preparation,	 ionization	 modes	 and	 instrumental	 designs	 have	 been	established	to	analyse	particular	SL	classes	individually	by	MS123.	For	 further	 insight	 into	 the	 contribution	 of	 Gata6	 on	 SL	 metabolism,	 I	established	two	different	LC-MS/MS	methods	were	using	a	quadrupole-linear-ion	trap	(6500	QTrap,	operating	in	QQQ	mode).	These	methods	will	allow	me	to	quantify	individual	lipid	species	present	in	Mf.	Unlike	the	global	method	I	used	in	 Chapter	 6,	which	 only	 provided	 unvalidated	 putative	 identifications.	 These	MRM	methods	allow	a	far	higher	degree	of	selectivity	and	sensitivity,	through	the	combination	 of	 chromatography	 and	 multiple	 reaction	 monitoring	 (MRM)	detection.		Additionally,	 SL	 changes	 will	 be	 correlated	 with	 transcriptional	 changes	observed	in	pResMf-KOmye.	
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6.1.1 Aims	
• To	develop	LC-MS/MS	methods	for	targeted	analysis	of	SL	in	pResMf.	
• To	perform	a	targeted	analysis	of	the	different	classes	of	SL	in	Gata6-WT	and	-KOmye	pResMf.	
• To	 assess	 how	 Gata6	 deficiency	 contributes	 to	 the	 Mf	sphingolipidome.	
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6.2 Results	
In	this	Chapter	I	will	determine	whether	the	myeloid	deficiency	of	GATA6	is	associated	 with	 significant	 changes	 in	 SL	 levels.	 An	 untargeted	 lipidomics	workflow	(described	in	Chapter	4)	used	to	characterise	the	lipidomic	differences	between	 Gata6-KOmye	 and	 –WT	 pResMf	 (Chapter	 5)	 found	 that	 putatively	identified	SL	were	significantly	increased	in	Gata6-KOmye.	Herein	I	will	analyse	
Gata6-KOmye	and	–WT	pResMf	 samples	using	LC-MS/MS	methods,	 in	order	 to	validate	my	 findings.	This	 approach	will	 allow	me	 to	precisely	 investigate	 the	contribution	 of	 GATA6	 to	 the	 sphingolipidome	 of	 murine	 pResMf,	 and	 to	determine	which	SL	classes/species	are	the	most	affected	by	GATA6-deficiency.	To	determine	if	the	myeloid	deficiency	of	GATA6	is	associated	with	significant	changes	in	SL	levels,	extracts	from	both	cell	types	were	analysed	by	LC-MS/MS.	Briefly,	peritoneal	lavages	collected	from	Gata6-WT	and	-KOmye	female	mice	were	phenotyped	 and	 combined7	 (details	 in	 Materials	 and	 Methods,	 Chapter	 2).	pResMf	were	isolated	by	FACS	(2	x	106	cells/replicate),	and	cell	pellets	stored	at	-80°C,	 until	 ready	 for	 extraction.	 When	 all	 three	 biological	 replicates	 were	collected,	 lipids	 were	 extracted	 using	 a	 method	 optimised	 for	 SL	 recovery,	previously	described	in	the	literature	by	R.	L.	Shaner	et	al.156.	Next,	in	order	to	analyse	 SL,	 I	 needed	 to	 establish	 methods	 that	 would	 allow	 separation	 of	different	SL	classes,	since	these	were	the	lipids	found	to	be	different	using	the	global	lipidomics	approach.	The	SL	classes	of	interest	were:	sphingoid	bases	(So	and	Sa),	Cer,	SM,	mono-	(GlcCer	and	GalCer)	and	dihexocylCer	(LacCer),	Figure	6.1.			 	
																																																								
7	Due	to	the	low	recovery	of	pResMf	in	GATA6	deficient	mice,	it	was	necessary	to	combine	peritoneal	lavages	from		~15	mice.	In	order	to	obtain	2	x	106	cells/replicate.	
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Figure	 6.1	 Higher	 order	 SL	 depicted	 symbolically	 to	 demonstrate	 complexity	 and	
compare	similarities	of	added	headgroups	to	the	Cer	base	unit.		 	
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6.2.1 Establishment	of	LC-MS/MS	methods	for	analysis	of	SL	The	 first,	 of	 the	 two	 approaches	 used	 in	 this	 Chapter,	 will	 allow	 the	quantification	of	SL,	and	is	be	based	on	the	LC	method	used	for	the	untargeted	lipidomics	 approach,	 described	 in	 Chapter	 4,	 in	 combination	 with	 an	 MRM	method,	 derived	 from	 the	 one	 described	 by	 R.	 L.	 Shaner	 et	 al.156.	 The	 second	approach	will	complement	the	first,	by	separating	GlcCer	and	galactosylCer,	and	is	an	adaptation	of	a	method	also	described	by	R.	L.	Shaner	et	al.156.			
a) Quantitative	analysis	of	SL	in	cell	extracts	by	LC-MS/MS	The	LC	method	I	used	for	the	targeted	analysis	of	SL	species	was	based	on	the	LC	conditions,	described	previously,	for	the	untargeted	analysis.	Briefly,	the	lipid	extracts	were	separated	on	a	Accucore	C18	column	(150	x	2.1	mm,	2.6	µm)	using	an	 isocratic	 mobile	 phase	 A	 (H2O:ACN	 80:20	 v/v)	 and	 a	 phase	 B	 (IPA:	 ACN,	70:30	v/v)	 at	 a	 flow	 rate	 of	 0.4	mL/min	 over	 35	min,	 with	 4	mM	 ammonium	acetate.	 Samples	were	maintained	 at	 4	°C	 and	 the	 column	 at	 25	°C.	 These	 LC	conditions	 had	 already	 proven	 useful	 in	 the	 separation	 of	 SL	 (Chapter	 5,	untargeted	lipidomics),	thus	adapting	them	for	a	targeted	method	allowed	for	the	comparison	of	retention	times	between	the	two	approaches.	The	 system	 used	 for	 these	 analyses	was	 a	 Shimadzu	 LC-30	 AD	 VP	 binary	pump	system	coupled	to	a	Shimadzu	SIL-30	AC	200	autosampler	coupled	to	a	6500	 quadrupole	 linear-ion	 trap	 (QTrap)	 (AB	 SCIEX™,	 Warrington,	 UK)	operating	in	a	triple	quadrupole	mode.		Next,	 the	 optimal	 conditions	 for	 ionization	 and	 fragmentation	 were	determined	for	each	analyte.	An	internal	standard	mix	developed	by	the	LIPID	MAPS	Consortium	was	used,	allowing	the	quantification	of:	sphingoid	bases,	as	well	as	more	complex	species,	such	as	SM,	Cer,	mono-	and	di-hexosylCer.	The	SL	standard	mix	was	dissolved	at	a	concentration	of	1	–	10	pmol/µL	and	infused	into	the	 ion	 source	 at	 a	 rate	 of	 10	µL/min	 to	 determine	 the	 optimal	 ionization	conditions	by	varying	the	declustering	potential	(DP)	and	entrance	potential	(EP)	for	the	6500	QTrap.	After	the	Q1	settings	were	determined,	product	ion	spectra	were	 collected	 across	 a	 range	 of	 collision	 energies	 (CE),	 structurally	 specific	
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product	 ions	 were	 identified,	 and	 collision	 energies	 and	 collision	 cell	 exit	potentials	(CXP)	were	manipulated	to	produce	optimal	signal.		Once	 the	 settings	 were	 identified	 (Materials	 and	 Methods),	 the	precursor/product	 ion	 pairs	 were	 placed	 in	 MRM	 methods	 as	 described	 in	Materials	and	Methods.	LC	ESI-MS/MS	elution	profiles	for	the	SL	were	confirmed	(Figure	6.2).	
i) Standard	curves	for	quantitative	analysis	of	SL	by	LC-MS/MS	Once	 the	 LC	 and	 MRM	 methods	 were	 established,	 standard	 curves	 were	determined	 under	 these	 conditions.	 The	 Cer/Sphingoid	 Internal	 Standard	Mixture	 II	 from	 Avanti	 was	 used,	 it	 contains	 So	 (C17	 base),	 Sa	 (C17	 base),	Sphingosine-1-P	(C17	base),	Sphinganine-1-P	(C17	base),	Lactosyl(ß)	C12	Cer,	12:0	SM,	Glucosyl(ß)	C12	Cer,	12:0	Cer,	12:0	Cer-1-P.	The	concentration	of	the	individual	components	of	the	standard	cocktail	was	25	µM.	These	were	serially	diluted	 into	 the	 appropriate	 LC	 solvent	 (starting	 condition	 mobile	 phase)	immediately	 before	 analysis	 to	 provide	 0.5	–	1000	pmol	 of	 each	 standard	 per	20	µL	injection.	Each	was	then	analysed	by	LC-MS/MS	to	generate	the	standard	curves	such	as	those	shown	in	Figure	6.3,	then	to	calculate	the	linear	regression	lines.		According	to	the	literature,	none	of	the	lipid	species	present	in	the	standard	mix	 have	 been	 found	 in	 mammalian	 cells228.	 Additionally,	 it	 was	 previously	reported	 that	 the	 signal	 response	 across	 the	 different	 chain	 lengths	(C12:0	–	C25:0)	for	all	the	SL	classes	is	very	similar,	with	little	difference	in	cps	due	to	the	length	of	the	fatty	acyl	chain,	allowing	the	C12	standard	to	be	used	for	all	species156.				 	
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Figure	 6.2	 LC	 ESI-MS/MS	 elution	 profiles	 for	 the	 SL	 standards	 on	 reverse	 phase	
chromatography.		Shown	 are	 the	 elution	 profiles	 of	 sphingoid	 bases,	 Cer,	 LacCer,	 GlcCer	 and	 of	 an	 internal	standard	cocktail	(500	pmol	of	each	internal	standard)	from	an	Accucore	C18	column	(150	x	2.1	mm,	2.6	μm)	and	analysis	by	MRM	in	positive	ionization	mode	as	described	under	in	the	methods	section	(Chapter	2).	The	abbreviations	identify	the	lipid	classes:	So	C17,	sphingosine	d17:1;	Sa	C17,	sphinganine	d17:0;	Cer	C12,	d18:1/C12:0	Cer;	GlcCer	C12,	d18:1/C12:0	Glucosyl	Cer;	LacCer	C12,	d18:1/C12:0	Lactosyl	Cer;	SM	C12,	d18:1/C12:0	SM.			 	
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Figure	6.3	Signal	response	for	SL	standards	using	a	6500	Qtrap.		Each	compound	was	analysed,	in	duplicate,	over	the	shown	range	in	amounts	per	injection	using	 the	 LC-MS/MS	 protocol	 for	 sphingoid	 bases,	 Cer,	 SM,	 LacCer	 and	 GlcCer	 on	 reverse	chromatography	and	positive	ion	mode	MS/MS,	using	optimised	ionisation,	fragmentation	and	MRM	conditions	as	described	in	Materials	and	Methods	(Chapter	2).		 	
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b) MonohexosylCer	(HexCer)	HexCer	are	Cer	with	one	sugar	residue	joined	in	a	β-glycosidic	linkage	at	the	1-hydroxyl	position,	either	glucose	or	galactose,	which	are	epimers	of	each	other.	Thus,	 glucosyl-	 and	 galactosylCer	 have	 the	 same	 molecular	 formula,	 and	fragmentation	patern,	but	differ	in	the	configuration	of	a	stereocentre	(depicted	in	blue,	Figure	6.4A).	The	difference	in	configuration	allows	the	separation	of	the	two	structures	by	LC	(Figure	6.4B).	HexCer	were	 analysed	 using	 the	method	 described	 by	 R.	L.	Shaner	et	al.156	(materials	and	methods),	without	any	modifications,	where	 it	was	established	that	standards	GlcCer	and	GalCer	with	comparable	backbones	did	not	reveal	any	differences	 in	 ion	 yield	 and	 therefore,	 the	 C12-GlcCer	 internal	 standard	 is	adequate	 for	 analysis	 of	 total	 HexCer	 (i.e.,	 where	 the	 stereochemistry	 of	 the	carbohydrate	is	not	specified).			
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Figure	6.4	Separation	of	different	monohexosylCer.		A-	 Depiction	 of	 the	 major	 fragmentations	 of	 different	 monohexosylCer	 (Glucosyl-	 and	GalactosylCer).	Depicted	in	the	structures,	are	the	monohexosyl	groups	at	position	1,	and	R1	and	R2	are	the	alkyl	sidechains	for	the	sphingoid	base	and	fatty	acid,	respectively,	which	can	vary	in	length	 and,	 to	 some	 extent,	 unsaturation.	 Red-	 major	 fragment	 obtained;	 Blue-	 are	 epimeric	position	where	glusose	and	galactose	differ.	B-	chromatographic	separation	of	GlcCer	and	GalCer.		 	
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6.2.2 Analysis	of	SL	in	pResMf	
The	analysis	of	SL	in	pResMf	extracts	was	conducted	in	MRM	mode	where	specific	precursor-product	pairs	are	monitored	during	the	LC	elution.	I	compiled	a	 list	 of	 SL	 putatively	 identified	 in	 Chapter	 5,	 as	well	 as,	 others	 known	 to	 be	present	in	Mf95,156.	The	transitions	for	these	lipid	species	were	obtained	from	the	literature,	or	derived	from	existing	ones156.		To	quantify	the	amounts	of	the	SL	analytes	of	interest	in	Gata6-WT	and	-KOmye	pResMf	 extracts,	 the	 elution	 profiles	 for	 each	MRM	pair	were	 examined.	 The	areas	under	the	peaks	generated	for	both	analytes	and	internal	standards	were	integrated	with	the	software	Multiquant97.	I	first	established	SL	levels	in	Gata6-WT	pResMf	and	then	compared	them	with	those	in	Gata6-KOmye	pResMf.	The	analysis	of	various	SL	classes	is	described	in	detail	in	the	following	sections.	
a) Sphingoid	bases	Here	 I	 analysed	 long-chain	 bases	 (So,	 Sa)	 and	 their	 derivatives	 (sphingoid	base	1-phosphates,	glycosphingosine),	described	in	Table	6.1	(Figure	6.5	shows	a	representative	example	of	LC-MS/MS	analysis	of	So	and	Sa	in	pResMf	cells),	they	 are	 highly	 bioactive	 compounds	 that	 appear	 as	 intermediates	 of	 SL	metabolism	and	cell	signalling,	and	are	elevated	on	disruption	of	SL	metabolism	in	disease229.	I	first	established	the	lipid	levels	in	Gata6-WT	pResMf	and	was	able	to	quantify	4	of	 the	5	 lipid	 species	 in	Table	6.1.	Additionally,	 I	 found	 that	 the	relative	amounts	of	sphingoid	bases	varies	significantly,	and	that	So	were	more	abundant	than	Sa	(Figure	6.6C	and	D,	respectively).	
Next,	 I	 compared	 Gata6-WT	 and	 -KOmye	 pResMf	 and	 found	 the	 following	changes.	 Of	 the	 four	 lipids	 analysed,	 in	 this	 class,	 only	 the	 levels	 of	 So	 were	significantly	changed	in	Gata6-KOmye	(Figure	6.6A),	displaying	a	30	%	increase.	Both	 Sa	 and	 So	 are	 precursors	 for	 DHSL	 and	 SL	 (Figure	 6.7),	 which	 could	potentially	lead	to	higher	levels	of	SL	vs	DHSL	when	comparing	Gata6-KOmye	with	-WT	 pResMf.	 In	 particular	 DH-Cer	 and	 Cer,	 the	 first	 lipid	 species	 produced	directly	from	Sa	and	So,	which	will	be	analysed	in	the	next	section.		 	
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Table	6.1	Parent	to	daughter	ion	transitions	used	for	measuring	sphingoid	bases,	and	
concentrations	found	in	Gata6-WT	pResMf.	ND,	not	detected.	
		 	
Lipid Q1	Mass	(Da) Q3	Mass	(Da) Concentration	(pmol/106	cells)C17:0	Sa 288.44 270.2 StandardC17:0	Sa-1-P 368.4 252.2 StandardC17:1	So 286.45 268.2 StandardC17:1	So-1-P 366.3 250.2 StandardC18:0	Sa 302.4 252.2 0.2C18:0	Sa-1-P 382.4 266.4 NDC18:1	So 300.4 282.4 6.1C18:1	So-1-P 380.4 264.4 5.0Lyso-GlcCer 490.4 252.2 0.4
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Figure	 6.5	Representative	 example	 of	 the	 LC-MS/MS	 analysis	 of	 sphingoid	 bases	 in	
pResMf	cells.		Lipid	 extracts	 from	 pResMf	 cells	 were	 analysed	 by	 LC-MS/MS.	 Shown	 are	 the	chromatograms	obtained	for	So	(blue)	and	Sa	(Red),	and	the	respective	integrated	areas	(shaded	area).			 	
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Figure	6.6	Quantitative	analysis	of	sphingoid	bases	in	Gata6-KOmye	and	-WT	pResMf	
cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	Materials	and	Methods	(Chapter	2).	Shown	are	the	means	±	SEM	for	three	separate	replicates	with	cells	pooled	from	15	Gata6-KOmye	and	15	-WT	animals.	A	-	shows	the	amounts	of	sphingoid	bases;	B	-	E,	chemical	structures	of	a	So,	Sa,	S1P	and	glucosyl	sphingosine,	respectively.		 	
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Figure	6.7	Steps	of	SL	biosynthesis.		The	 figure	depicts	metabolites	 (circles)	 that	 participate	 in	 early	 steps	 of	 SL	biosynthesis:	Sa1P,	 sphinganine-1-phosphate;	 EP,	 ethanolamine	 phosphate;	 S1P,	 sphingosine-1-phosphate;	3KSa,	 3-ketosphinganine;	 Sa,	 Sa;	 So,	 sphingosine;	 DH-Cer,	 dihydroCer;	 Cer,	 Cer;	 DH-SM,	dihydrosphingomyelin;	SM,	sphingomyelin;	GalCer,	galactosylCer;	GlcCer,	GlcCer;	Cer1P,	Cer-1-phosphate;	LacCer,	lactosylCer.	The	metabolites	analysed	by	LC-MS,	as	previously	described,	are	highlighted	in	black.	Sphinganine	(Sa)	and	sphingosine	(So),	are	depicted	in	red.			
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b) Cer	Here	I	analysed	Cer	and	CerP	species,	described	in	Table	6.2	(Figure	6.8	shows	a	representative	example	of	LC-MS/MS	analysis	of	Cer	and	CerP	in	pResMf	cells),	they	are	considered	backbone	signalling	subspecies	of	SL134.	 I	 first	established	the	lipid	levels	in	Gata6-WT	pResMf	and	found	that	I	could	not	detect	any	of	the	DH-Cer	species,	Table	6.2.	Regarding	the	analysis	of	Cer1P,	only	the	C16	and	C24	species	were	observed,	namely	d18:0/24:0-CerP,	d18:0/24:1-CerP,	d18:1/16:0-CerP,	 d18:1/24:0-CerP.	 The	 relative	 amounts	 of	 Cer	 varied	 considerably	 for	different	chain-lengths	(Figure	6.9B),	with	C16:0	being	most	abundant,	followed	by	C24:1	and	C24:0.	Comparing	saturated	with	monounsaturated	forms,	revealed	that	the	latter	presented	lower	levels	for	all	species,	except	C24.	
Next,	I	compared	the	levels	of	Cer	and	CerP	in	Gata6-KOmye	and	-WT	pResMf,	and	observed	that	even	though	all	lipid	species	tended	to	be	increased	in	Gata6-KO	cells,	d18:0/16:0-CerP	was	the	only	CerP	to	be	significantly	different	(Figure	6.9).	 With	 respect	 to	 Cer,	 2	 species	 were	 increased	 significantly	 upon	 Gata6	knockdown,	d18:1/24:0-Cer	and	d18:1/25:0-Cer.			 	
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Table	6.2	Parent	 to	daughter	 ion	 transitions	used	 for	measuring	Cer	and	CerP,	and	
concentrations	found	in	Gata6-WT	pResMf.	ND,	not	detected.	
					
N-Acyl Q1	Mass	(Da) Q3	Mass	(Da) Concentration	(pmol/106	cells)C16:0 540.7 266.4 NDC18:0 568.7 266.4 NDC20:0 596.6 266.4 NDC22:0 624.6 266.4 NDC24:0 652.9 266.4 NDC24:1 650.9 266.4 NDC26:0 680.7 266.4 NDC26:1 678.7 266.4 NDC24:0 732.9 266.4 0.1C24:1 650.6 266.4 1.0C12:0 562.5 264.5 StandardC16:0 618.7 264.4 131.8C24:0 730.9 264.4 3.2C12:0 482.6 264.2 StandardC16:0 538.7 264.4 90.5C18:0 566.5 264.4 2.9C18:1 564.5 264.4 0.2C20:0 594.6 264.4 2.4C20:1 592.6 264.4 0.3C20:0 622.6 264.4 4.7C22:1 620.6 264.4 1.2C24:0 650.6 264.4 3.4C24:1 648.6 264.4 10.9C25:0 664.8 264.4 0.6C26:0 678.7 264.4 NDC26:1 676.7 264.4 0.4
DHCer
DH-CerP
CerP
Cer
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Figure	6.8	Representative	example	of	the	LC-MS/MS	analysis	of	Cer	in	pResMf	cells.		Lipid	 extracts	 from	 pResMf	 cells	 were	 analysed	 by	 LC-MS/MS.	 Shown	 are	 the	chromatograms	 obtained	 for	 Cer	 d181/16:1	 (blue)	 and	 CerP	 d18:1/16:0	 (Red),	 and	 the	respective	integrated	areas	(shaded	area).	
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Figure	6.9	Quantitative	analysis	of	Cer	and	Cer-1-phosphate	in	Gata6-KOmye	and	-WT	
pResMf	cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	Materials	and	Methods	(Chapter	2).	Shown	are	the	means	±	SEM	for	three	separate	replicates	with	cells	pooled	from	15	Gata6-KOmye	and	15	-WT	animals.	A	-	shows	the	amounts	 of	 Cer-1-phosphates;	 B	 -	 shows	 the	 amounts	 of	 C	 and	D,	 chemical	 structures	 of	 Cer	d18:1/12:0	and	Cer-1-phosphate	d18:1/12:0,	respectively.		 	
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c) HexCer	Here	I	analysed	DH-HexCer	and	Cer	species,	described	in	Table	6.3.	 	Figure	6.10	shows	a	representative	example	of	LC-MS/MS	analysis	of	Cer	and	CerP	in	pResMf	cells.	I	first	established	the	lipid	levels	in	Gata6-WT	pResMf	and	found	that	whilst	all	the	HexCer	species	were	detected,	only	50	%	of	DH-HexCer	were	above	the	LOD.	Furthermore,	the	levels	of	dihydro	forms	are	ca.	45	times	lower	than	those	of	HexCer	for	the	same	chain-lengths	Table	6.3.		Regarding	the	comparison	of	DH-HexCer/HexCer,	the	ratio	between	these	2	classes	increases	from	45	(Gata6-WT	pResMf)	to	55,	when	comparing	amounts	in	Gata6-KOmye	 pResMf	 (Figure	 6.11A	 and	 B).	 Analysis	 of	 DH-HexCer	 (Figure	6.11D)	showed	that	5	out	of	7	detected	lipids	increased	significantly	 in	Gata6-KOmye	pResMf	(Figure	6.11A),	which	is	considerably	higher	than	what	was	found	for	HexCer,	where	only	7	out	of	12	molecules	were	significantly	changed.		Many	cells	do	not	contain	galacto-family	SL,	so	distinguising	between	GlcCer	and	GalCer	is	not	required156.	Nonetheless,	there	is	the	possibility	that	GalCer	was	enriched	in	Gata6-KOmye	pResMf,	therefore,	it	was	necessary	to	separate	GlcCer	and	GalCer.	SL	analysis	using	the	method	described	in	section	6.2.1b)	showed	no	evidence	of	GalCer	lipids	in	either	pResMf	from	-KOmye	and	-WT	(Figure	6.12).	
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Table	 6.3	 Parent	 to	 daughter	 ion	 transitions	 used	 for	 measuring	 HexCer	 and	
concentrations	found	in	Gata6-WT	pResMf.	ND,	not	detected.	
						
N-Acyl Q1	Mass	(Da) Q3	Mass	(Da) Concentration	(pmol/106	cells)C14:0 674.5 266.4 NDC14:1 672.5 266.4 NDC16:0 702.6 266.4 0.2C16:1 700.6 266.4 0.0C18:0 730.6 266.4 NDC18:1 728.6 266.4 0.3C20:0 758.6 266.4 0.3C20:1 756.6 266.4 NDC22:0 786.7 266.4 0.2C22:1 784.6 266.4 NDC24:0 814.9 266.4 0.2C24:1 812.7 266.4 0.3C26:0 842.7 266.4 NDC26:1 840.7 266.4 NDC12:0 644.7 264.5 StandardC14:0 672.5 264.4 0.8C16:0 700.6 264.4 11.2C16:1 698.5 264.4 1.0C18:0 728.6 264.4 0.7C18:1 726.6 264.4 16.1C20:0 756.6 264.4 1.4C20:1 754.6 264.4 0.6C22:0 784.6 264.4 5.7C22:1 782.6 264.4 1.6C24:0 812.7 264.4 7.1C24:1 810.7 264.4 11.5C26:0 840.7 264.4 2.5C26:1 838.7 264.4 2.5
HexCer
DH-HexCer
  
199 
			
	
Figure	6.10	Representative	example	of	 the	LC-MS/MS	analysis	of	HexCer	 in	pResMf	
cells.		Lipid	 extracts	 from	 pResMf	 cells	 were	 analysed	 by	 LC-MS/MS.	 Shown	 are	 the	chromatograms	obtained	for	HexCer	d18:1/16:0	(blue)	and	HexCer	d18:0/16:0	(Red),	and	the	respective	integrated	areas	(shaded	area).			
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Figure	6.11	Quantitative	analysis	of	DH	HexCer	and	HexCer	in	Gata6-KOmye	and	-WT	
pResMf	cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	Materials	and	Methods	(Chapter	2).	Shown	are	the	means	±	SEM	for	three	separate	replicates	with	cells	pooled	from	15	Gata6-KOmye	and	15	-WT	animals.	A	-	shows	the	amounts	of	DH	HexCer;	B	 -	 shows	 the	amounts	of	HexCer.	C	and	D,	chemical	 structures	of	an	HexCer	(GlcCer	d18:1/12:0)	and	an	DH	HexCer	(DH-GlcCer	d18:1/12:0),	respectively.				
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Figure	6.12	Gata6-KOmye	pResMf	show	no	evidence	of	GalCer	lipids.		LC	 ESI-MS/MS	 elution	 profiles	 for	 HexCer	 on	 normal	 phase	 chromatography.	 The	 figure	shows	 a	 representative	 chromatogram	of	 the	 separation	 of	 GluCer	 and	GalCer	 (d18:1/C24:1-GlcCer	and	-GalCer)	using	a	Supelco	2.1mm	i.d.	×	25	cm	LC-Si	column	and	the	conditions	described	under	“Materials	and	Methods.”.	Blue-	standards;	Red-	Gata6-KOmye	pResMf	cells.				 	
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d) LactosylCer	Here,	I	analysed	the	LacCer	species,	described	in	Table	6.4.	Figure	6.13	shows	a	representative	example	of	LC-MS/MS	analysis	of	LacCer	in	pResMf	cells.	I	first	established	their	levels	in	Gata6-WT	pResMf	and	found	that	out	of	the	11	LacCer	species	analysed,	4	were	below	the	limit	of	detection.		Next,	I	compared	LacCer	levels	in	Gata6-WT	and	-KOmye,	and	observed	that	there	was	a	noticeable	 increase,	 in	all	LacCer	species,	 in	Gata6-KOmye	pResMf,	however,	 only	 the	 changes	 in	 d18:1/18:0-LacCer,	 d18:1/22:0-LacCer,	d18:1/24:0-LacCer,	 d18:1/24:1-LacCer	 were	 statistically	 significant	 (Figure	6.14).				 	
  
203 
			
Table	 6.4	 Parent	 to	 daughter	 ion	 transitions	 used	 for	 measuring	 LacCer	 and	
concentrations	found	in	Gata6-WT	pResMf.	ND,	not	detected.	
							 	
N-Acyl Q1	Mass	(Da) Q3	Mass	(Da) Concentration	(pmol/106	cells)C12:0 806.7 264.4 StandardC16:0 862.7 264.4 0.2C18:0 890.7 264.4 0.1C18:1 888.6 264.4 NDC20:0 918.7 264.4 0.4C20:1 816.7 264.4 NDC22:0 946.8 264.4 0.2C22:1 844.7 264.4 0.1C24:0 974.8 264.4 0.2C24:1 972.7 264.4 0.2C26:0 1002.8 264.4 NDC26:1 1000.8 264.4 ND
LacCer
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Figure	6.13	Representative	example	of	 the	LC-MS/MS	analysis	of	 LacCer	 in	pResMf	
cells.		Lipid	 extracts	 from	 pResMf	 cells	 were	 analysed	 by	 LC-MS/MS.	 Shown	 are	 the	chromatograms	obtained	 for	LacCer	d18:1/24:1	 (blue)	and	LacCer	d18:1/24:0	 (Red),	and	 the	respective	integrated	areas	(shaded	area).										
38.0 39.0 40.0 41.0 42.0 43.0 44.0 45.0 46.0 47.0 48.0
Time, min
39.65
In
te
ns
ity
, c
ps
45.05
C24:1-LacCer
(LacCer d18:1/24:1)
m/z 972.7/264.4 Da
C24:0-LacCer
(LacCer d18:1/24:0)
m/z 974.7/264.4 Da
  
205 
		
	
Figure	6.14	Quantitative	analysis	of	LacCer	in	Gata6-KOmye	and	-WT	pResMf	cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	Materials	and	Methods	(Chapter	2).	Shown	are	the	means	±	SEM	for	three	separate	replicates	with	cells	pooled	from	15	Gata6-KOmye	and	15	-WT	animals.	A	-	shows	the	amounts	of	LacCer;	B	structure	of	LacCer	d18:1/12:0.		 	
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e) Sphingomyelin	I	analysed	DH-SM	and	SM	species,	described	in	Table	6.5.	Figure	6.15	shows	a	 representative	 example	 of	 LC-MS/MS	 analysis	 of	DH-SM	and	 SM	 in	 pResMf	cells.	 I	 first	 established	 the	 lipid	 levels	 in	Gata6-WT	pResMf	 and	 found	 that	 I	could	not	detect	the	C14	DH-SM	species	and	that	C16	was	the	most	abundant	of	the	 7	 species	 analysed,	 Table	 6.5.	 Notably,	 the	 relative	 amounts	 of	 SM	 varied	considerably	for	different	chain-lengths	(Figure	6.16B),	with	C16:0	being	most	abundant,	 followed	 by	 C24:1	 and	 C24:0.	 Comparing	 saturated	 with	monounsaturated	forms	revealed	that	the	latter	were	present	at	lower	levels	for	all	species,	except	C24.	Next,	 I	 compared	 the	 levels	 of	 DH-SM	 and	 SM	 in	 Gata6-KOmye	 and	 -WT	pResMf.	All	lipid	species	tended	to	be	increased	in	Gata6-KO	cells,	however,	of	the	6	DH-SM	analysed,	only	4	were	significantly	altered.	With	respect	to	SM,	out	of	the	13	SM	detected,	8	lipids	were	significantly	increased,	representing	roughly	half	of	all	SM	species	analysed.	A	similar	finding	is	seen	DH-SM,	i.e.	65%	of	lipids	are	 changed,	 which	 is	 higher	 than	 that	 of	 their	 precursors	 DH-Cer	 and	 Cer	(roughly	25%).			 	
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Table	 6.5	 Parent	 to	 daughter	 ion	 transitions	 used	 for	 measuring	 SM	 and	
concentrations	found	in	Gata6-WT	pResMf.	ND,	not	detected.	
							
N-Acyl Q1	Mass	(Da) Q3	Mass	(Da) Concentration	(pmol/106	cells)C14:0 677.6 184.4 NDC16:0 705.6 184.4 44.2C18:0 733.8 184.4 1.9C20:0 761.6 184.4 1.1C22:0 789.7 184.4 3.2C24:0 817.9 184.4 5.5C26:0 845.7 184.4 0.0C12:0 647.7 184.1 StandardC14:0 675.5 184.4 1.4C16:0 703.6 184.4 531.5C16:1 701.6 184.4 32.4C18:0 731.8 184.4 22.4C18:1 729.6 184.4 8.4C20:0 759.6 184.4 11.2C20:1 757.6 184.4 2.0C22:0 787.6 184.4 25.6C22:1 785.6 184.4 4.3C24:0 815.9 184.4 49.8C24:1 813.7 184.4 125.5C26:0 843.7 184.4 0.1C26:1 841.7 184.4 0.5
SM
DH-SM
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Figure	6.15	Representative	example	of	the	LC-MS/MS	analysis	of	SM	in	pResMf	cells.		Lipid	 extracts	 from	 pResMf	 cells	 were	 analysed	 by	 LC-MS/MS.	 Shown	 are	 the	chromatograms	obtained	for	SM	d181/24:1	(blue)	and	SM	d18:0/24:0	(Red),	and	the	respective	integrated	areas	(shaded	area).	
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Figure	6.16	Quantitative	analysis	of	DH	SM	and	SM	in	Gata6-KOmye	and	-WT	pResMf	
cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	Materials	and	Methods	(Chapter	2).	Shown	are	the	means	±	SEM	for	three	separate	replicates	with	cells	pooled	from	15	Gata6-KOmye	and	15	-WT	animals.	A	-	shows	the	amounts	 of	 DH	 SM;	 B	 -	 shows	 the	 amounts	 of	 SM.	 C	 and	 D,	 chemical	 structures	 of	 an	 SM	d18:1/12:0	and	an	DH	SM	d18:1/12:0,	respectively.		 	
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6.2.3 GATA6	deficiency	leads	to	a	significant	 increase	in	SL	and	DHSL	in	
pResMf	
Figure	6.17	summarises	all	of	the	subspecies	of	SL	that	have	been	analysed	in	
Gata6-KOmye	and	-WT	pResMf.	Volcano	plots	were	generated,	representing	fold-change	and	p-value	of	lipids	in	Gata6-KOmye	relative	to	-WT	pResMf	cells,	clearly	show	that	GATA6	deficiency	leads	to	significant	increases	in	SL	levels,	where	the	majority	of	altered	lipids	have	long	and	saturated	fatty	acyl	chains.		A	comparison	between	 the	number	of	 lipids	significantly	changed	 for	each	class,	revealed	that	the	most	affected	 lipid	class	by	GATA6	deficiency	was	DH-HexCer,	 followed	 by	 DH-SM	 and	 SM.	 Considering	 that	 DH-Cer/Cer	 are	 the	precursors	for	DH-SM/SM,	the	fact	that	the	changes	observed	in	DH-Cer/Cer	do	not	 translate	 to	 DH-SM/SM,	 suggests	 that	 the	 enzymes	 involved	 in	 the	metabolism	of	DH-SM/SM	might	 be	 affected	by	GATA6	deficiency,	 or	 that	 the	assay	 might	 be	 close	 to	 its	 limits	 of	 detection.	 Likewise,	 DH-HexCer/HexCer	increase,	 in	Gata6-KOmye,	 cannot	 be	 explained	by	 variations	 in	 substrate	 (DH-Cer/HexCer).		In	the	next	section	I	will	explore	the	possibility	that	the	dysregulation	of	SL	metabolism	related	genes	directly	impacts	SL	levels.			 	
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Figure	6.17	GATA6	deficiency	leads	to	a	significant	increase	in	SL	and	DH-SL	in	pResMf.		Lipid	extracts	from	Gata6-KOmye	and	-WT	pResMf	cells.	SL	and	DHSL	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	(AB	Sciex).	Volcano	plots	representing	fold-change	and	 p-value	 of	 lipids	 in	 Gata6-KOmye	 relative	 to	 -WT	 pResMf	 cells.	 Statistical	 significance	determined	 without	 correction	 for	 multiple	 comparisons,	 with	 alpha=0.05%.	 Each	 row	 was	analyzed	 individually,	without	 assuming	a	 consistent	 SD.	Differential	 levels	were	 classified	as	significant	when	P<0.05	and	FC>1.5	(grey	lines).	Numbers	on	the	upper	right	corner	of	each	plot	correspond	to	the	percentage	of	significantly	change	lipids	in	each	category.			 	
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6.2.4 Correlation	between	lipidomics	and	transcriptomics	data	reveals	a	
potential	mechanism	for	SM	accumulation	
The	main	changes	in	lipid	levels	observed	in	Gata6-KOmye	pResMf	were	the	increase	 of	 DH-SM/SM	 and	 DH-GlcCer/GlcCer,	 however	 these	 could	 not	 be	explained	 by	 substrate	 availability,	 given	 that	 only	 18.2	%	 of	 Cer	 were	significantly	altered.	Thus,	I	next	analysed	the	expression	of	genes	involved	in	SL	metabolic	pathways.	Figure	6.18	shows	the	expression	of	genes	involved	in	SL	biosynthesis	 for	 Gata6-KOmye/WT	 pResMf.	 Gene	 expression	 data	 for	 the	 SL	metabolic	enzymes	from	the	microarray	are	coloured	by	fold-change,	where	red	represents	 upregulation,	 and	 green	 down	 regulation	 in	Gata6-KOmye	 pResMf.	These	reveal	significant	changes	in	gene	expression	that	could	potentially	lead	to	the	observed	lipid	dysregulation,	and	this	is	described	in	more	detail	below.	
a) CerS	 expression	 directly	 impacts	 fatty	 acyl	 chain-length	 in	 SL	 in	
pResMf		
The	 six	 (DH)Cer	 synthases	 (CerS),	 represented	 in	 Figure	 6.18	 transfer	variable	length	fatty	acid	chains	to	the	free	amine	group	of	Sa	to	form	dihydroCer	(DH-Cer)135.	Each	of	these	enzymes	utilizes	fatty	acyl-CoA	substrates	of	various	chain	 lengths	 resulting	 in	 the	 formation	 of	 different	 DH-Cer	 subspecies128,130	(Chapter	1).	CerS2	is	responsible	for	synthesising	Cer	with	chain-lengths	C22-26,	whilst	CerS4	catalyses	formation	of	C18-20	Cer135,230.	Thus,	an	up-regulation	in	
CerS2	and	down-regulation	in	CerS4	would	in	theory	lead	to	an	increase	of	C22-26	 Cer.	 Indeed,	 this	was	 observed	 in	 the	microarray.	 Furthermore,	 Cer	 is	 the	precursor	for	complex	SL	and	changes	in	its	composition	are	likely	to	affect	DH-SM/SM	and	DH-GlcCer/GlcCer,	i.e.	the	chain	length	of	Cer	has	a	direct	impact	in	the	chain	length	of	complex	SL,	such	as	SM	and	GlcCer,	thus	if	there	is	an	increase	in	 CerS	 of	 a	 particular	 chain	 length	 that	 will	 be	 reflected	 in	 metabolites	downstream	of	Cer.	Accordingly,	out	of	the	6	classes	analysed	(sphingoid	bases,	Cer,	SM,	GlcCer,	GalCer,	LacCer),	C20	SL	only	increase	significantly	in	DH-GlcCer.			 	
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b) Downregulation	 of	 Smpd1	 in	 Gata6-KOmye	 pResMf	 leads	 to	
accumulation	of	DH-SM	and	SM.		Acid	sphingomyelinase	(SMPD1)	catalyses	the	breakdown	of	DH-SM/SM	into	DH-Cer/Cer,	whilst	sphingomyelinase	synthase	(SMS2)	mediates	the	production	of	 SM	 from	 Cer	 in	 the	 plasma	 membrane231(Chapter	 1).	 Hence	 the	 down-regulation	 of	 SMPD1	 combined	 with	 the	 up-regulation	 of	 SMS2,	 will	 lead	 to	accumulation	of	DH-	SM/SM,	as	seen	in	Figure	6.18.	
c) Downregulation	 of	 Gba2	 in	 Gata6-KOmye	 pResMf	 leads	 to	
accumulation	of	DH-GlcCer/GlcCer	Non-lysosomal	Glucosylceramidase	(GBA2)	catalyses	the	conversion	of	DH-GlcCer/GlcCer	 into	 DH-Cer/Cer	 in	 the	 endoplasmic	 reticulum,	 whilst	 GlcCer	synthase	 (UGCG)	 mediates	 the	 production	 of	 DH-GlcCer/GlcCer	 in	 the	 Golgi	apparatus.	Thus,	an	up-regulation	 in	Ugcg	 and	down-regulation	 in	Gba2	 could	explain	 an	 increase	 of	 DH-GlcCer/GlcCer,	 which	 is	 in	 accordance	 with	 the	targeted	lipidomics	data	(section	6.2.2).			 	
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Figure	6.18	Expression	of	Genes	Involved	in	SL	Biosynthesis	for	the	Gata6-Komye/WT	
pResMf.			Gene	expression	data	for	the	SL	metabolic	enzymes	from	microarray	coloured	by	fold	change	(WT/KO);	 Green	 –	 Downregulated,	 Red-	 Upregulated.	 Sa	 is	 acylated	 to	 DH-Cer	 by	 (DH)Cer	synthases	 (CerS)	 and	 incorporated	 into	 more	 complex	 DH-SL	 (Like	 SM/DH-SM),	 GlcCer/DH-GlcCer,	GalCer/DH-GalCer)	or	desaturated	to	Cer	followed	by	headgroup	addition.	Also	included	are	a	number	of	the	catabolic	genes,	e.g.,	sphingomyelinases	(SMPD),	ceramidases	(ASAH).	The	major	contributions	of	each	CerS	isoform	to	de	novo	and	salvage	synthesis	of	different	Cer	species	are	depicted.	SL	represented	in	red	and	DH	SL	in	blue.			 	
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6.3 Discussion	
In	this	Chapter	I	performed	a	comprehensive	analysis	of	the	sphingolipidome	of	Gata6-KOmye	and	-WT	pResMf.	I	used	a	targeted	sphingolipidomic	approach	to	determine	the	changes	of	lipid	levels	upon	GATA6	knockdown,	and	thus	explored	the	role	of	Gata6	in	regulating	Mf	SL	metabolism.	I	then	compared	changes	in	SL	gene	expression	with	the	lipid	changes	observed	in	order	to	identify	the	control	checkpoints	responsible.		SL	 have	 central	 roles	 in	 cell	 structure	 and	 function	 as	 well	 as	 in	 the	pathophysiology	of	many	diseases.	Many	of	the	intermediates	of	SL	biosynthesis	are	 highly	 bioactive	 and	 often	 have	 antagonistic	 activities.	 For	 instance,	 Cer	promotes	 apoptosis	 while	 S1P	 can	 inhibit	 apoptosis	 and	 induce	 cell	 growth.	Therefore,	quantification	of	SL	metabolites,	in	Gata6-KOmye	and	-WT	pResMf,	is	crucial	for	an	understanding	the	role	of	GATA6	in	SL	biology.		The	abundance	of	individual	SL	species	was	determined	in	Gata6-KOmye	and	-WT	pResMf.	This	analysis	allowed	me	to	compare	the	relative	amounts	of	 the	different	SL	classes.	Similar	to	what	had	been	shown	for	RAW	264.7,	So	levels	are	higher	than	Sa,	and	SM	is	the	most	abundant,	followed	by	Cer	and	HexCer232.	The	relative	amounts	of	sphingoid	bases	vary	significantly,	and	the	amount	of	So	is	higher	 than	 Sa	 (Figure	 6.6C	 and	 D,	 respectively),	 again	 agreeing	 with	 the	literature	 for	 RAW264.795,156.	 Interestingly,	 in	 the	 literature	 the	 reported	amounts	of	So	are	ca.	10	times	higher	than	Sa	 for	RAW	264.7	cells,	which	 is	3	times	lower	than	what	I	found	for	pResMf,	Figure	6.6A,	whilst	for	CerP	studies	have	reported	that	levels	of	the	dihydro	forms	are	considerably	lower	than	those	CerP,	 under	basal	 conditions	 for	Mf-like	 cells95,156,232.	 These	differences	 likely	represent	 cell	 type	 specificity.	 Conversely,	 in	 RAW264.7	 cells	 under	 basal	conditions,	Cer1P	of	C16:0,	C24:0	and	C24:1	are	detected,	whilst	for	DH-Cer1P	only	the	C16:0	is	found156.	According	to	the	literature,	levels	of	Cer	are	200	times	higher	than	those	of	DH-Cer	in	Mf-like	cells,	for	the	same	chain	lengths,	under	basal	conditions232.	Thus,	it	is	possible	that	the	levels	of	DH-Cer	were	under	the	LOD.	The	majority	of	these	SL	are	enriched	in	the	plasma	membrane233,	however,	subcellular	organelle	lipidomics	in	Mf	has	shown	that	headgroup	and	acyl	chain	
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composition	dictate	where	 lipids	accumulate232.	Additionally,	 their	 localisation	and	relative	amounts	are	known	to	shift	upon	cell	activation.	Thus,	I	believe	that	a	 subcellular	 organelle	 sphingolipidomics	 analysis	 would	 give	 an	 important	insight	into	lipid	function	in	GATA6	deficient	pResMf.	
Herein	 I	have	shown	that	GATA6	deficiency	 leads	to	 increases	 in	SL	 levels,	where	the	majority	of	significantly-altered	lipids	contain	long	and	saturated	fatty	acids.	 This	 finding	 supports	 those	 from	Chapter	 5,	where	 I	 found	 that	Gata6-KOmye	 showed	 increased	 levels	 of	 SL	 in	 pResMf,	 in	 particular	 in	 longer	 chain	HexCer	and	SM.		The	common	denominator	between	 the	 three	SM	species	 that	changed	 the	most	 is	 the	 fact	 that	 other	 than	 the	 plasma	 membrane	 they	 are	 all	 mainly	enriched	in	the	endoplasmic	reticulum,	whilst	the	last	is	mainly	enriched	in	the	mitochondria.	Research	has	shown	that	membranes	rich	in	these	SL	are	thicker	and	 less	 fluid,	due	to	the	tight	packing	of	 their	hydrophobic	tails	and	stronger	lipid-lipid	interactions234–236.			In	 regard	 to	 fatty	 acid	 chain-length,	 the	 dysregulation	 of	 Cer	 synthase	expression	(upregulation	of	CerS2	and	downregulation	of	CerS4)	can	potentially	be	 contributing	 to	 the	 differences	 observed	 in	 the	 significantly	 increased	 SL	levels.	However,	further	studies	are	necessary	in	order	to	access	the	contribution	of	Cer	synthases	in	GATA6	deficient	pResMf	(described	in	Chapter	8).		
It	 should	 also	 be	 noted	 that,	 although	 acyl	 chain	 composition	 may	 be	influenced	by	fatty	acid	availability,	the	lipid	composition	can	also	be	a	function	of	additional	organelle-specific	factors	as	the	fatty	acyl	profiles.	Thus,	a	targeted	analysis	of	fatty	acyls	would	undoubtedly	help	explain	why	the	SL	with	long	and	saturated	fatty	acids	tend	to	change	more	significantly.		
Lipidomic	analysis	of	Gata6-KOmye	and	-WT	pResMf	suggests	a	relationship	between	the	accumulation	of	different	SL	classes	and	the	genes	responsible	for	the	metabolism	of	 these	 lipids.	As	 a	 result,	 the	next	Chapter	will	 focus	on	 the	knockdown	of	two	selected	genes	encoding	for	the	enzymes	responsible	for	the	degradation	of	the	two	SL	classes	that	changed	the	most	significantly,	DH-SM/SM	
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and	DH-GlcCer/GlcCer	 (Smpd1	 and	Gba2)	 and	 do	 a	 targeted	 sphingolipidomic	analysis	to	investigate	if	the	SL	accumulation	observed	in	Gata6-KOmye	pResMf	can	be	replicated	by	downregulating	Smpd1	and	Gba2.		Similarly,	I	chose	a	third	gene	whose	expression	was	decreased	by	18	fold	in	Gata6-KOmye	pResMf,	since	its	downregulation	is	known	to	impact	lysosomal	metabolism	(cathepsin	E),	and	can	lead	to	lipid	accumulation	in	pResMf237.			 	
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Chapter	7 Downregulation	of	Smpd1,	Gba2	
and	Ctse	leads	to	sphingolipid	
accumulation	
	 	
  
219 
7.1 Introduction		
In	 the	 previous	 Chapters	 I	 characterised	 transcriptomic	 (Chapter	 3)	 and	lipidomic	 (Chapter	 5	 and	 6)	 changes	 in	 GATA6	 deficient	 pResMf,	 which	suggested	a	contribution	of	SMPD1	and	GBA2	in	the	regulation	of	SL	metabolism	in	pResMf.		
GSL,	in	particular,	are	ubiquitous	membrane	components	of	eukaryotic	cells.	They	participate	in	various	cell	recognition	events	and	can	regulate	enzymes	and	receptors	within	the	plasma	membrane238.	SMPD1	catalyses	the	hydrolysis	of	SM	to	Cer	and	choline239,	whilst	GBA2	is	responsible	for	the	conversion	of	GlcCer	to	free	glucose	and	Cer240.	The	downregulation	of	genes	encoding	for	SMPD1	and	GBA2	leads	to	an	accumulation	of	GSL	in	eukaryotic	cells.	GSL	accumulation	leads	to	disease	 in	particular	sphingolipidoses,	where	 lipid	accumulates	 in	cells	as	a	result	of	specific	enzyme	deficiencies241.	For	example,	downregulation	of	Smpd1	results	in	Niemann-Pick	disease,	which	is	characterised	by	accumulation	of	SM	within	 the	 endo-lysosomal	 compartment242.	 On	 the	 other	 hand,	 enzymatic	dysfunction	 of	 glucosidases	 results	 in	 Gaucher’s	 disease240.	 In	 this	 disorder,		downregulation	 of	 Gba2	 in	 mice	 results	 in	 build-up	 of	 GlcCer	 outside	 the	lysosomes	 in	 various	 tissues	 (e.g.	 testis	 and	 liver)	 and	 impairs	 sperm	development	and	liver	regeneration243.		I	also	showed	in	Chapter	3	that	the	Ctse	gene	was	downregulated	in	GATA6	deficient	pResMf	by	18-fold,	when	compared	to	WT	controls.	The	protein	this	encodes,	CTSE,	is	an	intracellular	aspartic	protease	of	the	pepsin	superfamily	and	is	 mainly	 expressed	 in	 cells	 of	 the	 immune	 system,	 but	 its	 location	 varies	depending	on	the	cell	type244.	For	example,	in	mouse	Mf	CTSE	is	mostly	found	in	endosomal	 compartments245.	 The	 tissue	 distribution	 of	 CTSE	 is	 controlled	 by	regulation	of	the	Ctse	gene,	so	that	it	is	expressed	only	in	certain	types	of	cells.	Transcription	 of	 Ctse	 depends	 on	 the	 balance	 between	 specific	 transcription	factor	activities,	including	as	GATA1	and	PU1246.	Lack	of	Ctse	expression	leads	to	a	 lysosomal	 storage	disorder	 characterised	by	 accumulation	of	 the	 two	major	lysosomal	membrane	sialoglycoproteins	LAMP-1	and	LAMP-2	and	consequently	the	elevation	of	lysosomal	pH169.	However,	nothing	is	known	regarding	the	lipid	
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accumulation	originating	from	this	lysosomal	disorder.	Studies	in	ARPE-19	cells,	show	that	Lamp-2	accumulation	induces	vacuole	formation,	cell	death,	cytosolic	lipid	build-up	and	decreased	exogenous	dextran	uptake247.	 In	particular,	when	the	 lysosome's	 ability	 to	 degrade	 intra-	 and	 extracellular	 material	 is	 lost,	undegraded	 material	 is	 oxidized,	 turning	 to	 lipofuscin,	 which	 is	 formed	 by	polymeric	 substances,	 primarily	 composed	 of	 cross-linked	 lipid	 and	 protein	residues	due	to	iron-catalysed	oxidative	processes247.		In	 this	Chapter,	 I	will	describe	 the	knockdown	of	Smpd1,	Gba2	 and	Ctse	 in	RAW	264.7	cells	using	a	 lentiviral	shRNA	vector	and	perform	a	SL	analysis	on	these	cells.	This	is	a	crucial	step	in	answering	the	question	of	whether	the	lipid	changes	observed	in	my	experiments	is	at	least	in	part	controlled	through	altered	expression	of	these	genes	by	GATA6,	and	it	will	allow	me	to	compare	the	results	obtained	from	GATA6	deficient	pResMf	with	the	targeted	knockdowns.	
I	 will	 begin	 by	 producing	 the	 lentiviral	 vectors	 to	 knockdown	 mRNAs	 of	interest,	 then	 evaluate	 how	 effective	 they	 are	 at	 down-regulating	 gene	expression.	Once	 the	down-regulation	 is	satisfactory,	 I	will	engineer	 three	cell	lines,	with	selective	knockdown	of	Smpd1,	Gba2	and	Ctse.	I	will	then	quantify	the	SL	levels	in	these	cells,	using	the	methods	described	in	Chapter	7.	Additionally,	I	will	assess	how	the	lipid	changes	observed	when	specific	genes	are	knockdown	compare	to	lipid	changes	already	seen	on	Gata6-KOmye	pResMf	(Chapter	6).	
7.1.1 Aims	
• To	produce	lentiviral	vectors	to	knockdown	genes	of	interest,	Smpd1,	
Gba2	and	Ctse,	in	RAW	264.7	cells.		
• To	 determine	 how	 the	 expression	 of	 SL	 metabolism	 related	 genes	contribute	to	the	pResMf	lipidome.	
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7.2 Results	
In	 order	 to	 answer	 the	 question	 of	whether	 the	 lipid	 changes	 observed	 in	GATA6	deficient	pResMf	can	be	explained	by	the	modulation	of	the	expression	of	Ctse,	Gba2	 and	Smpd1,	 I	used	 lentiviral	vectors	 to	generate	cell	 lines	where	these	 genes	 were	 down-regulated.	 I	 then	 performed	 a	 quantitative	 lipidomic	analysis	 of	 SL	 in	 these	 cell	 lines	 using	 LC-MS/MS,	 where	 the	 results	 were	compared	against	a	 control	 cell	 line	 (RAW	264.7	cells	 transfected	with	a	non-silencing	shRNA).		
7.2.1 Validation	and	characterisation	of	in	vitro	knockdown	In	order	 to	 select	 the	best	 cell	population	 in	which	 to	perform	 the	 in	 vitro	knockdown	of	the	selected	genes,	I	first	analysed	expression	levels	of	each	gene	in	different	cell	populations	by	qPCR:	RAW	264.7	cells,	monocyte	precursor	cells	(MOPs)	and	pResMf	(as	a	reference	for	levels	of	expression	found	in	vivo).	The	data,	presented	in	Figure	7.1,	showed	that	MOPs	do	not	express	Ctse	.	However,	the	 RAW	 264.7	 cell	 line	 expressed	 all	 three	 genes,	 therefore	 it	 was	 the	 best	candidate	for	in	vitro	knockdown	of	Ctse	,	Smpd1	and	Gba2.			 	
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Figure	7.1	Ctse	,	Smpd1	and	Gba2	in	Mf.		
		 	
Ctse,	Smpd1	and	Gba2	mRNA	expression	compared	by	qPCR	between	pRes	Mf,	Monocyte	precursors	(MOPs)	and	RAW	264.7	cells.	Data	shows	relative	expression,	mean	±SEM	from	one	of	two	independent	experiments	and	is	normalized	to	reflect	the	number	of	pResMf.	
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7.2.2 Lentiviral	vector	induced	in	vitro	knockdown	In	order	to	determine	whether	these	proteins	(CTSE,	SMPD1	and	GBA2)	were	at	 least	partly	 responsible	 for	 the	altered	 lipidomic	phenotype	of	 cells	 lacking	GATA6,	I	first	needed	to	downregulate	the	genes	responsible	for	their	enconding.	The	 strategy	 used	 was	 RNA	 interference	 (RNAi),	 which	 is	 a	 form	 of	posttranscriptional	 gene	 silencing	 mediated	 by	 short	 double-stranded	 RNA,	known	 as	 small	 interfering	 RNA	 (siRNA).	 These	 siRNAs	 can	 been	 delivered	through	 lentiviral	 vectors,	 to	 achieve	 sustained	 knockdown	 of	 target	 gene	expression248.	Herein,	the	silencing	method	used	was	the	production	of	dsRNA,	through	sh	(short	hairpin)	RNA,	where	complementary	RNA	folds	into	a	hairpin	structure	and	base-pairs	to	form	ds-shRNA12.		Constructs	were	designed	to	silence	the	expression	of	Smpd1,	Gba2	and	Ctse,	following	the	strategy	described	in	Chapter	2,	section	2.5.2.	Three	constructs	for	each	 gene:	 non-silencing	 RNA,	 Ctse,	 Smpd1	 and	 Gba2	 (Table	 2.4).	 Figure	 7.2	depicts	the	SU6EW	plasmid	containing	an	shRNA	insert,	used	for	all	constructs.	Recombinant	 plasmids	were	 digested	with	XhoI	 and	PmeI,	 and	 the	 fragments	were	identified	on	1.5%	agarose	gel	(Figure	7.3).	The	results	of	DNA	sequencing	provided	 further	 confirmation	 of	 the	 presence	 of	 the	 recombinant	 plasmids,	indicating	that	all	the	shRNA	expression	plasmids	carried	the	correct	sequence.	
7.2.3 Efficiency	of	lentiviral	infection	in	Jurkat	cells	Flow	cytometry	was	used	to	quantify	the	efficiency	of	eGFP	transfection	 in	Jurkat	cells	infected	with	the	12	constructs	generated	from	the	SUE6W	plasmid,	as	 described	 in	 the	 materials	 and	 methods	 section	 2.5.2.	 Results	 showed	 a	proportional	increase	of	percentage	of	infected	cells	with	the	volume	of	lentivirus	added	 to	 the	 Jurkat	 cells	 (Figure	 7.4).	 All	 12	 constructs	 were	 thus	 used	 for	transfection	of	RAW	264.7	cells.		 	
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Figure	7.2	Key	rgions	within	SU6EW	containing	an	shRNA	insert.		U6	promoter,	drives	RNA	Polymerase	III	transcription	for	generation	of	shRNA	transcripts;	shRNA,	 short	 hairpin	RNA;	 eGFP,	 green	 fluorescence	 protein;	 Factor	 Xa	 site,	where	 factor	 Xa	cleaves	after	the	arginine	residue	in	its	preferred	cleavage	site;	AmpR,	ampicillin	resistence;	RRE,	Rev	 response	 element,	 allows	 for	 Rev-dependent	 mRNA	 export	 from	 the	 nucleos	 to	 the	cytoplasm;	 cPPT,	 Central	 polypurine	 tract,	 improves	 transduction	 efficiency	 by	 facilitating	nuclear	import	of	the	vector’s	preintegration	complex	in	the	transduced	cells;	LTR	long	terminal	repeat.		
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Figure	7.3	Representative	agarose	gel	displaying	digestion	of	plasmids	with	XhoI	and	
PmeI.		Recombinant	plasmids	were	digested	with	XhoI	and	PmeI,	and	the	fragments	were	identified	on	1.5%	agarose	gel.	First	lane-	1kB	DNA	ladder;	numbers	2-5	indicate	bacterial	colonies	tested	for	digestion	of	plasmids;	N	–	negative	control	(undigested	plasmid).										
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Figure	7.4	Efficiency	of	eGFP	transfection	in	Jurkat	cells	increases	with	viral	load.		Scatter	plot	showing	the	percentage	of	Jurkat	infected	with	an	eGFP-expressing	lentivirus	vs	the	volume	(μl)	of	virus	used,	5	days	post	infection.		 	
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7.2.4 Specific	lentiviral	infection	of	RAW	264.7	cells		
a) shRNA	knockdown	efficiency	After	confirming	that	all	12	lentiviruses	engineered	were	able	to	transduce	Jurkat	cells	(Figure	7.4),	RAW	264.7	cells	were	infected	in	vitro.	All	cell	cultures	exhibited	eGFP+	cells	5	days	after	transduction	(Figure	7.5).	The	eGFP+	cells	were	then	 isolated	 using	 Flow	 sorting	 and	 kept	 in	 culture	 for	 another	 5	 days,	 to	increase	cell	numbers,	at	which	point	the	RNA	was	extracted	and	the	 levels	of	expression	for	the	genes	of	interest	were	analysed	(Figure	7.6).			The	 constructs	 that	maximally	 reduced	 the	 expression	 of	Ctse,	Smpd1	 and	
Gba2	were	then	selected	as	follows:	Of	 the	3	Ctse	shRNAs,	2	of	 them	showed	reduced	Ctse	expression	 (in	RAW	264.7	cells)	when	compared	to	the	non-silencing	shRNA	(Figure	7.6A),	shRNA1	induced	 a	 reduction	 of	 51.6%	 and	 shRNA2	 induced	 a	 22.15%	 reduction.	However,	with	regard	to	the	3	different	Smpd1	shRNAs,	only	shRNA2	decreased	
Smpd1	expression	(by	57.9%),	Figure	7.6B.	For	Gba2,	all	3	shRNAs	reduced	gene	expression,	by	36-44.6%	(Figure	7.6C).			The	 gene	 knockdown	 levels	 obtained	 above	 were	 below	 60%	 for	 all	constructs	tested,	and	this	was	considered	to	not	be	sufficient	for	proceeding	to	conduct	 lipidomics.	Therefore,	 I	 increased	 the	viral	 load	by	2-fold	using	 the	3	constructs	that	had	most	strongly	reduced	expression	of	Ctse,	Smpd1	and	Gba2	
(Figure	7.7)	
b) Transfection	efficiency	The	 eGFP+	 cells	 were	 then	 isolated	 using	 flow	 sorting,	 then	 cultured	 for	another	5	days.	With	the	higher	amount	of	virus,	there	was	more	than	75%	eGFP+	RAW	cells	at	day	5	(Figure	7.8).	RNA	and	lipids	were	then	extracted	from	these	samples	 to	 analyse	 knockdown	 levels	 by	 qPCR	 and	 perform	 a	 targeted	sphingolipidomic	analysis.	
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Figure	7.5	eGFP+	expression	in	RAW	264.7	transfected	with	3	different	shRNAs	and	1	
Non-silencing	shRNA.		Figure	shows	representative	examples	of	RAW	264.7	 transfected	with	3	different	shRNAs	expressing	eGFP	5	days	after	transduction	 imaged	on	an	EVOS	cell	 imaging	system,	excitation	480nm.	Left	hand	side	panels,	brightfield;	right	hand	side,	fluorescence.	Bar	size	=	200	microns		 	
NS NS
Smpd1 Smpd1
Ctse Ctse
Gba2 Gba2
  
229 
	
	
Figure	7.6	Lentiviral	knockdown	of	gene	expression	in	RAW	264.7	cells	in	vitro.		eGFP+	cells	were	isolated	using	Flow	sorting	3	days	post	transfection,	and	kept	in	culture	for	5	days,	RNA	was	extracted	and	the	levels	of	expression	for	the	genes	of	interest	were	analysed.	Gene	knockdowns	compared	by	qPCR	(Sybr	green)	 in	RAW	264.7	transfected	with	3	different	shRNAs	 and	 1	 Non-silencing	 shRNA.	 Data	 shows	 mean	 ±SEM	 from	 one	 of	 two	 independent	experiments.	A-	Ctse	,	B-Smpd1,	C-	Gba2.			 	
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Figure	7.7	Lentiviral	knockdown	of	Smpd1,	Gba2	and	Ctse	expression	 in	RAW	264.7	
cells	in	vitro.		eGFP+	cells	were	isolated	using	Flow	sorting	3	days	post	transfection,	and	kept	in	culture	for	5	days,	RNA	was	extracted	and	the	levels	of	expression	for	the	genes	of	interest	were	analysed.	Gene	 expression	 compared	 by	 qPCR	 in	 RAW	264.7	 transfected	with	 Smpd1	 shRNA	 and	Non-silencing	shRNA.	Data	shows	mean	±SEM	from	one	of	three	independent	experiments.		 	
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Figure	7.8	Specific	lentiviral	infection	of	RAW	264.7	cells	in	vitro.		eGFP+	cells	were	isolated	using	Flow	sorting3	days	post	transfection.	Bar	plot	showing	the	percentage	 of	 GFP	 positive	 RAW	 264.7	 cells,	 5	 days	 after	 infection	with	 an	 eGFP-expressing	lentivirus.	Data	shown	is	from	the	shRNAs	with	the	best	knockdown	in	RAW	264.7	cells	(n=	3	per	group).		
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7.2.5 Sphingolipidomic	analysis	
a) SMPD1	knockdown	
Smpd1	expression	was	knocked	down	by	62%	in	RAW	264.7	cells	(Figure	7.7).	Based	on	the	reactions	where	the	enzyme	is	involved	(namely	degradation	of	SM	and	 DH-SM),	 this	 decrease	 may	 lead	 to	 accumulation	 of	 SL,	 in	 particular	 SM	(Figure	 7.9).	 However,	 this	 will	 depend	 both	 on	 post	 transcriptional	modifications	as	well	as	protein	turnover,	so	caution	must	be	applied	here.	Next,	lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	Smpd1	shRNA	were	analysed	in	tandem.	Complex	SL	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	(AB	Sciex),	using	the	targeted	LC-MS/MS	method	I	developed	in	Chapter	7	(described	in	Section	2.6.3).		Using	this	approach,	a	total	of	86	SL	were	quantified,	of	which	13	were	found	to	 show	 significant	 differences	 in	 levels	 between	 the	 two	 groups	 (RAW	 cells	transfected	with	a	non-silencing	shRNA	and	a	Smpd1	shRNA),	with	all	of	them	increasing	in	SMPD1-deficient	RAW264.7.	Of	the	13	6	were	SM,	4	were	DH-SM,	2	HexCer	and	1	LacCer,	with	SM	and	DH-SM	changing	the	most	(Figure	7.10).		Structural	comparison	of	the	10	significantly	altered	SM	and	DH-SM	tended	to	be	saturated	or	mono-unsaturated	(Figure	7.11).			 	
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Figure	7.9	Steps	of	SL	biosynthesis.		The	figure	depicts	SL	genes	(rectangles)	and	metabolites	(circles)	that	participate	in	early	steps	 of	 SL	 biosynthesis.	 The	 metabolites	 analysed	 by	 LC-MS,	 as	 previously	 described,	 are	highlighted	in	black.	The	downregulated	gene,	Smpd1,	is	depicted	in	red.			 	
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Figure	7.10	SMPD1	deficiency	causes	an	increase	in	SM	in	RAW	cells.		Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	a	Smpd1	shRNA.	Sa	and	So	backbones	(black),	Cer	(blue),	CerP	(light	blue),	HexCer	(yellow),	DH-HexCer	(orange),	SM	(purple),	DH-SM	(pink)	and	LacCer	(green)	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	(AB	Sciex).	Volcano	plots	representing	FC	and	p-value	of	lipids	in	RAW	cells	transfected	with	a	non-silencing	shRNA	relative	 to	RAW	cells	 transfected	with	Smpd1	 shRNA.	Statistical	significance	was	determined	using	the	Holm-Sidak	method,	with	alpha=	5.00	%.	Each	row	was	analysed	 individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P	<	0.05	and	|FC|	>	1.5	(red	lines).			
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Figure	 7.11	 Quantitative	 analysis	 of	 significantly	 altered	 SL	 and	 DH-SL	 in	 SMPD1-
deficient	RAW264.7	cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	Chapter	2,	section	2.6.2.	Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	 shRNA	and	a	Smpd1	 shRNA	were	analysed.	Complex	SL	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	(AB	Sciex).	Statistical	significance	determined	using	the	 Holm-Sidak	 method,	 with	 alpha=5.000%.	 Each	 row	 was	 analysed	 individually,	 without	assuming	a	consistent	SD,	the	graphs	depict	the	mean	and	SEM.	p-value,	*<0.05,	**<0.01.		 	
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b) Gba2	knockdown	To	 investigate	 the	 role	 of	 GBA2	 in	 dysregulation	 of	 specific	 lipid	 levels,	 I	analysed	 the	 sphingolipidome	 of	 GBA2-deficient	 cells.	 Using	 the	 strategy	described	in	Materials	and	Methods	section	2.5.3,	I	obtained	knockdown	of	63%	expression	of	GBA2	in	RAW	264.7	cells	(Figure	7.7).	I	predicted	this	would	lead	to	a	disruption	 in	SL	metabolism,	 in	particular,	an	accumulation	of	SL,	such	as	GlcCer	(Figure	7.12).	To	determine	this,	I	conducted	a	sphingolipidomic	analysis	of	RAW	cells	transfected	with	a	Gba2	shRNA	and	compared	these	to	non-silencing	controls.	Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	 a	Gba2	 shRNA	were	 analysed	 by	 LC-MS/MS	 as	 described	 in	 the	 previous	section.	 The	 volcano	 plot	 in	 Figure	 7.13,	 representing	 FC	 and	 p-value	 of	 the	analysed	 SL	 shows	 that,	 of	 the	 24	 HexCer	 and	 DH-HexCer	 analysed,	 14	were	significantly	increased,	of	which	7	were	HexCer	and	7	DH-HexCer.			Comparison	of	 the	14	significantly	altered	SL	and	DH-SL	 in	GBA2-deficient	RAW264.7	cells	(Figure	7.14)	revealed	no	obvious	structural	similarities	in	these	lipids,	other	than	the	fact	that	they	all	belonged	to	the	GlcCer	class.					 	
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Figure	7.12	Steps	of	SL	biosynthesis.		The	figure	depicts	SL	genes	(rectangles)	and	metabolites	(circles)	that	participate	in	early	steps	 of	 SL	 biosynthesis.	 The	 metabolites	 analysed	 by	 LC-MS,	 as	 previously	 described,	 are	highlighted	in	black.	The	downregulated	gene,	Gba2,	is	depicted	in	red.	
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Figure	7.13	GBA2	deficiency	causes	an	increase	in	GlcCer	in	RAW	cells.		Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	a	Gba2	shRNA.	Sa	and	So	backbones	(black),	Cer	(blue),	CerP	(light	blue),	HexCer	(yellow),	DH-HexCer	(orange),	SM	(purple),	DH-SM	(pink)	and	LacCer	(green)	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	 (AB	 Sciex).	 Volcano	 plots	 representing	 FC	 and	 p-value	 of	 lipids	 in	 RAW	 cells	transfected	 with	 a	 non-silencing	 shRNA	 relative	 to	 RAW	 cells	 transfected	 with	Gba2	 shRNA.	Statistical	significance	was	determined	using	the	Holm-Sidak	method,	with	alpha=5.00	%.	Each	row	was	analysed	 individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P	<	0.05	and	|FC|	>	1.5	(red	lines).	
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Figure	 7.14	 Quantitative	 analysis	 of	 significantly	 altered	 SL	 and	 DH-SL	 in	 GBA2-
deficient	RAW264.7	cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	in	section	Chapter	2,	section	2.6.2.	Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	a	Gba2	shRNA	were	analysed.	Complex	SL	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	(AB	Sciex).	Statistical	significance	determined	using	the	Holm-Sidak	method,	with	alpha=5.000%	on	 log	transformed	data.	Each	row	was	analysed	individually,	without	assuming	a	consistent	SD,	 the	graphs	depict	 the	mean	and	SEM.	p-value,	*<0.05,	**<0.01,	***<0.001.		 	
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c) CTSE	knock-down	To	 determine	 the	 effect	 of	 the	 downregulation	 of	 CTSE	 on	 lipid	 levels,	 I	conducted	 a	 sphingolipidomic	 analysis	 of	 RAW	 cells	 transfected	 with	 a	 Ctse	shRNA	 and	 compared	 these	 to	 non-silencing	 controls.	 Lipid	 extracts	 were	analysed,	with	complex	SL	quantified	by	LC-MS/MS,	and	data	was	analysed	as	described	in	section	8.3.4.c.	Here,	using	lentiviral-delivered	shRNAs	in	vitro,	I	obtained	an	85%	reduction	of	Ctse	expression	 in	Raw264.7	 cells.	 Furthermore,	 I	 found	 that	 acute	 shRNA-mediated	CTSE	reduction	led	to	significant	elevations	in	HexCer	and	DH-HexCer.	The	volcano	plot	 in	 Figure	7.15	 shows	 that,	 of	 the	24	HexCer	 and	DH-HexCer	analysed,	 10	were	 significantly	 increased,	 of	which	7	were	HexCer	 and	5	DH-HexCer.		Comparing	 the	 structures	 of	 the	 10	 significantly-altered	 SL	 and	 DH-SL	 in	CTSE-deficient	 RAW264.7	 cells	 (Figure	 7.16)	 revealed	 structural	 similarities,	since	all	lipids	increased	were	found	to	be	either	HexCer	or	DH-HexCer.						 	
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Figure	7.15	CTSE	deficiency	causes	an	increase	in	GlcCer	in	RAW	cells.		Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	a	Ctse	shRNA.	Sa	and	So	backbones	(black),	Cer	(blue),	CerP	(light	blue),	HexCer	(yellow),	DH-HexCer	(orange),	SM	(purple),	DH-SM	(pink)	and	LacCer	(green)	were	quantified	by	LC-MS/MS	on	a	6500	QTrap	mass	spectrometer	 (AB	 Sciex).	 Volcano	 plots	 representing	 FC	 and	 p-value	 of	 lipids	 in	 RAW	 cells	transfected	 with	 a	 non-silencing	 shRNA	 relative	 to	 RAW	 cells	 transfected	 with	 Ctse	 shRNA.	Statistical	 significance	was	determined	using	 the	Holm-Sidak	method,	with	alpha=5.0	%.	Each	row	was	analysed	 individually,	without	assuming	a	consistent	SD.	Differential	expression	was	classified	as	significant	when	P	<	0.05	and	|FC|	>	1.5	(red	lines).		
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Figure	 7.16	 Quantitative	 analysis	 of	 significantly	 altered	 SL	 and	 DH-SL	 in	 CTSE-
deficient	RAW264.7	cells.		The	 amounts	 of	 these	 lipids	 were	 measured	 by	 LC-MS/MS	 using	 the	 internal	 standard	cocktail	as	described	Chapter	2,	section	2.6.2.	Lipid	extracts	from	RAW	cells	transfected	with	a	non-silencing	shRNA	and	a	Ctse	shRNA	were	analysed.	Complex	SL	were	quantified	by	LC-MS/MS	on	 a	6500	QTrap	mass	 spectrometer	 (AB	Sciex).	 Statistical	 significance	determined	using	 the	Holm-Sidak	 method,	 with	 alpha=5.000%	 on	 log	 transformed	 data.	 Each	 row	 was	 analysed	individually,	without	assuming	a	consistent	SD,	 the	graphs	depict	 the	mean	and	SEM.	p-value,	*<0.05,	**<0.01.	 	
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7.3 Discussion		
GSL	are	degraded	in	a	strictly	sequential	pathway	by	endolysosomal	enzymes	with	 the	 assistance	 of	 small	 lipid	 binding	 proteins,	 the	 so-called	 ‘sphingolipid	activator	proteins’.	 Inherited	metabolic	defects	 in	any	one	of	 the	 steps,	where	these	proteins	are	involved,	may	lead	to	a	block	of	degradation	and	accumulation	of	 the	 corresponding	 substrates,	 resulting	 in	 a	 group	 of	 lysosomal	 storage	diseases,	termed	sphingolipidoses250.		In	this	study,	I	used	lentiviral	vectors	to	induce	specific	knockdown	of	Smpd1,	
Gba2	and	Ctse	 in	RAW	264.7	cells,	combined	with	a	targeted	sphingolipidomic	approach	to	determine	the	role	of	these	genes	in	regulating	SL	metabolism	in	Mf.	
Initially,	this	experiment	was	designed	to	test	the	knockdown	conditions	that	would	later	be	reproduced	in	vivo.	However,	due	to	time	constraints	it	was	not	possible	to	proceed	to	in	vivo	experiments.		
7.3.1 Smpd1	knockdown	SMPD1	 occupies	 an	 important	 position	 in	 SL	 catabolism,	 catalysing	 the	hydrolysis	of	SM	to	Cer	and	phosphorylcholine242.	Insights	into	the	importance	of	 SMPD1,	 come	 from	 the	 study	 of	 the	 human	 lysosomal	 storage	 disorder	Niemann	Pick	Disease	Types	A	(NPD	A)	and	B	(NPD	B)251.	The	accumulation	of	excessive	levels	of	SM	in	NPD	patients	was	initially	described	by	Klenk	in	1934252.	Since	 then,	 studies	 using	 Smpd1−/−	 mice	 have	 shown	 age-dependent	accumulation	 of	 SM	 and	 development	 of	 Niemann-Pick	 syndrome	 A	 or	 B,	depending	on	the	residual	activity	of	SMPD1.		Despite	 the	 multitude	 of	 studies	 implicating	 the	 SMPD1/Cer	 pathway	 in	important	cellular	processes,	few	have	addressed	how	altering	gene	expression	modulates	the	accumulation	of	different	lipid	species	from	this	large	family.	The	quantitative	analysis	of	complex	SL	in	RAW	cells	transfected	with	Smpd1	shRNA	relative	 to	 RAW	 cells	 transfected	 with	 a	 non-silencing	 shRNA	 by	 LC-MS/MS,	revealed	an	increase	not	only	in	SM	and	DH-SM,	but	also	in	LacCer	and	HexCer	lipids	(Figure	7.11).	These	data	seem	to	largely	agree	with	the	findings	previously	
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reported	by	M.	Koberlin,	et	al.	in	Smpd1	knockdowns	in	RAW	cells98.	However,	in	this	study	they	observe	a	significant	decrease	in	Cer	levels	that	my	data	did	not	show,	which	could	be	due	to	the	fact	that	the	method	used	by	M.	Koberlin,	et	al.	for	 lipid	 quantification	 was	 less	 specific,	 which	 could	 lead	 to	 significant	differences	 in	results.	Nevertheless,	 this	change	 in	Cer	 levels	was	expected,	as	previously	mentioned,	SMPD1	is	responsible	for	the	conversion	of	SM	into	Cer,	thus	less	degradation	of	SM	should	have	an	impact	on	the	levels	of	Cer.	According	to	published	data,	accumulation	of	SM,	is	positively	correlated	with	cholesterol	levels	 in	 the	 circulation	 as	 well	 as	 the	 retention	 of	 cholesterol	 in	 the	 plasma	membrane253,254,	and	the	regulation	of	cell	migration255,	and	can	potentially	be	the	cause	for	some	of	these	phenotypical	changes	when	observed	in	Gata6-KOmye	pResMf69.		
7.3.2 Gba2	knockdown		
Gba2	is	a	β-glucosidase,	responsible	for	the	cleavage	of	GlcCer	(to	glucose	and	Cer).	GlcCer	is	not	only	a	main	precursor	for	other	GSL	but	it	is	also	a	relevant	intermediate	 in	 the	 pathways	 of	 GSL	 metabolism	 and	 plays	 key	 roles	 in	 the	regulation	 of	 cell	 physiology.	 The	 molecular	 mechanisms	 by	 which	 GlcCer	regulates	 cellular	 processes	 are	 unknown,	 but	 might	 involve	 changes	 in	membrane	biophysical	properties	and	formation	of	lipid	domains256.		Knockout	studies	have	shown	that	GBA2-deficient	mice	accumulate	GlcCer	in	tissues	 that	have	 the	greatest	expression	of	GBA2,	 i.e.	 in	 the	brain,	 spleen	and	testis243,257.	This	indicates	an	active	role	for	GBA2	in	metabolising	GlcCer	in	these	sites.	 Accumulation	 of	GlcCer	 leads	 to	male	 infertility	 due	 to	 the	 formation	 of	aberrant	 sperm	 (large	 round	 heads	 ,	 abnormal	 acrosomes,	 and	 defective	mobility),	 and	 delayed	 liver	 regeneration	 after	 partial	 hepatectomy258,259.	 The	mechanisms	 responsible	 for	 these	 phenotypes	 remain	 unknown	 because	 the	signalling	function	of	GlcCer	is	not	well	understood,	in	particular,	the	fate	of	non-lysosomal	GlcCer243.	My	work	showed	that	the	knockdown	of	Gba2	in	RAW	264.7	cells	disrupted	SL	metabolism,	leading	to	accumulation	of	GlcCer	and	DH	GlcCer	(Figure	7.13),	
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whereas	 total	 levels	 of	 sphingoid	 bases,	 Cer,	 SM,	 and	 LacCer	 were	 not	significantly	affected	(Figure	7.13).		This	type	of	SL	accumulation	(GlcCer	and	DH-GlcCer),	has	been	shown	to	lead	to	 the	 same	disruptions	 in	 cell	metabolism	as	 those	observed	 in	Gata6-KOmye,	such	 as	 alternative	 activation	 of	 Mf	 activation,	 tissue	 inflammation	 and	proinflammatory	cytokine	production	(IL-6	and	TNF-α)71,251,260.	However,	there	is	no	evidence	that	the	same	mechanisms	are	responsible	for	the	phenotypical	changes	observed	in	Gata6-KOmye.		
7.3.3 Ctse	knockdown		CTSE	 is	 an	 intracellular	 aspartic	 protease	 of	 the	 endolysosomal	 pathway,	predominantly	expressed	in	cells	of	the	immune	system.	It	has	been	implicated	in	several	physiological	and	pathological	processes	however,	so	far	the	functional	importance	 of	 CTSE	 is	 not	 completely	 understood261.	 Studies	 using	 knockout	mice	 have	 provided	 some	 information	 regarding	 the	 contribution	 of	 CTSE	 to	physiology.	 Mf	 from	 CTSE-deficient	 mice	 exhibit	 a	 form	 of	 lysosome	 storage	disorder,	 exhibiting	 the	 accumulation	 of	 the	 two	major	 lysosomal	membrane	sialoglycoproteins	 LAMP-1,	 LAMP-2	 and	 LC3	 and	 the	 elevation	 of	 lysosomal	pH169.	However,	nothing	is	known	regarding	the	lipid	dysregulation	originating	from	 this	 lysosomal	 disorder.	 Herein,	 I	 analysed	 cells	 where	 Ctse	 was	downregulated,	and	observed	that	the	knockdown	of	Gba2	and	Ctse	in	RAW	264.7	cells	led	to	a	disruption	in	SL	metabolism,	with	similar	effects,	i.e.	accumulation	of	 GlcCer	 and	 DH	 GlcCer	 (Figure	 7.15).	 However,	 there	was	 no	 evidence	 of	 a	preferential	 accumulation	 of	 the	 same	 lipid	 species	 that	 were	 significantly	increased	in	Gata6-KOmye	cells.	In	fact,	all	SL	species	increased	to	some	degree,	but	only	the	changes	in	GlcCer	and	DH	GlcCer	levels	were	significant.	This	result	was	quite	unexpected	as	the	only	information	in	the	literature	regarding	CTSE	and	lipid	metabolism	referred	only	to	a	lysosomal	disorder,	without	any	mention	of	its	influence	in	lipid	metabolism.	It	can	be	speculated	that	this	accumulation	could	potentially	be	due	to	the	dysregulation	of	lysosome	function	caused	by	the	accumulation	of	LAMP-1	and	LAMP-2.	
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Even	 though	 CTSE	 is	 not	 a	 lysosomal	 cathepsin,	 as	 it	 is	 only	 present	 in	endosomes,	 it	 still	 plays	 an	 important	 role	 in	 lysosomal	 function,	 with	 its	deficiency	 leading	 to	 impaired	 fusion	 of	 autophagosomes	with	 lysosomes	 and	leading	to	increased	oxidative	stress262.	The	phenotype	of	CTSE-deficient	Mf	is	similar	to	that	of	cells	lacking	lysosomal	proteins.	For	example,	LC3	protein	levels	are	elevated	in	cells	lacking	lysosomal	proteins,	in	phenotypes	found	in	neuronal	ceroid	 lipofuscinosis,	 and	 Niemann-Pick	 Type	 C	 disease,	 where	 there	 is	accumulation	of	SL	262.	However,	I	was	not	able	to	find	literature	indicating	that	GlcCer	 and	DH-GlcCer	would	 be	more	 affected	 by	 the	 downregulation	 of	Ctse	compared	with	other	lipid	species.	Thus,	these	findings	are	quite	novel	and	this	is	a	topic	that	requires	further	investigation.	
7.3.4 GlcCer	and	SM	accumulation	Overall,	 the	 lipidomics	 results	 from	CTSE/GBA2	and	SMPD1	deficient	 cells	combined,	 support	 my	 hypothesis	 that	 GATA6	 regulates	 SL	 metabolism	 in	peritoneal	Mf	by	altering	 the	expression	of	 these	genes.	This	 further	suggests	that	 these	 pathways	 and	 lipids	 could	 be	 essential	 regulators	 of	 the	 pResMf	phenotype	in	mice.		Future	functional	experiments	designed	to	address	this	hypothesis,	focussing	on	restoring	the	WT	phenotype	in	GATA6-KOmye	by	modulating	CTSE,	GBA2,	and	SMPD1	activity,	will	be	discussed	in	the	next	Chapter.					 	
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Chapter	8 General	discussion	
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ResMf	 are	 distributed	 throughout	 the	 body	 and	 play	 important	 roles	 in	pathogen	 detection	 and	 homeostasis263.	 In	 tissues,	 these	 cells	 exhibit	 distinct	phenotypes	and	activities,	 yet	 the	precise	mechanisms	 that	 regulate	 these	are	still	 largely	unknown65.	pResMf	perform	an	essential	 role	 in	 the	 regulation	of	infectious	 and	 inflammatory	 diseases.	 Although	 recent	 progress	 on	 murine	pResMf	has	revealed	multiple	aspects	on	their	origin	and	mechanisms	involved	in	their	maintenance	in	this	compartment,	little	is	known	on	their	characteristics	in	homeostasis.	 In	 this	 thesis	 I	 investigated	whether	 the	myeloid	deficiency	of	GATA6	was	associated	with	alterations	in	lipid	metabolism,	at	a	transcriptional	and	molecular	 level	 in	pResMf.	GATA6	is	a	master	regulator	of	 the	phenotype	and	function	of	pResMf,	whose	deficiency	results	in	dysregulated	proliferative	renewal	 during	 homeostasis	 and	 altered	 inflammatory	 responses,	 associated	with	delays	in	resolution69.	However,	whether	GATA6	can	directly	influence	lipid	metabolism	was	not	known	before	now,	apart	from	some	preliminary	findings	in	a	 transcriptional	 dataset	 that	 showed	 several	 differentially	 expressed	 genes	involved	 in	 lipid	 metabolism69.	 Among	 the	 first	 genes	 identified	 were	 ABCA,	ALOX15,	 SPTLC2,	 FABP4	 and	 LDLR.	 Such	 changes	 in	 gene	 expression	 are	presumably	linked	to	alterations	in	lipid	metabolism	related	pathways.		Lipids	play	multiple	essential	roles	in	cell	signalling	and	subcellular	structure.	Mf	are	required	to	deal	with	the	lipids	they	obtain	through	the	phagocytosis	of	dying	 cells,	 however,	 it	 is	 clear	 from	 the	 transcriptional	 profiles	 of	 different	ResMf	that	some,	namely	the	alveolar	Mf,	pResMf,	and	Kupffer	cells,	are	more	highly	specialised	in	this	function	than	others57,66,264.	This	is	a	crucial	function	of	these	 Mϕ	 as	 defective	 or	 absent	 lipid	 metabolism	 can	 result	 in	 several	pathologies	 including	 inflammatory	 diseases	 and	 abdominal	 cancers	 in	 the	peritoneal	 cavity.	 Furthermore,	 progress	 of	 pathologies	 can	 also	 lead	 to	 the	recruitment	of	inflammatory	monocyte-derived	Mϕ	which,	in	turn,	take	up	lipids	and	subsequently	need	to	be	able	to	process	them,	potentially	having	dramatic	effects	on	disease	progression	and	patient	outcome	 such	as	 in	 atherosclerotic	plaques.	Thus,	it	is	evident	that	Mϕ	play	key	roles	in	lipid	metabolism	and	in	the	pathogenesis	of	lipid-related	diseases.	However,	it	is	also	clear	that	this	is	not	yet	fully	 understood.	 Thus,	 there	 is	 still	much	 to	 learn	 regarding	 the	 roles	 of	Mϕ	
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particularly	 in	 lipid	 metabolism.	 Importantly,	 as	 the	 understanding	 of	 Mϕ	increases,	both	in	terms	of	their	common	and	tissue-specific	features,	it	is	easier	to	 design	 new	 tools	 to	 address	 such	 specific	 questions.	 Hence	 a	 systematic	analysis	of	the	total	lipid	structure	of	a	cell	or	organism,	can	reveal	novel	avenues	for	therapeutic	intervention	and	diagnosis.	The	 data	 presented	 within	 this	 thesis	 has	 contributed	 to	 the	 growing	knowledge	 on	 Mf	 lipid	 biology.	 I	 found	 that	 the	 GATA6	 transcription	 factor	regulates	 the	 expression	 of	 lipid	 metabolism	 related	 genes	 in	 pResMf,	 in	particular,	SL	metabolism-related	genes	(Figure	8.1,	transcriptomic	analysis),	as	evidenced	by	the	dysregulation	of	SL	metabolism-related	pathways	and	causal	mechanisms	(Chapter	3).	A	wide	range	of	genes	with	roles	in	lysosomal	function	were	 found	 to	 be	 dysregulated	 (Chapter	 3).	 I	 next	 optimised	 the	 LC-MS	conditions	 necessary	 to	 perform	 an	 untargeted	 lipidomic	 analysis	 of	 Mf-like	cells,	using	pResMf	and	RAW	264.7,	and	thus	I	found	that	the	lipidome	of	these	2	cell	 types	 is	 significantly	 different,	which	 suggests	 considerable	 differences	 in	phenotype	(Chapter	4).		Specifically,	RAW	264.7	cells	showed	increased	levels	of	lipids	that	are	known	to	lead	to	a	pro-resolving	phenotype	(steroid	lipids),	whilst	pResMf	 show	 the	 opposite,	 levels	 of	 bile	 acids	 are	 significantly	 higher,	which	implies	a	more	pro-inflammatory	phenotype198–200.		After	optimising	the	LC-MS	conditions	in	Chapter	4,	I	explored	the	metabolic	defect	caused	by	the	KO	of	Gata6,	by	comparing	the	lipidome	of	Gata6-KOmye	and	WT	pResMf,	using	the	high-resolution	LC-MS	based	global	lipidomics	approach	established	in	Chapter	4.		This	revealed	that	putatively	identified	SM	and	HexCer	lipids	were	significantly	 increased	in	Gata6-KOmye	cells	(Figure	8.1,	untargeted	analysis)	(Chapters	5).		Mapping	 the	 expression	 results	 onto	 the	 known	 SL	 metabolic	 pathway	showed	 that	 13	 of	 the	 20	 genes	 were	 dysregulated	 in	 GATA6-defficient	 cells	(Figure	8.2),	consistent	with	the	fact	that	that	SL	and	GPL	levels	were	increased.	The	genes	induced	by	GATA6	were	associated	with	the	de	novo	synthesis	of	Cer	(Sptlc2	and	CerS2)	and	their	downstream	processing	into	other	key	SL	including	SM	 by	 Cola3bp,	 and	 GluCers	 by	 Ugcg.	 In	 contrast,	 genes	 involved	 in	 the	
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degradation	 of	 SM	 (Smpd1	 and	 related	 genes)	 and	 GlcCer	 (Gba2)	 were	predominantly	 downregulated.	 This	 significant	 and	 consistent	 transcriptional	pattern	 across	 the	 network	 suggested	 increased	 levels	 of	 SM	 and	 GlcCer,	 as	indeed	observed	in	the	untargeted	lipidomics	data	lipidomics	data	(Figure	8.1).	
To	 directly	 quantify	 SL	 in	 pResMf,	 I	 then	 developed	 and	 validated	 a	quantitative	assay	which	I	applied	to	determine	the	changes	of	lipid	levels	upon	
Gata6	KO,	and	thus	explored	the	role	of	GATA6	in	regulating	SL	metabolism	in	Mf.	Using	 this	approach,	 I	 found	 that	HexCer	and	SM	 lipids	were	significantly	increased	 in	GATA6	deficient	 cells,	which	suggests	a	 relationship	between	 the	accumulation	 of	 different	 SL	 classes	 and	 the	 genes	 responsible	 for	 the	metabolism	of	 these	 lipids	 (Chapter	 6)	 (Figure	 8.1,	 targeted	 sphingolipidomic	analysis).	 SM	 and	 HexCer	 are	 involved	 in	 cell	 proliferation,	 apoptosis	 and	metabolic	 regulation265,266.	 Their	 accumulation	 in	 tissues	 has	 been	 previously	implicated	 in	 a	 plethora	 of	 health	 complications	 such	 as	 development	 of	neurological	 dysfunctions,	 atherosclerosis,	 diabetes,	 and	 heart	 failure242.	Therefore,	 I	 next	 examined	 the	 ability	 of	 GATA6	 to	modulate	 their	 levels,	 by	regulating	the	expression	of	genes	involved	in	SL	metabolism	(Chapter	7).	The	increase	 in	 SL	 levels	 linked	 with	 downregulation	 of	 Gba2,	 Ctse	 and	 Smpd1,	observed	 during	 the	microarray	 analysis,	 was	 confirmed	 by	 supressing	 these	pathways,	in	RAW	264.7	cells,	by	means	of	knockdown	(shRNA)	methodologies.	Using	this	approach,	I	showed	that	downregulation	of	Smpd1,	leads	to	an	increase	in	some	of	the	DH-SM	and	SM	species	affected	by	GATA6	deficiency	(Figure	8.3).	Some	difference	in	the	SL	species	present	was	expected	considering	the	results	obtained	from	the	untargeted	lipidomic	analysis	of	pResMf	and	RAW	264.7	cells	(Chapter	4),	where	66%	putatively	identified	SL	were	found	to	be	significantly	dysregulated,	with	more	species	present	in	RAW	264.7.	SMPD1	is	part	of	the	SL	
de	novo	pathway,	and	it	was	expected	to	have	a	direct	impact	on	SM	levels242.			 	
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Figure	8.1	Regulation	of	lipid	metabolism	by	GATA6,	an	integrated	‘omics’	approach.		The	figures	depicts	the	main	findings	obtained	after	analysing	Gata6-KOmye	and	WT	pResMf	from	female	mice,	using	different	omics	approaches.	Transcriptomic	analysis	–	GATA6	deficiency	leads	to	activation	of	gene	networks	that	suggest	increased	levels	of	SL;	Untargeted	lipidomics-	GATA6	deficiency	leads	to	accumulation	of	putatively	identified	SL;	targeted	sphingolipidomics	–	validation	of	increased	SL	levels	and	possible	contribution	of	genes	involved	in	their	metabolism.		 	
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Figure	8.2	GATA6	Transcription	of	the	SL	Metabolic	Network.		Selected	SL	and	glycerophospholipid	metabolic	reactions	(KEGG),	shown	together	with	main	metabolites	(rounded	rectangles)	and	24	selected	genes	(rectangles).	Heatmaps	show	relative	expression	 of	 20	 selected	 genes	 after	 Gata6-KO,	 measured	 by	 microarray	 analysis,	 coloured	according	 to	 the	 scale	 shown	on	 the	 figure.	Metabolites	 are	 coloured	 as	 either	 green	 or	 grey	depending	on	whether	they	were	found	to	be	increased,	or	not	significantly	altered,	respectively.		 	
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Figure	8.3	Transcriptional	impact	on	DH-SM	and	SM	levels	in	Mf.		Colour	 map	 describing	 the	 impact	 of	 gene	 expression	 in	 DH-SM	 and	 SM	 levels	 when	compared	to	the	respective	controls.	Each	column	represents	a	KO	or	KD	of	a	specific	gene,	in	pResMf	(Gata6)	and	RAW	264.7	(Gba2,	Ctse,	Smpd1),	whilst	each	row	represents	different	chain	lengths	 of	 DH-SM	 or	 SM.	 Black-	 Lipid	 not	 detected;	 grey-	 lipid	 detected	 but	 not	 significantly	changed;	green-	lipid	levels	significantly	increased	when	compare	to	control	samples.	Control	for	
Gata6-KO	pResMf	were	WT	littermates,	whilst	for	RAW	264.7	it	was	cells	from	the	same	cell	line	transfected	with	a	non-silencing	shRNA.			 	
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Next,	I	found	that	downregulation	of	both	Ctse	and	Gba2,	led	to	an	increase	in	some	of	the	DH-GlcCer	and	GlcCer	species	affected	by	GATA6	deficiency	(Figure	8.4).	However,	the	2	knockdowns	had	an	effect	on	different	lipid	species,	with	the	downregulation	 of	Ctse	 leading	 to	 an	 increase	 of	most	 DH-GlcCer	 and	 GlcCer,	whilst	downregulation	of	GlcCer	seemed	to	have	an	effect	only	on	some	chain-lengths,	that	matched	the	ones	increased	upon	Gata6	KO.	The	results	obtained	upon	downregulation	of	Ctse	were	novel,	as	CTSE	deficiency	is	known	to	lead	to	a	 lysosomal	storage	disorder,	however,	 there	 is	no	information	regarding	how	the	lipidome	is	affected169.	While	this	study	does	not	offer	a	conclusive	answer	to	the	question	of	how	the	GATA6	transcription	factor	regulates	lipid	metabolism	in	pResMf,	 and	 how	 that	 impacts	 the	 cell	 phenotype,	 the	 findings	 that	 I	 have	presented	suggest	a	potential	mechanism	through	which	GATA6	controls	 lipid	levels	in	pResMf.	This	is	important	because	it	contributes	to	our	understanding	of	Mf	biology	and	will	help	guide	future	research.			
Lipids	are	a	complex	class	of	molecules	that	participate	in	many	facets	of	cell	structure	and	function.	Therefore,	the	use	of	“-omic”	approaches	–	i.e.,	to	analyse	as	many	as	possible	of	the	molecular	species	and	mRNAs	for	pathway	genes	–	is	likely	 to	 uncover	 interesting,	 and	 sometimes	 unexpected,	 links	 between	 their	metabolism.	Using	the	multi-faceted	approach	of	lipidomic	and	genomic	analyses	combined	techniques,	my	studies	integrated	various	aspects	of	 lipid	biology	in	order	 to	 obtain	 a	 more	 clearly	 defined	 ‘big	 picture’	 of	 the	 cellular	 effects	 of	transcriptional	 regulation,	 on	 lipid	 metabolism	 and	 the	 associated	 functional	consequences.					
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Figure	8.4	Transcriptional	impact	on	DH-GlcCer	and	GlcCer	levels	in	Mf.		Colour	map	describing	the	impact	of	gene	expression	in	DH-GlcCer	and	GlcCer	levels	when	compared	to	the	respective	controls.	Each	column	represents	a	KO	or	KD	of	a	specific	gene,	in	pResMf	(Gata6)	and	RAW	264.7	(Gba2,	Ctse,	Smpd1),	whilst	each	row	represents	different	chain	lengths	 of	 DH-GlcCer	 or	 GlcCer.cBlack-	 Lipid	 not	 detected;	 grey-	 lipid	 detected	 but	 not	significantly	 changed;	 green-	 lipid	 levels	 significantly	 increased	 when	 compare	 to	 control	samples.	Control	for	Gata6-KO	pResMf	were	WT	littermates,	whilst	for	RAW	264.7	it	was	cells	from	the	same	cell	line	transfected	with	a	non-silencing	shRNA.		 	
Ga
ta6
-K
O
Gb
a2
-K
D
Ct
se
-K
D
Sm
pd
1-K
D
Ga
ta6
-K
O
Gb
a2
-K
D
Ct
se
-K
D
Sm
pd
1-K
D
C14:0
C16:0
C16:1
C18:0
C18:1
C20:0
C20:1
C22:0
C22:1
C24:0
C24:1
C26:0
C26:1 -1.0
DH-GlcCer GlcCer
Not detected
Not significant
Significantly increased
-0.5
0
0.5
1.0
  
256 
8.1 Limitations		
The	main	limitations	of	this	work	can	be	categorised	in	into	four	areas.	The	first	one	lies	with	the	untargeted	lipidomics	analysis	performed	in	Gata6-WT	and	-KOmye	 pResMf	 (chapter	 5),	 which	 is	 an	 invaluable	 tool	 that	 allowed	 me	 to	acquire	an	overview	of	the	lipid	changes	caused	by	GATA6	deficiency.	However,	the	 information	 I	 can	 obtain	 from	 this	 analysis	 is	 limited	 by	 the	 extraction	procedure,	 LC	 conditions,	 as	 well	 as	 the	 entries	 available	 in	 public	 lipid	databases.	The	lipid	extraction	should	be	capable	of	effectively	extracting	lipids	representative	of	the	sample	under	study	without	bias,	inducing	the	degradation	of	lipids,	or	introducing	contamination267.	Thus,	the	success	in	the	identification	and	profiling	of	lipids	is	critically	dependent	on	the	efficiency	of	the	extraction	step.	 Herein	 I	 used	 an	 established	 extraction	 procedure	 known	 to	 efficiently	extract	 different	 lipid	 categories/classes.	 Nevertheless,	 the	 issue	 still	 remains	that	some	lipid	species	might	be	under-represented,	which	could	potentially	be	artificially	 increased	 during	 the	 LC	 separation,	 and	 subsequent	 data	 analysis.	Conversely,	 I	 am	 confident	 that	 my	 lipid	 extraction	 and	 LC-MS	 conditions	minimised	these	limitations	and	that	the	conclusions	drawn	from	the	untargeted	analysis	are	representative	of	the	lipidome	of	pResMf.	
Second,	in	the	interest	of	time,	and	to	follow	a	logical	flow	in	this	project,	I	chose	 to	 study	 in	 depth	 the	 changes	 cause	 by	 GATA6	 deficiency	 in	 SL	 levels	(chapter	6).	In	addition	to	SL,	both	FA	and	GPL	were	also	affected,	which	can	lead	to	 significant	 metabolic	 effects	 in	 pResMf.	 Fatty	 acid	 and	 GPL	metabolism	 is	known	to	be	involved	in	the	modulation	of	inflammatory	responses	in	Mf268,269.	Thus,	having	analysed	only	one	lipid	category	is	a	limitation,	and	knowing	how	GATA6	contributes	to	their	regulation	will	help	get	an	overview	of	its	influence	in	pResMf	phenotype.				
Third,	it	is	imperative	to	study	the	lipidomic	changes	in	Gata6-WT	and	-KOmye	pResMf,	not	only	in	basal	conditions,	but	also	under	inflammatory	stimuli.	This	is	a	gap	that	I	hope	to	address	in	the	near	future.	
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Last,	the	knockdown	experiments	in	Chapter	7	were	performed	in	RAW	264.7	cells.	This	was	due	to	both	time	constraints	and	logistics,	as	these	cells	are	more	readily	 available	 than	 pResMf.	 These	 experiments	 provided	 valuable	information,	however,	the	fact	still	remains	that	GATA6	is	not	expressed	in	RAW	264.7	cells,	and	the	basal	levels	of	some	lipids	are	significantly	different	between	the	 two	 cell	 types	 (Chapter	 4).	 Therefore,	 the	 mechanisms	 by	 which	 lipid	metabolism	is	regulated,	and	its	effects,	might	be	different	to	pResMf.		
In	conclusion,	ResMf	represent	favourable	targets	for	modern	medicine,	as	a	wide	 spectrum	 of	 diseases,	 such	 as	 autoimmune,	 neurodegenerative	 and	metabolic	disorders,	as	well	as	tumour	growth,	have	been	linked	to	their	specific	dysfunctions270.	Nevertheless,	in	order	to	be	able	to	exploit	Mf	functionalities	it	is	necessary	to	better	understand	the	underlying	mechanisms	controlling	their	development	 and	 maintenance.	 I	 believe	 this	 thesis	 has	 contributed	 to	 this	purpose.	In	the	next	section	I	will	address	the	future	directions,	as	well	as	how	the	 knowledge	 obtained	 during	 this	 study	 can	 be	 used	 to	 modulate	 pResMf	phenotype	for	therapeutic	purposes.	
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8.2 Future	directions	
8.2.1 Inflammatory	challenge		
ResMf	are	tissue-specialised	immune	sentinels,	which	have	key	functions	in	homoeostasis	and	inflammation2,271.	As	previously	mentioned,	like	many	ResMf,	pResMf	are	not	originally	derived	from	monocytes,	but	rather	from	embryonic	progenitors	seeded	into	tissues	before	birth,	with	the	populations	maintained	by	local	proliferation29,42,272,273.	These	cells	exist	 in	complex	environments	and	do	not	fit	traditional	polarisation	categories,	such	as	LPS	and	IFN-γ	stimulated	pro-inflammatory	and	IL-4	stimulated	anti-inflammatory2,274.	Furthermore,	GATA6-deficient	 Mf	 demonstrate	 an	 altered	 proliferation	 state	 during	 peritonitis69.	Thus,	 it	would	 be	 relevant	 to	 investigate	 the	 changes	 in	 lipid	 levels	 under	 an	inflammatory	stimulus.	
8.2.2 Gene	knockdowns	in	pResMf	
The	majority	of	Mf	research	has	been	performed	using	cell	 lines	and/or	in	vitro-derived	 BMDM.	 Accordingly,	 precise	 mechanisms	 of	 how	 cells	 meet	metabolic	 demands	 in	 vivo	 remain	 unknown,	 making	 it	 critical	 to	 assess	 cell	function	 in	 conjunction	 with	 tissue-niche	 metabolites275.	 Thus,	 in	 order	 to	determine	whether	the	modulation	of	Smpd1	and	Ctse	expression	by	GATA6	has	a	significant	impact	in	pResMf	phenotype,	the	first	step	would	be	to	knockdown	
Smpd1	and	Ctse/Gba2	expression	in	WT	pResMf.		
8.2.3 Cancer	research	The	 peritoneal	 cavity	 is	 a	 common	 site	 of	 tumour	 development	 and	metastasis.	Ovarian	epithelial	cancer	frequently	spreads	to	the	peritoneal	cavity	and	 is	 treated	 similarly	 to	 primary	 peritoneal	 cancer276.	 There	 is	 clearly	 the	potential	for	extensive	cross-talk	between	tumour	cells	and	pResMf	within	the	peritoneal	cavity.	The	ability	for	Mf	to	produce	immunosuppressive	cytokines,	tumour-promoting	growth	and	angiogenic	factors	has	been	well	described	in	the	literature277.	 In	 the	peritoneum,	Mf	depletion	can	reduce	tumour	progression,	metastasis278	 and	 ascites	 fluid	 formation279.	 Mf-targeted	 therapies	 are	 thus	
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promising	 strategies	 for	 the	 treatment	 of	 ovarian	 carcinoma	 and	 peritoneal	tumours.	 Furthermore,	 GATA6	 has	 been	 shown	 to	 play	 important	 roles	 in	different	 types	 of	 cancer,	 such	 as,	 promoting	 cell	 invasion	 in	 colon	 cancer280,	regulating	tumour	dissemination	in	pancreatic	cancer.	Whilst	at	the	same	time,	SL	 metabolism	 is	 dysregulated	 in	 cancer	 cells134,281–283.	 Cancer	 cells	 undergo	profound	 changes	 in	 lipid	 metabolism	 and	 homeostasis,	 thus	 offering	 new	diagnostic	and	therapeutic	opportunities	that	could	be	unravelled	by	lipidomics.	However,	 no	 link	 has	 been	made	 between	 GATA6	 and	 the	 regulation	 of	 lipid	metabolism	in	tumour	development	and	metastasis.	Thus,	I	propose	that	future	studies	 involving	 GATA6	 focus	 on	 its	 role	 in	 cancer	 progression.	 Preliminary	studies	could	be	performed	using	colon	cancer	cell	lines	and	characterising	their	phenotypes,	and	 lipid	 levels	upon	dysregulation	of	 targeted	genes,	such	as	the	transcription	factor	GATA6,	as	well	as	Smpd1,	Gba1/Gba2	and,	Ctse	,	which	I	have	found	to	be	key	players	in	the	regulation	of	lipid	metabolism	in	pResMf.			
8.2.4 	Lipidomics	analysis	Lastly,	 the	 lipidomics	 studies	 performed	 during	 the	 course	 of	 this	 project	were	based	on	an	untargeted	lipidomics	approach,	used	to	obtain	an	overview	of	the	 impact	 of	 GATA6-deficiency	 on	 lipid	 metabolism,	 followed	 by	 a	 targeted	approach	 applied	 to	 the	 SL	 category.	 However,	 an	 in-depth	 analysis	 of	 the	lipidomic	changes	caused	by	GATA6-defficiency	on	other	lipid	categories,	such	as	FA	and	GPL,	would	contribute	to	the	knowledge	of	how	GATA6	regulates	 lipid	metabolism	in	pResMf.	Additionally,	detailed	in-sight	into	lipid	function	requires	knowledge	of	the	subcellular	localisation	of	individual	lipids.	Hence,	it	would	be	of	 value	 to	 perform	 fractional	 organelle	 lipidomics	 on	 Gata6-WT	 and	 KOmye	pResMf.		
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